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Abstract 
Individuals with chronic kidney disease (CKD) have an alarmingly high rate of 
sudden cardiac death, largely attributable to arrhythmias. The burden of arrhythmias has 
been difficult to study because arrhythmias are often transient and asymptomatic, and the 
current practice is limited by short periods of arrhythmia monitoring. This dissertation 
therefore predominantly used a new continuous monitoring device in the Atherosclerosis 
Risk in Communities study to assess the following four aims. 
 First, we conducted a systematic review and meta-analysis to examine the burden 
of all types of arrhythmia in CKD. Most studies found that estimated glomerular filtration 
rate (eGFR) was associated with a higher risk of atrial fibrillation (AF). Some studies 
also reported a higher incidence of ventricular arrhythmia related to reduced eGFR, but 
overall, limited number of studies examined albuminuria and other arrhythmias.  
Second, we quantified across CKD severity the burden of major arrhythmias (i.e., 
AF, non-sustained ventricular tachycardia [NSVT], long pause, atrioventricular block 
[AVB]) and minor arrhythmias (i.e., ventricular ectopy [VE], supraventricular 
tachycardia [SVT] and ectopy [SVE]). Compared to no-CKD, CKD was associated with 
higher presence of AF and NSVT, higher frequency of long pause and VE, and a lower 
frequency of AVB.  
Third, we investigated the relationships between several biomarkers representing 
cardiac overload (i.e., natriuretic peptide [NT-proBNP]), cardiac injury (i.e., high-
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sensitivity cardiac troponin-T [hs-cTnT]), electrolyte abnormalities (i.e., potassium and 
magnesium), and anemia (i.e., hemoglobin) with arrhythmias in CKD. NT-proBNP and 
hs-cTnT were associated with many major arrhythmias. Electrolytes were associated with 
some arrhythmias, while hemoglobin was not robustly associated with any arrhythmias. 
Fourth, we characterized the diurnal patterns of intermittent AF and assessed 
whether they vary by CKD status. There was a biphasic pattern of AF with a peak 
occurring around midnight and a nadir around noon.  
Taken together, this dissertation provided a broader understanding of the burden 
of various arrhythmias, their risk factors and markers, and a diurnal pattern of AF in 
CKD. Our research highlights the relevance of various arrhythmias in CKD and the 
importance of cardiac overload and injury in the pathophysiology of arrhythmias, while 
demonstrating a diurnal pattern of AF with potential clinical implications.  
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Chronic kidney disease (CKD) is characterized by either or both of a reduced 
kidney function, as measured by estimated glomerular filtration rate (eGFR), and kidney 
damage, as typically measured by albuminuria. CKD affects more than 10%-15% of the 
adult population globally1 and increases of the risk of cardiovascular disease (CVD). 
Indeed, CVD is the leading cause of death in individuals with CKD.2-4  
Sudden cardiac death (SCD), often due to a cardiac arrhythmia, is a major 
contributor of cardiovascular mortality in CKD.5 Indeed, end-stage renal disease patients 
have an overwhelmingly high rate of SCD that accounts for up to 25% of all deaths.6,7 In 
earlier stages of CKD, kidney function and albuminuria are also associated with an 
increased risk of SCD.8,9 An abnormal myocardium vulnerable to irregular ventricular 
conduction and electrolyte abnormalities are considered to play an important role in the 
development of various arrhythmias in CKD,5,10 but the actual burden and underlying 
pathogenesis of different arrhythmias in this clinical population are not well-understood.  
This is a critical knowledge gap to strategize effective and efficient prevention and 
management of life-threatening arrhythmias in vulnerable population with CKD. 
Limited data on arrhythmias across all stages of CKD 
Previous studies reporting prevalence estimates of arrhythmias in CKD have been 
limited to individuals with end-stage renal disease requiring dialysis treatments and/or 
specific types of arrhythmias. As shown in Table 1, there are more studies available 
 2 
among the dialysis population. However, considering the fact that only approximately 1-
1.5% of individuals with CKD are in end-stage,11 it is important to explore CKD patients 
who are not receiving dialysis treatments.  
In terms of types of arrhythmias, most previous studies explored a single type of 
arrhythmia, atrial fibrillation (as shown in Table 1). This suggests an important 
relationship between CKD and prevalent atrial fibrillation; however, the burden of other 
types of arrhythmias, such as ventricular tachycardia or prolonged pauses, remain 
unclear, especially among those with CKD not requiring dialysis.12,13  
Even for the relationship between CKD and atrial fibrillation, when we dig the 
literature deeper, most studies only investigated kidney function but not kidney damage 
in this context (Table 2). This is important to consider because CKD is examined as 
measure of both kidney function and damage (albuminuria), as recommended by the 
Kidney Disease: Improving Global Outcomes (KDIGO guidelines) (Figure 1). 
Furthermore, many studies have shown that albuminuria is a potent predictor (often 
stronger than kidney function) of various cardiovascular phenotypes, therefore, our 
current understanding of CKD and atrial fibrillation may be underestimated.  
The limitations of current heart rhythm monitoring practice 
Conventional first-line methods of heart rhythm monitoring such as the clinical 
12-lead electrocardiogram (ECG), which records for ~10 seconds, or the ambulatory 
Holter monitor, which records for 24-48 hours, have a low diagnostic yield, as many 
 3 
arrhythmias are paroxysmal and asymptomatic, and can take longer time to detect. For 
asymptomatic arrhythmias, individuals may not even seek an opportunity undergo an 
ECG test. These arrhythmias are important to diagnose, as asymptomatic or undetected 
paroxysmal arrhythmias can also lead to adverse events.14  
A new wearable ECG patch can overcome current limitations  
The Zio Patch (iRhythm Technologies Inc., San Francisco, California) allows for 
up to 14 days of monitoring, which is one of the longest monitoring periods offered by a 
small non-invasive ECG patch (Figure 2). Two weeks of monitoring is suggested to be 
the optimal duration for monitoring, as a past study on invasive cardiac monitoring has 
demonstrated that the diagnostic yield of arrhythmias significantly decreases after two 
weeks (1.04, 0.15, 0.01 additional diagnoses per patient in week 1, 2, 3, respectively).15 
Studies comparing the Zio Patch to the conventional Holter monitor have also shown that 
the Zio Patch can detect more arrhythmic events (Table 3) and is more comfortable and 
easier to use without the need for removal, thereby allowing a timelier detection of events 
that could be missed by the Holter monitor.16  
 To date, only a few studies have used the Zio Patch to describe the prevalence of 
arrhythmias in patients who have clinical indications (e.g., those with history of stroke or 
transient ischemic attack, those undergoing evaluation or management for atrial 
fibrillation, etc.) for undergoing Zio Patch monitoring.16-19 However, data on the presence 
of different arrhythmias in a community-based setting are sparse. This device will allow 
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us to compare the burden of various types of arrhythmia in individuals with and without 
CKD. Moreover, with the continuous ECG monitoring data, we can characterize diurnal 
patterns of arrhythmias that may be unique to the CKD population and have potential 
clinical implications.  
Importance of identifying risk factors or markers associated with arrhythmias in 
CKD 
Although quantifying disease burden is a critical initial step for strategizing 
disease prevention and management, kidney function (estimated by eGFR) itself is not 
currently modifiable, and it is unclear whether circulating biomarkers can help better 
predict the risk of arrhythmias in CKD. Thus, it is crucial to identify modifiable risk 
factors or markers of arrhythmias to better manage or risk stratify individuals with CKD 
at a high risk of arrhythmias. Due to the limited data on the burden of arrhythmias in 
CKD, the risk factors or markers for various arrhythmias in CKD have not been 
intensively evaluated. Previous studies identified age, sex, race, smoking, cardiovascular 
disease, C-reactive protein, and left ventricular hypertrophy as risk factors for prevalent 
atrial fibrillation in CKD;20,21 however, the association of cardiac biomarkers, 
electrolytes, or anemia have not been widely studied in association with various 
arrhythmias in CKD. We will therefore focus on cardiac biomarkers, electrolyte 
imbalance, and anemia, as these are common complications in CKD and play important 
roles in the cardiac action potential as well as cardiac inotropy and chronotropy. 
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Biologically, serum levels of potassium play critical roles in the electrical 
conduction of the heart.22 Magnesium, alongside potassium, has also been implicated in 
electrophysiological alterations leading to ventricular arrhythmias.23 Epidemiologic 
studies have thus demonstrated that these electrolyte levels are associated with 
cardiovascular mortality and/or SCD; however, their associations with various 
arrhythmias across stages of CKD are unknown.22,24-27  
In comparison to electrolytes, the associations of circulating biomarkers such as 
natriuretic peptide and troponin with various arrhythmias remain relatively unclear, 
especially by CKD status. Some studies have previously demonstrated a potential link 
between cardiac biomarkers and atrial fibrillation or ventricular tachycardia;28-37 
however, these studies did not examine the relationships in the context of CKD. 
Furthermore, the extent to which the cardiac biomarkers may be associated with other 
types of arrhythmias are unclear according to the literature. It is possible that cardiac 
biomarkers could be robust markers of various arrhythmias, as levels of natriuretic 
peptide and troponin could change as a consequence of cardiac stress and damage that 
could either precede or follow arrhythmias.28,33,38   
Anemia is implicated in left ventricular remodeling, which can subsequently lead 
to adverse cardiovascular outcomes; however, the association of anemia with arrhythmia 
across CKD stages similarly remains unknown.39 
Characterizing diurnal patterns of atrial fibrillation over two weeks 
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  The importance of chronobiology in cardiovascular-related functions such as 
blood pressure have been described previously;40 however, the temporal structure of 
arrhythmias, especially of atrial fibrillation among CKD given the relatively robust 
relationship between the two, has not been well-studied9,41 because most of these studies 
have looked at the presence or incidence of atrial fibrillation as a dichotomous outcome. 
To date, very few studies have explored the diurnal patterns of intermittent atrial 
fibrillation and found inconsistent results, with studies reporting different numbers and 
timing of peaks and/or nadirs. Also, some studies were limited in terms of data collection 
by monitoring only for 24 hours or with a transtelephonic ECG relying on patient 
symptoms or focusing on a specific study population such as those with implantable 
cardioverter defibrillator.42-46 Furthermore, some studies investigated only the first 
episodes of atrial fibrillation, without accounting for repeated episodes and some 
inadequately treated all episodes within the same individual as independent uncorrelated 
events. Moreover, none investigated whether diurnal patterns vary by CKD status.  
  Based on findings from past studies, we propose to characterize diurnal patterns 
of atrial fibrillation and how these may vary by CKD. Identifying the circadian variation 
of atrial fibrillation may help uncover underlying biological mechanisms and may have 
therapeutic implications (e.g., timing of taking antiarrhythmic medication). Furthermore, 
as arrhythmias are often difficult to detect, identifying ‘high-risk’ times of onset may help 
guide future monitoring efforts to maximize the chance of detection. By characterizing 
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the diurnal patterns of atrial fibrillation, this research will also lay the methodological 
groundwork for examining the diurnal patterns of other arrhythmias in the future. 
Study aims 
  The objective of the proposed research is to examine the overall burden (presence, 
frequency, and percent time), risk factors or markers, and diurnal patterns of various 
arrhythmias in CKD using the Zio Patch in community-dwelling older adults. The 
specific aims are to:  
Aim 1) Conduct a systematic review and meta-analysis to summarize the relationships 
between CKD and various types of arrhythmia 
Aim 2) Examine the two-week summary measures of the burden (presence, frequency, 
and percent time) of various arrhythmias by CKD status 
Aim 3) Identify CKD-related risk factors or markers of various arrhythmias  
Aim 4) Characterize the diurnal patterns of atrial fibrillation how the patterns vary by 
CKD status 
Dissertation data source 
  For Aims 2-4, the analyses were performed using data from the ARIC study. The 
ARIC study was originally designed to investigate the natural history of atherosclerotic 
disease from midlife to late-life. It is an ongoing study with participants recruited from 
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four U.S. communities: Forsyth County, NC; Jackson, MS; suburbs of Minneapolis, MN; 
and Washington County, MD. Detailed rationale and study design have been described 
previously.47 At the baseline study examination (visit 1) during 1987-1989, the study 
included 15,792 men and women aged 45-64 years, and participants were followed up for 
six visits (visit 2 in 1990-1992, visit 3 in 1993-1995, visit 4 in 1996-1998, visit 5 in 2011-
2013, visit 6 in 2016-2017, visit 7 in 2018-2019). The proposed research used data from 
study visit 6, when Zio Patch was first applied to ARIC participants. 
  Generally, study visit clinic examinations included measurements of 
cardiovascular conditions and risk factors through the following elements: sitting blood 
pressure; anthropometry; venipuncture (for blood samples to be analyzed); interviews for 
medical history, and medication use. In addition to clinic examinations, participants were 
followed up with annual phone interviews, which changed to semi-annual interviews 
since 2012. The telephone questionnaire included questions on general health, 
hospitalization, and events such as stroke or transient ischemic attack. The community-
wide surveillance component alongside study examinations and semi-annual 
questionnaires were used to identify medical events including hospitalizations.  
 Arrhythmias were primarily measured through the Zio Patch. The Zio Patch 
devices were administered at the ARIC study visit 6 as part of an ancillary study (PI: Dr. 
Lin Y. Chen). Approximately 4,000 participants who attended visit 6 and did not have a 
pacemaker or an implantable cardioverter defibrillator (ICD) were asked to wear the Zio 
Patch, and ~2,600 complied. Each participant wore the device for up to two weeks and 
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mailed it back to iRhythm (San Francisco, California), where the heart rhythm data were 
processed using a proprietary algorithm, various arrhythmias were diagnosed, and the 
results were reviewed by a trained cardiology technician. The Zio Patch diagnosed 
various major and minor types of arrhythmias as listed in Table 4. We had access to two 
types of data for each arrhythmia: summary-level data (i.e., presence, frequency, percent 
time) and a more granular dataset consisting of time-specific episodic data (i.e., time of 
onset and start/end time). For logistical reasons, the time-specific episodic data were only 
available for atrial fibrillation. The summary-level data was used for Aims 2 and 3, and 
time-specific episodic data was used to examine diurnal patterns in Aim 4. 
 
Dissertation structure 
  This dissertation comprises of four chapters that correspond to the four aims and a 
conclusion. Each chapter is written in manuscript format. The conclusion section 
summarizes and discusses the overall findings from the dissertation and outlines the steps 
for future research.  
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Chronic kidney disease, non-dialysis Dialysis 
# studies Study 
population size 
range 
Prevalence range, % 




Atrial/Supraventricular       
Atrial fibrillation 420,21,48,49 900-27,000 3-20 2241,50-52 60-200,000 3-27 
Premature atrial 
contractions 
0 - - 253,54 94-221 7-56 
Bradycardia 0 - - 113 66 20 
Asystole 0 - - 113 66 9 
Atrioventricular       
Atrioventricular block 0 - - 154 221 5 
Ventricular       
Ventricular fibrillation 0 - - 255,56 75-110 14-65 
Ventricular tachycardia 0 - - 313,55,56 66-110 2-64 
Ventricular arrhythmias, 
premature contraction  
157 111 35 253,54 94-221 12-8553,54,57 
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Table 2. Associations of kidney disease measures with prevalent arrhythmias 
 
Authors (year) Arrhythmia(s) Kidney disease measure(s) Adjusted estimate(s) (95% confidence interval) 
Iguchi et al (2008)58 AF eGFR 
OR 1.91 (1.54-2.38) for eGFR<63 vs >76 
OR 1.12 (0.88-1.42) for eGFR 63-76 vs >76 
McManus et al (2009)48 AF eGFR, ACR 
OR 3.37 (1.02-11.14) for eGFRcys<62 vs >79 
OR 1.59 (0.57-4.40) for eGFRcr<66 vs >85 
OR 4.36 (1.45–13.05) for ACR>15 vs <7 
Soliman et al (2010)21 AF eGFR OR 1.12 (0.92-1.35) for eGFR<45 vs 45 
Ananthapanyasut et al 
(2010)49 AF eGFR 
OR 1.01 (0.99-1.02) per 1 unit of eGFR 
Deo et al (2010)59 AF eGFR, cystatin C 
OR 1.22 (0.89-1.66) per 1 unit of eGFR 
OR 1.53 (1.03-2.28) for highest vs lowest quartile 
of cystatin C 
Liu et al (2011)60 AF eGFR, creatinine 
OR 1.00 (0.98-1.02) per 1 unit of creatinine 
OR 0.98 (0.95-1.00) per 1 unit of eGFR 
Baber et al (2011)20 AF CKD stages OR 2.86 (1.38-5.92) for CKD stage 4-5 vs no CKD 
Suzuki et al (2012)61 AF eGFR, proteinuria 
OR 0.99 (0.98-1.00) per 1 unit of eGFR 
OR 0.90 (0.55-1.48) for proteinuria vs no 
proteinuria  
Gorczyca-Michta et al 
(2013)62 AF eGFR 
OR 0.99 (0.98-0.99) per 1 unit of GFR 
Ohyama et al (2013)63 AF eGFR OR 2.66 (1.07-6.60) eGFR<60 vs 90 
Liu et al (2015)64 AF Cystatin C OR 1.93 (1.12-3.07) per 1 unit of Cystatin C 
Ohsawa el at (2016)65 AF ESRD 
PR 2.53 (1.88-3.19) for dialysis vs community 
dwellers 
Mene-Afejuku et al (2017)66 VT, PVC Creatinine 
OR 0.002 per 1 SD increase in creatinine for PVC 
OR 4.22 per 1 SD increase in creatinine for VT 
Yonezawa et al (2018)67 AF eGFR, creatinine clearance OR 1.58 (0.86-3.09) for eGFR<60 vs >90 
AF=atrial fibrillation; VT=ventricular tachycardia; PVC=premature ventricular contraction; ESRD=end-stage renal disease; OR=odds 
ratio; SD=standard deviation; eGFR=estimated glomerular filtration rate 
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Figure 1. Chronic kidney disease (CKD) status and prognosis by glomerular filtration rate (GFR) and 
albuminuria 
 
Figure from http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf 
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Holter (24 hours) 
Any of 6 arrhythmias 
  No At least 1 
Zio XT Patch (total 
wear time) 
Any of 6 arrhythmias 
No 49 1 
Yes 36 
60 
Six arrhythmias include atrioventricular block, pause, polymorphic ventricular tachycardia, 
supraventricular tachycardia, ventricular tachycardia, or atrial fibrillation 
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occurrence of at 
least one episode 
during two 
weeks (i.e., yes 
or no for each 
arrhythmia) 





two weeks or 
percent of total 
analyzable time 
 X X X X X X 
Percent time: 
percentage of 
device wear time 
spent in 
arrhythmia  
X       





X       
Start and end 
time of each 
episode 
X       
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Chapter 1. Chronic Kidney Disease and Cardiac 
Arrhythmias: A Systematic Review and Meta-Analysis  
 
Co-authors: Ning Ding, Junichi Ishigami, Manabu Hishida, Xuejuan Ning, Yijing Feng, 
Josef Coresh, Lin Y. Chen, Kunihiro Matsushita 
Abstract 
Rationale & Objective: Chronic kidney disease (CKD) strongly predicts sudden cardiac 
death and may elevate the risk of certain cardiac arrhythmias like atrial fibrillation (AF); 
however, the relationships between different measures of CKD and various types of 
arrhythmia are not well-characterized.  
Study design: Systematic review and meta-analysis. 
Setting & Study populations: Adults with measures of CKD and arrhythmia. 
Selection criteria for studies: Embase and PubMed were searched for prospective, cross-
sectional, and case-control studies that were published until July 2018. We performed 
qualitative assessment of studies using the Newcastle Ottawa Quality Assessment Scale.  
Analytical approach: Pooled estimates were obtained using random-effects model. 
Results: Among 16,245 articles, we identified 33 prospective (n=24,159,972), 21 cross-
sectional (n=253,328), and 4 case-control (n=217,932) studies that included diverse study 
populations from 19 countries and were mostly high quality. Twenty-four prospective 
studies examined the relationship between estimated glomerular filtration rate (eGFR) 
and AF, and demonstrated that lower eGFR was associated with a higher risk of AF 
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(pooled hazard ratio [HR] for AF 1.72 [95% CI: 1.30, 2.27] comparing reduced vs. 
referent eGFR groups). A few studies demonstrated that higher albuminuria was 
associated with AF (pooled HR for AF 2.16 [95% CI: 1.74, 2.67] comparing high vs. low 
albuminuria). Results were similar for cross-sectional studies. Several prospective studies 
examined ventricular arrhythmias inducing implantable cardioverter-defibrillator (ICD) 
shock and reported a higher incidence in the reduced eGFR group (pooled HR for ICD 
shock 2.32 [95% CI: 1.74, 3.09] comparing reduced vs. referent eGFR groups). Only four 
studies examined other types of arrhythmia. 
Limitations: High heterogeneity across prospective studies and exclusion of non-English 
articles. 
Conclusion: We identified robust data on the CKD-AF relationship. In clinical population 
requiring ICD, reduced kidney function was associated with life-threatening ventricular 
arrhythmias. Our review also highlights a large gap in knowledge on other types of 
arrhythmia in CKD. 
Introduction 
Chronic kidney disease (CKD) is characterized by reduced kidney function or 
kidney damage and is a major public health problem that affects over 10% of adults 
worldwide.1,68-71 Individuals with CKD, especially at advanced stages, have a high risk of 
sudden cardiac death (SCD), which suggests that they may also have a high burden of 
cardiac arrhythmias.9 Indeed, several studies have demonstrated that there may be a 
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relationship between CKD and the prevalence or incidence of some types of arrhythmia 
such as atrial fibrillation and ventricular arrhythmias.61,72,73 These relationships, however, 
are not necessarily well-characterized due to the inconsistent definitions for CKD (e.g., 
estimated glomerular filtration rate [eGFR], albuminuria) across studies.41 Therefore, it is 
important to identify all studies examining the associations between different measures of 
CKD and arrhythmias in order to make appropriate comparisons and conclusions.  
Furthermore, it is unknown if and how CKD is associated with arrhythmias other 
than atrial fibrillation or ventricular arrhythmias such as bradycardias and 
supraventricular arrhythmias. Recent studies have implicated bradyarrhythmia in addition 
to ventricular arrhythmia as the terminal arrhythmia leading to SCD in CKD, suggesting 
that CKD patients may have a high burden of arrhythmias that are not as widely 
studied.12,13 Therefore, it is imperative to review the literature and examine the burden of 
all types of arrhythmia in this high-risk population to provide a better knowledge base of 
the relationships between CKD and various types of arrhythmia. We therefore conducted 
a systematic review and meta-analysis of studies reporting relationships between CKD 
and various types of arrhythmia. 
Methods 
Literature search strategy 
This systematic review was conducted and reported in accordance with the 
recommendations by the PRISMA guideline.74 Based on the pre-determined protocols, 
 19 
we systematically searched prospective, cross-sectional, and case-control studies that 
examined the association between CKD and arrhythmias in adults aged 18 years or older. 
We did not impose any restriction on the year of publication. Our search excluded case 
reports, case series, conference abstracts, narrative reviews, and articles not written in 
English.  
The main exposure of interest was any measure of CKD and included various 
terms related to kidney disease such as CKD, renal insufficiency, kidney failure, dialysis, 
uremia, creatinine, cystatin C, eGFR, beta-2-microglobulin, albuminuria, proteinuria, 
albumin-creatinine ratio (ACR), and urine excretion of albumin or protein. As for the 
comparison group, since our objective was to examine the association between CKD and 
cardiac arrhythmia, we were interested in including studies that compared more than one 
CKD stage (or group or category) so that relative estimates of arrhythmia burden across 
CKD severity could be provided. 
The primary outcome was any type of cardiac arrhythmia that included but was 
not limited to the following: tachycardia, bradycardia, atrial fibrillation or flutter, 
atrioventricular block, long pause, premature atrial or ventricular contraction, torsades de 
pointes, sick sinus syndrome, and other heart rhythm abnormalities.  
We performed the literature search on Embase and PubMed for all relevant 
articles on July 11, 2018 using a detailed search strategy as outlined in Table A-1.  
Study selection 
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All articles found through our search strategy were exported to EndNote X7 
reference manager (Clarivate Analytics; Thomson Reuters, Philadelphia, PA) by an 
author (ND) who sorted and removed duplicate articles. The remaining articles were then 
uploaded to Covidence (Melbourne, Australia), which was the main tool used to screen 
the articles. Six reviewers (EK, ND, JI, MH, XN, YF) worked in pairs to independently 
perform title and abstract screening of all articles. All conflicts were resolved by either 
one of the two reviewers (EK, ND) who did not initially screen the articles involved in 
the conflict. With the remaining articles, the same six reviewers working in pairs 
performed full-text screening using the same prespecified inclusion and exclusion criteria 
while recording reasons for exclusion. Conflicts were resolved by either one of the two 
reviewers (EK, ND) who did not screen the articles involved in the conflict. We focused 
on studies that demonstrated associations that adjusted for at least one other variable.  
Data collection and quality assessment  
Various data elements (as listed in Table A-2) were extracted from each article 
and recorded in Microsoft Excel (Microsoft Office Professional Plus 2016, Microsoft 
Corporation, Redmond, WA) by six reviewers (EK, ND, JI, MH, XN, YF) who worked 
in pairs. All conflicts were resolved by discussion between each pair of reviewers.  
 All studies were assessed for risk of bias and overall quality using variations of 
the Newcastle Ottawa Quality Assessment Scale (NOS).75 For prospective studies, we 
used the NOS for cohort studies (Table A-3), which evaluates the quality of studies by 
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assessing eight items related to selection, comparability, and outcome. The maximum 
possible score was nine, and a score greater than six was used to indicate a high-quality 
study. Cross-sectional studies were evaluated using the adapted version of NOS (Table 
A-4) which similarly assessed items related to selection, comparability, and outcome for 
a maximum possible score of ten.76 Studies with a score higher than seven were 
considered high in quality.77 Case-control studies were evaluated using the NOS for case-
control studies (Table A-5) that assessed eight items related to selection, comparability, 
and exposure.75 The maximum score was nine, and a score higher than six indicated high 
quality.78 The quality assessment was performed by pairs of the same six reviewers, and 
conflicts were resolved by discussion between each pair.  
Data synthesis and analysis 
We conducted a random-effects meta-analysis to pool the results of prospective 
studies and cross-sectional studies separately. We chose to categorize studies that 
examined post-operative arrhythmias among patients who underwent surgery as cross-
sectional because even though these studies included some follow-up time, the 
arrhythmias, mainly atrial fibrillation, were captured during relatively short post-
operative periods (typically <30 days). We further separated the analyses by arrhythmia 
type and different measures of CKD (either eGFR or any measure of albuminuria). We 
pooled the results only when there were more than two studies that examined the same 
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arrhythmia type and the same CKD measure. We did not pool results from case-control 
studies, as there was a limited number of studies.  
 To examine associations of eGFR with various arrhythmias, we pooled the results 
that included eGFR calculated based on serum creatinine or cystatin C. When pooling 
studies that handled eGFR as a categorical variable, we included the hazard ratios (HRs) 
(for prospective studies) or odds ratios (ORs) (for cross-sectional studies) that compared 
the reduced eGFR category (defined using the lowest eGFR category available below 60 
ml/min/1.73m2) versus the referent eGFR category (as chosen by the study authors). 
When pooling studies that included eGFR as a continuous variable, we rescaled the 
hazard HRs (for prospective studies) or ORs (for cross-sectional studies) so that we could 
examine the risk or odds of arrhythmias per -15 ml/min/1.73m2 of eGFR across studies. 
For studies that examined either ACR or proteinuria, we pooled the HRs or ORs that 
compared the highest category versus the lowest category. For all analysis, we included 
estimates from the most extended model (the model with the largest number of 
covariates) from each study.  
 We visually checked for potential publication bias using funnel plots. 
Heterogeneity of studies was assessed using the I2 statistic, and I2 > 75% was used to 
indicate high heterogeneity. A two-tailed P < 0.05 was considered statistically significant. 
All analyses were performed using Stata/SE, version 15 (StataCorp, LLC, College 




We found a total of 16,245 articles from Embase and PubMed. After removing 
the duplicates (n=69), 16,176 articles underwent title and abstract screening (Figure 1). 
Of those, we excluded 15,977 articles that did not meet our criteria of interest and 
screened the full texts of the remaining 199 articles. Of the 199 articles, we excluded 141 
articles that were available only as abstracts (n=88), only examined unadjusted 
associations of CKD with arrhythmias (n=17), did not examine arrhythmias (n=13) or 
kidney disease (n=8), did not include a comparison group (n=9), were reviews (n=5), and 
were duplicate publications (n=1). After full-text screening, we included 58 articles for 
qualitative and quantitative analysis (Figure 1).  
The majority of studies (n=47) examined atrial fibrillation, with its prevalence 
ranging from 1-59% depending on the study population characteristics, and some (n=7) 
examined ventricular arrhythmias that were recorded by implantable cardioverter-
defibrillators (ICDs). Very few examined other types of arrhythmias such as sick sinus 
syndrome, bradyarrhythmias, conduction system diseases, and supraventricular 
tachycardia. Most studies assessed CKD using eGFR, and some used either ACR or 
proteinuria in addition to eGFR. There were few studies that used serum creatinine or 
cystatin C without calculating eGFR, and used CKD or end-stage renal disease diagnoses 
based solely on International Classification of Diseases codes (Table 1).  The majority of 
studies were considered high quality (Table A-6). 
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 There were 33 prospective studies that altogether consisted of 24,159,972 
participants (Table 2)59,72,73,79-108 ; 21 cross-sectional studies consisting of 253,328 
participants (Table A-7)20,48,49,58-63,65,67,109-118; and four case-control studies with a total of 
1,694 participants  (Table A-8).64,66,119-121 The studies were published between 2003 and 
2018 and represented various countries from North America, Asia, and Europe. The 
study population characteristics were diverse, ranging from population-based cohorts to 
individuals with ICDs. The mean age of the study participants ranged from 35 to 75 
years, and the prevalence of cardiovascular disease and its risk factors varied 
considerably depending on the study population characteristics (hypertension [range 17-
85%], coronary artery disease [2-100%], heart failure [1-100%], and diabetes [3-56%]). 
Most prospective studies had a mean or median follow-up time of greater than 5 years, 
and the longest mean follow-up was 17 years.      
Atrial Fibrillation 
There were 13 studies that examined the association between eGFR as a 
categorical variable and incident atrial fibrillation (Table 3, Table A-9, Figure 
2).59,79,80,84,86,93,99,100,103,107,108 All studies except one reported that the reduced eGFR group 
(mostly defined as eGFR <30 or <60 ml/min/1.73m2) had a higher risk of atrial 
fibrillation compared to the referent eGFR group (mostly defined as eGFR ≥60 or ≥90 
ml/min/1.73m2) in their most extended models, and most associations were statistically 
significant. The pooled HR was 1.81 (95% CI: 1.43, 2.27; I2 = 75.1%). Among studies 
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that examined eGFR as a continuous variable, almost all studies demonstrated that lower 
eGFR was associated with a higher risk of atrial fibrillation (Table 4, Table A-10, 
Figure 3). The pooled HR for incident atrial fibrillation per -15 ml/min/1.73m2 in eGFR 
was 1.05 (95% CI: 1.02, 1.07; I2 = 80.3%).  
Of the 8 studies that examined the cross-sectional association of eGFR categories 
with atrial fibrillation (Table A-11, Figure A-1), all studies reported that the reduced 
eGFR groups were associated with higher odds of atrial fibrillation compared to the 
referent eGFR groups, with most associations showing statistical significance. The 
pooled OR for atrial fibrillation in reduced eGFR vs. referent eGFR was 1.83 (95% CI: 
1.49, 2.25; I2 = 34.1%). Of the 5 studies that examined eGFR as a continuous measure, 4 
studies similarly reported higher odds of atrial fibrillation per -15 ml/min/1.73m2 in 
eGFR (pooled OR 1.18 [95% CI: 1.01, 1.38], I2 = 69.3%) (Table A-12, Figure A-2).  
There were six prospective studies and three cross-sectional studies that examined 
albuminuria, ACR, or proteinuria, and all but two studies reported that compared to the 
lowest albuminuria group, the highest albuminuria group was associated with a higher 
risk or odds of atrial fibrillation (pooled HR 2.16 [95% CI: 1.74, 2.67], I2 = 74.1%, Table 
5, Table A-13, Figure 4; pooled OR 2.21 [95% CI: 1.05, 4.68], I2 = 70.8%, Table Aa-
14, Figure A-3). 
The funnel plots for studies examining the association of eGFR categories with 
atrial fibrillation did not depict evident publication bias (Figure A-4). The funnel plot for 
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studies examining the association of albuminuria with atrial fibrillation did not indicate 
signs of publication bias either. 
Ventricular Tachycardia or Fibrillation 
There were eight prospective studies that examined the incidence of ventricular 
tachycardia or fibrillation among participants with implanted ICDs. Of these, four studies 
assessed eGFR in relation to ICD therapy, and reported a 2-fold or 3-fold higher risk of 
ICD shock among the reduced eGFR group (eGFR <60 ml/min/1.73m2) compared to the 
referent eGFR group (eGFR >60 ml/min/1.73m2). The pooled HR was 2.32 (95% CI: 
1.73, 3.09; I2 = 0%) (Table 6, Table A-15, Figure 5). Other prospective studies 
examined ICD therapy or diagnosed ventricular arrhythmias with various CKD measures 
such as serum creatinine and diagnosed CKD or ESRD, and found that worse CKD was 
significantly associated with a higher risk of ventricular arrhythmias (Table A-16). One 
cross-sectional study by Soman et al. showed independent associations of lower 
creatinine clearance (CrCl) with different types of tachycardia (accelerated 
idioventricular rhythm, non-sustained and sustained ventricular tachycardia, and 
ventricular fibrillation) among patients in coronary care unit (Table A-16). Two case-
control studies by Dalal et al. and Mene-Afejuku et al. similarly reported statistically 
significant relationships between CKD as measured by eGFR or serum creatinine and 
ventricular tachycardia or fibrillation (Table A-16). 
Bradycardia 
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There were a limited number of studies that examined bradyarrhythmias (two 
prospective studies, one cross-sectional and one case-control study). Khurshid et al. and 
Jensen et al. examined the prospective associations of either diagnosed CKD or eGFR 
with the risk of bradyarrhythmias, conduction system diseases, or sick sinus syndrome 
after adjusting for various confounders, and found that bradyarrhythmias or conduction 
system diseases but not sick sinus syndrome were associated with CKD measures.  
 Soman et al. also examined a few bradyarrhythmias (i.e., complete heart block 
and asystole) cross-sectionally in relation to CrCl, and found that after adjusting for 
several important confounders, lower CrCl was associated with higher odds of both 
arrhythmias (Table A-16). In contrast, a case-control study by Lu et al. demonstrated no 
significant relationship between eGFR and symptomatic bradycardia (Table A-16). 
Discussion 
Our systematic review identified 58 relevant articles examining the associations 
of CKD measures with various arrhythmias, most of which were prospective and cross-
sectional in design. The majority of studies were high quality, published recently, and 
represented many countries (n=19) from North America, Europe, and Asia. Many studies 
were relatively large (n>1000) due to the inclusion of several population-based cohorts. 
Regardless of the study design, the majority of studies examined atrial fibrillation (81% 
focused on atrial fibrillation vs. 20% on ventricular tachycardia/fibrillation), and 
regardless of the definition for CKD (mostly based on eGFR, but also included 
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albuminuria), CKD was consistently associated with a higher risk of atrial fibrillation. 
There were several prospective studies that also examined life-threatening ventricular 
arrhythmias that were recorded by ICDs, and all studies demonstrated significant 
associations between lower kidney function and ICD shock. There were, however, no 
studies that examined albuminuria in this context. There were only a few prospective, 
cross-sectional, and case-control studies that examined other types of arrhythmia, and 
most relationships suggested that CKD was associated with higher risks of various 
arrhythmias (i.e., ventricular tachycardia and fibrillation, supraventricular arrhythmias, 
complete heart block, asystole, conduction system diseases); however, some of these 
studies used only diagnosis-based CKD and CrCl as measures of CKD, and no studies 
included albuminuria.  
 The robust association between CKD and atrial fibrillation corroborates and 
supports conclusions from the Kidney Disease: Improving Global Outcomes (KDIGO) 
conference which states that there generally seems to be an independent relationship 
between CKD and the risk of atrial fibrillation.41 Indeed, most associations between CKD 
and atrial fibrillation, regardless of the study population characteristics, were consistent 
and statistically significant.20,58,61-63,79-81,84,86,87,93,99,100,103,107-109,114 More importantly, our 
review further demonstrated that regardless of how eGFR is examined (i.e., as a 
continuous or categorical variable using different cutoffs), lower eGFR is strongly 
associated with a higher risk of atrial fibrillation, which suggests that this association may 
consistently exist across the full spectrum of eGFR.61,80,103,107 We further demonstrated 
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that in most studies that examined albuminuria, higher albuminuria is generally 
associated with a higher risk of atrial fibrillation, suggesting that the relationship between 
CKD and atrial fibrillation is robust.48,61,63,79,80,86,97,99  
 The second most frequently invested arrhythmia in the context of CKD was 
ventricular arrhythmias.72,83,105 Of note, compared to the associations for atrial 
fibrillation, the associations for ICD shock were stronger and more consistent, suggesting 
that worse kidney function may lead to a higher risk of lethal ventricular arrhythmias than 
atrial fibrillation. This finding is in line with past studies reporting higher incidence of 
SCD among CKD.8,9 The results that we examined, however, were among individuals 
with ICD; therefore, future studies are needed to further examine the burden of 
ventricular arrhythmia in CKD patients without ICD. Also, data regarding albuminuria 
and ventricular arrhythmia are warranted. 
Our study identified the limited evidence on the relationships of CKD with other 
arrhythmia aside from atrial fibrillation and ventricular arrhythmia-related ICD 
therapy.66,88,90,117,120,121 While a few studies reported significant associations of low eGFR 
or high serum creatinine levels with some types of tachycardia and 
bradycardia,66,88,90,117,120,121 there still remains a large gap in knowledge about the burden 
of various arrhythmias across the spectrum of CKD including eGFR and albuminuria 
stages.  
There are several potential mechanisms that may underlie the relationships 
between CKD measures and the risk of arrhythmias, though they are likely multifactorial. 
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For example, ischemic heart disease, heart failure, and left ventricular hypertrophy are 
common in CKD, and resulting cardiac damage and fibrosis may interfere the normal 
conduction in the heart triggering the development of atrial and ventricular 
arrhythmia.4,61,122-126 In addition, chronic pathophysiological conditions in CKD such as 
neuro-hormonal activations (e.g., renin-angiotensin-aldosterone, sympathetic nervous 
system), chronic inflammation, and electrolyte abnormality (e.g., high potassium, low 
magnesium) may also enhance the triggering of arrhythmia.61,127-131 Finally, multiple 
comorbidities surrounding CKD such as older age and diabetes may also have some 
roles. Nonetheless, it remains uncertain the extent to which certain pathophysiology is 
shared by the different types of arrhythmias.   
Our study overall highlights a few potential implications for clinical care and 
future research. The robust relationship between CKD and atrial fibrillation suggests that 
healthcare providers should pay attention to atrial fibrillation in patients with CKD. 
Whether and if so what kind of screening (e.g., 24-holter or longer monitoring using 
wearable devices16) are optimal in this clinical population requires future investigation. 
This is an important clinical question since the excess risk of stroke in CKD patients has 
been consistently reported.132 Similarly, our results suggest that it may be important to 
monitor and manage severe ventricular arrhythmias among this high-risk population. 
Since atrial fibrillation and ventricular arrhythmias can be simultaneously monitored, the 
value of arrhythmia monitoring in CKD should be evaluated comprehensively. The 
limited data on arrhythmias other than atrial fibrillation and ventricular arrhythmia may 
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be largely attributed to the shortcoming of conventional heart rhythm monitoring such as 
routine clinic ECGs and short-term ambulatory devices, which are likely to miss 
asymptomatic or transient arrhythmia episodes. However, recent advancements in 
continuous monitoring using non-invasive wearable ECG devices will allow us to 
investigate a number of arrhythmia types across CKD.  
There are a few limitations that should be noted in this study. Likely reflecting a 
heterogeneity of study designs, populations, and methods, we observed high 
heterogeneity across prospective studies when examining the relationship between eGFR 
and atrial fibrillation; therefore, the pooled estimates should be interpreted with caution. 
Nonetheless, the results were qualitatively consistent (i.e., similar direction of 
association) in most studies. Our review also excluded articles not written in English and 
may have excluded some studies from certain geographic regions; however, the articles 
that we identified were still representative of many countries from various continents.  
To our knowledge, this is the first systematic review and meta-analysis 
summarizing the associations of CKD with various arrhythmias. Our study summarizes 
that CKD is generally associated with atrial fibrillation and ventricular tachycardia or 
fibrillation; however, there are limited number of studies that include measures of 
albuminuria and other types of arrhythmia. Our review supports the importance of 
monitoring and appropriately managing the high burden of arrhythmias in CKD and 
highlights critical knowledge gaps to be addressed in future studies.  
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Table 1. Arrhythmia and chronic kidney disease measurements used in the 58 
studies included in the systematic review 
 
Prospective studies 
Reference Year Arrhythmia type Arrhythmia 
measurement 
Chronic kidney disease 
measurement 
Alonso  2011 AF Diagnosis codes eGFR; ACR 
Babu 2016 VF/VT ICD eGFR  
Bansal 2017 AF ECG, diagnosis 
codes 
eGFR; ACR 
Deo§ 2010 AF ECG, diagnosis, self-
report 
eGFR; cystatin C 
Eisen 2017 AF Diagnosis codes eGFR 
Elahi 2003 AF ECG, notes Renal failure based on 
serum creatinine 
Hage  2011 ICD therapy ICD  eGFR 
Hai 2017 Sudden arrhythmic 
death or sustained VT 
requiring ICD 
therapy 
Death, ICD eGFR 
Horio 2010 AF ECG eGFR and proteinuria 
combined 
Hreybe 2006 ICD shock for VF or 
VT 
ICD Serum creatinine 
Hsu 2013 AF and flutter Diagnosis codes eGFR; proteinuria 
Iguchi 2010 AF ECG eGFR 
Jensen 2013 AF ECG, diagnosis 
codes 
Cystatin C 
Jensen 2014 Sick sinus syndrome Diagnosis codes eGFR; cystatin C 








Diagnosis codes CKD based on diagnosis 
codes 
Kreuz 2010 ICD therapy for 
malignant ventricular 
arrhythmias 
ICD Serum creatinine 
Kreuz 2011 ICD therapy for 
malignant ventricular 
arrhythmias 
ICD Serum creatinine 
Laukkanen 2016 AF Linkage to registry eGFR 
Lee 2016 AF Diagnosis codes ESRD based on diagnosis 
codes 
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Liao 2017 AF Diagnosis codes ESRD based on diagnosis 
codes 
Liao 2015 AF Diagnosis codes ESRD based on diagnosis 
codes 
Lim 2017 AF Diagnosis codes Proteinuria 
Marcos 2017 AF ECG eGFR; cystatin C; serum 
creatinine; urine albumin; 
ACR; urine albumin 
excretion 
Molnar 2017 AF Diagnosis codes eGFR; ACR  
Naruse 2011 AF recurrence ECG eGFR 
Nelson 2012 AF Diagnosis codes CKD based on diagnosis 
codes 
Robin 2006 ICD shock for VF ICD ESRD 




Shen 2016 AF Diagnosis codes ESRD 
Takahashi 2009 ICD shock for VF ICD eGFR 
Tokuda 2011 AF recurrence ECG eGFR 
Watanabe 2009 AF ECG eGFR 
Xu 2015 AF ECG eGFR 
Cross-sectional studies 
Reference Year Arrhythmia type Arrhythmia 
measurement 
Chronic kidney disease 
measurement 
Ananthapanyasut 2010 AF ECG, medical record eGFR 
Auer 2007 AF ECG, notes eGFR 
Baber 2011 AF ECG eGFR and ACR combined 
Chua 2013 AF ECG eGFR 
Deo§ 2010 AF ECG, diagnosis, self-
report 
eGFR; cystatin C 
Deshmukh 2017 AF ECG, implantable 
device, telemetry 
Serum creatinine 
Gorczyca-Michta 2013 AF Medical records eGFR 
Hashemzadeh 2013 AF ECG Renal dysfunction based on 
creatinine* 
Iguchi 2008 AF ECG eGFR 
Karatas 2015 AF ECG Serum creatinine 
Limite 2016 AF ECG eGFR 
Liu  2011 AF ECG, medical record eGFR; serum creatinine 
McManus 2009 AF ECG eGFR; ACR 
Nisanoglu 2007 AF ECG Renal dysfunction based on 
serum creatinine 
Ohsawa 2016 AF ECG Dialysis 
Ohyama 2013 AF ECG eGFR; proteinuria 
Soliman 2010 AF ECG, self-report eGFR 
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Soman 2002 AF or flutter, VT, 
VF, complete heart 
block, asystole 
Charts CrCl; dialysis 
Suzuki 2012 AF (paroxysmal, 
persistent) 
ECG eGFR; proteinuria 
Todorov 2017 AF (new onset, 
permanent) 
Patient files Serum creatinine 
Yonezawa 2018 AF ECG eGFR; creatinine clearance 
Case-control studies 
Reference Year Arrhythmia type Arrhythmia 
measurement 
Chronic kidney disease 
measurement 
Dalal 2012 VF ECG eGFR 




Lu 2016 Symptomatic 
bradycardia 
ECG eGFR 
Mene-Afejuku 2017 PVC, VT ECG Serum creatinine 
 
CKD=chronic kidney disease; AF=atrial fibrillation; VT=ventricular tachycardia; 
VF=ventricular fibrillation; PVC=premature ventricular contraction; ICD=implantable 
cardioverter defibrillator; eGFR=estimated glomerular filtration rate; ACR=albumin-
creatinine ratio; ESRD=end-stage renal disease 
§ This study is listed as both prospective and cross-sectional because it includes 
examinations of incident and prevalent atrial fibrillation 
* Unable to identify if creatinine is serum or urine creatinine 
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Table 2. Summary of 34 prospective studies included in the systematic review  
 











































Bansal 2017 USA 16,769 Population-based  63.1 (12.0) 41.6 - 12.8 
129.8 





Deo§ 2010 USA 4,663 
Population-based 


















CABG surgery 63.9 (8.7) 78.9 58.2 6.1 - 100 - - 19.7 1 year 





















heart disease 63.0 (11.0) 52.0 - 48.0 
146.0 














Hsu 2013 USA 30,533 
Population-based 
outpatients with 




Iguchi 2010 Japan 30,010 Population-based 
73.0 (66.0-
78.0)* 32.9 46.8 7.1 
132.0 
(120.0-
144)* - - - - 1 year 
Jensen 2013 USA 5,685 Population-based 72.7 (5.7) 42.0 65.2 - 
136.3 




Jensen 2014 USA 20,572 
Community-
based cohort 58.9 (10.1) 43.5 40.9  
125.4 




Khurshid  2018 
United 
Kingdom 502,627 Population-based 
58.0 (50.0-
63.0)* 45.6 28.4 11.2 - 3.1 0.6 1.6 5.5 
Median 
7 years 

















n 2016 Finland 1,840 Population-based 71.1 (5.8) 66.9 - - 
135.0 



















Liao 2017 Taiwan 18,617 
Population-based 
cohort with and 
without COPD 62.0 (11.5) 75.4 29.9 - - - 1.98 7.71 7.8 
15 
years  
Lim 2017 Korea 18,201,275 Population-based 45.3 (14.6) 53.3 28.7 26.0 
123.4 








participants 49.0 (13.0) 49.8 27.8 44.7 
129.0 





Molnar 2017 Canada 736,666 Population-based  59.8 (12.2) 50.4 59.0 - - 15.3 4.4 1.0 42.4 
Median 
6 years 










Nelson 2012 USA 1,092,649 Medicare-based 
70.0-












Sciacqua 2014 Italy 3,549 Population-based  60.7 (10.6) 52.4 67.9 39.4 
142.1 

































e 2009 Japan 223,877 Population-based 60.9 (11.7) 32.0 - - 
129.8 




Xu 2015 Japan 132,250 Population-based 59.3 (9.3) 31.5 - 27.6 
133.5 





* Median with interquartile interval 
** Characteristics of only those without cardiovascular disease 
*** Age range for 25% of the study population 
^ Percentage of participants with LVEF <30% 
& Among the control group 
$ In the JHS study only 
















HR (95% CI)  Adjusted HR (95% CI)  
Adjusted covariates** 
Age Sex Race 
Blood  
pressure Diabetes Smoking Lipids Other 
Watanabe 2010 ≥60,  
30-59,  
<30 
≥60 Not reported 30-59: 1.29 (1.05-1.58),   
<30: 1.42 (0.81-2.51) ✓ ✓  ✓ ✓   ✓ 





✓ ✓  ✓ ✓  ✓ ✓ 




2.18 (1.21-3.90)  
✓     ✓  ✓ 




≥90 Not reported 60-89: 0.91 (0.76-1.09),  
30-59: 1.24 (0.97-1.57),  
15-29: 3.41 (1.50-7.76) 
✓ ✓ ✓ ✓ ✓ ✓  ✓ 




2.089 (1.292–3.378)  
✓ ✓      ✓ 
Hsu 2013 ≥60,  
30-59, 
 <30 
≥60 Not reported 30-59: 1.1 (0.8-1.4),  
<30: 1.7 (1.2-2.4) ✓ ✓ ✓  ✓ ✓  ✓ 
Sciacqua 2014 >60,  
≤60 
>60 Not reported 1.528 (1.261-1.851) 
✓ ✓   ✓ ✓ ✓ ✓ 
Xu 2015 ≥90,  
60-90,  
<60 
≥90 Not reported 60-90: 1.38 (1.21-1.56),  
<60: 2.56 (2.09-3.13) ✓ ✓  ✓ ✓ ✓ ✓ ✓ 
Laukkanen 2016 ≥90,  
60-89,  
15-59 
≥90 Not reported 60-89: 1.44 (0.99-2.11),  
15-59: 2.74 (1.56-4.81) ✓ ✓  ✓ ✓   ✓ 






>90 Not reported 60-90: 1.09 (1.06-1.13),  
45-60: 1.27 (1.21-1.32),  
30-45: 1.43 (1.36-1.51),  
15-30: 1.55 (1.41-1.69),  
<15: 1.69 (1.12-2.54) 
✓ ✓   ✓   ✓ 
Bansal: 
JHS 
2017 ≥90,  
60-89,  
45-59,  
≥90 Not reported 60-89: 1.32 (0.98, 1.76),  
45-59: 0.97 (0.51, 1.83),  
30-44: 1.86 (0.84, 4.13),  




<30: 1.06 (0.32, 3.50) 
Bansal: 
MESA 





≥90 Not reported 60-89: 1.09 (0.89, 1.34),  
45-59: 1.33 (1.00, 1.77),  
30-44: 1.62 (1.05, 2.51),  
<30: 2.94 (1.48, 5.83) 
✓ ✓  ✓ ✓ ✓  ✓ 
Bansal: 
CHS 





≥90 Not reported 60-89: 1.03 (0.86, 1.24),  
45-59: 1.12 (0.91, 1.38),  
30-44: 1.48 (1.12, 1.94),  
<30: 1.57 (0.94, 2.60) 
✓ ✓  ✓ ✓ ✓  ✓ 
 
eGFR is calculated using serum creatinine 
* indicates eGFR calculated among those with albumin-creatinine ratio <3 
** full list of covariates available in Table A-9  
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The diamonds and their widths represent HRs and 95% confidence intervals, respectively. The cutoff values for 
reduced and referent eGFR groups are (in ml/min/1.73m2): Watanabe (2009) <30 vs. ≥60, Deo (2010) <60 vs. ≥60, 
Horio (2010) <60 and proteinuria 1+ vs. ≥60, Alonso (2011) 15-29 vs. ≥90, Naruse (2011) <60 vs. ≥60, Hsu (2013) 
<30 vs. ≥60, Sciacqua (2014) ≤60 vs. >60, Xu (2015) <60 vs. ≥90, Laukkanen (2016) 15-59 vs. ≥90, Molnar (2017) 
<15 and ACR <3 vs. >90 and ACR <3, Bansal (2017) <30 vs. ≥90. 
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Table 4. Summary of prospective study results on the association between continuous eGFR and atrial 
fibrillation  
 
Study Year eGFR scale 
(ml/min/1.73m2) 
Unadjusted 
HR (95% CI)  
Adjusted HR (95% 
CI)  
Adjusted covariates* 
Age Sex Race 
Blood  
pressure Diabetes Smoking Lipids Other 
Watanabe 2009 Per -10  Not reported  1.02 (1.00-1.03) 
✓ ✓  ✓ ✓   ✓ 
Iguchi 2010 Per 10  Not reported 0.93 (0.87-0.99) 
✓ ✓   ✓  ✓ ✓ 
Tokuda 2011 Per 1 Not reported 0.96 (0.94, 0.99) 
       ✓ 
Sciacqua 2014 Per 10   0.94 (0.903-
0.977) 
0.94 (0.903-0.977) 
✓ ✓  ✓  ✓ ✓ ✓ 
Eisen: No CVD 2017 Per -10  Not reported 1.005 (0.998-1.011) 
✓ ✓   ✓   ✓ 
Eisen: With 
CVD 
2017 Per -10  Not reported 1.011 (1.005-1.018) 
✓ ✓   ✓   ✓ 
Bansal: JHS 2017 Per -20  Not reported 1.12 (0.96, 1.30) 
✓ ✓  ✓ ✓ ✓  ✓ 
Bansal: MESA 2017 Per -20  Not reported 1.21 (1.09, 1.35)  
✓ ✓  ✓ ✓ ✓  ✓ 
Bansal: CHS 2017 Per -20  Not reported 1.13 (1.05, 1.21) 
✓ ✓  ✓ ✓ ✓  ✓ 
Macros 2017 Per 15  0.73 (0.62–0.86) 1.19 (0.97–1.45) 
✓ ✓   ✓ ✓  ✓ 
 
* Full list of covariates listed in Table A-10 
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Figure 3. Hazard ratios (HRs) of atrial fibrillation per -15 ml/min/1.73m2 of eGFR from prospective studies  
 
 





Table 5. Summary of prospective study results on the association between albuminuria groups and atrial 
fibrillation 
 





HR (95% CI)  
Adjusted HR (95% CI)  
Adjusted covariates** 
Age Sex Race 
Blood  
pressure Diabetes Smoking Lipids Other 




<30 Not reported 30-299: 1.91 (1.53-2.39), 
≥300: 2.90 (2.07-4.06) 
✓ ✓ ✓ ✓ ✓ ✓  ✓ 







0 Not reported 30: 1.5 (1.2-1.8),  
100: 1.4 (1.0-2.0),  
300: 1.7 (1.1-2.5),  
≥2000: 2.5 (1.5-4.3) ✓ ✓ ✓  ✓   ✓ 








Negative Not reported Trace: 1.13 (1.10-1.16),  
1+: 1.34 (1.31-1.38),  
2+: 1.53 (1.48-1.58),  
3+: 1.82 (1.71-1.94),  
4+: 1.86 (1.61-2.16) 
✓ ✓   ✓ ✓ ✓ ✓ 
Bansal: 
JHS 





<15 Not reported 15-29: 1.21 (0.76, 1.95),  
30-299: 1.16 (0.74, 1.82),  
≥300: 1.18 (0.56, 2.46) ✓ ✓  ✓ ✓ ✓  ✓ 
Bansal: 
MESA 





<15 Not reported 15-29: 0.91 (0.71, 1.18),  
30-299: 1.44 (1.15, 1.82),  
≥300: 1.60 (0.97, 2.64) ✓ ✓  ✓ ✓ ✓  ✓ 




<3 Not reported 3-30: 1.52 (1.45-1.6),  
>30: 2.54 (2.31-2.79) 
✓ ✓   ✓   ✓ 
 
* Among those with eGFR >90 
** Full list of covariates in Table A-13 
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The diamonds and their widths represent HRs and 95% confidence intervals, respectively. The cutoff values for high 
and low albuminuria groups are: Alonso (2011): ACR ≥300 vs. <30 mg/g; Hsu (2013): Proteinuria ≥2000 vs 0 mg/dl; 
Lim (2017) Dipstick 4+ vs. negative; Bansal-JHS (2017): ACR ≥300 vs. <15 mg/g; Bansal-MESA (2017) ACR ≥300 
vs. <15 mg/g; 
Molnar (2017) ACR >30 vs. <3 mg/g. 
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Table 6. Summary of prospective study results on the association between eGFR groups and ICD shock 
 









(95% CI)  
Adjusted HR 
(95% CI)  
Adjusted covariates* 
Age Sex Race 
Blood 
pressure Diabetes Smoking Lipids Other 
Takahashi 2009 ≥60,  
<60 
≥60 1.81 (1.23-2.66) 1.85 (1.24-2.77) 
       ✓ 
Hage 2011 ≥60,  
<60 
≥60 Not reported 3.53 (1.75-7.10) 
✓ ✓      ✓ 






✓ ✓      ✓ 
Hai 2017 >60,  
<60 
>60 5.43 (2.86-10.33) 2.43 (1.21-4.92) 
✓       ✓ 
 










The diamonds and their widths represent HRs and 95% confidence intervals, respectively. The cutoff values (in 
ml/min/1.73m2) for reduced and referent eGFR groups are: Takahashi (2009) <60 vs. ≥60, Hage (2011) <60 vs. ≥60, 
Babu (2016) ≤60 vs. >60, Hai (2017) <60 vs. ≥60. 
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Chapter 2. Two-week burden of arrhythmias across 
chronic kidney disease severity in a large community-
based cohort: The Atherosclerosis Risk in Communities 
(ARIC) Study 
 
Co-authors: Elsayed Z. Soliman, Josef Coresh, Kunihiro Matsushita, and Lin Y. Chen 
 
Abstract 
Background: Chronic kidney disease (CKD) is associated with sudden cardiac death and 
atrial fibrillation (AF). However, other types of arrhythmias and different burden 
measures (e.g., presence and frequency) have not been well-characterized in CKD. We 
therefore comprehensively quantified the burden of arrhythmias across CKD severity in 
community-dwelling older adults. 
Methods: In 2257 ARIC participants aged 71-94 years who underwent 2 weeks of non-
invasive single-lead electrocardiogram monitoring using the Zio XT Patch, we examined 
the associations of major arrhythmias (AF, non-sustained ventricular tachycardia 
[NSVT], long pause [>3 sec], Mobitz II or complete atrioventricular block [AVB]) and 
minor arrhythmias (ventricular ectopy [VE], and supraventricular tachycardia [SVT] and 
ectopy [SVE]) with CKD severity categorized as no CKD (low risk) and CKD with 
moderate, high, and very high risk according to estimated glomerular filtration rate 
(eGFR) and albuminuria. We examined various types of arrhythmia burden: presence, 
frequency, and percent time in arrhythmia.  
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Results: CKD with very high risk (vs. no CKD) had a higher prevalence of AF (12.8% vs. 
5.0%), NSVT (37.4% vs. 25.8%), long pause (5.8% vs. 1.7%), and VE (99.2% vs. 
98.6%). After adjusting for potential confounders, CKD with higher risk remained 
significantly associated with the presence of AF and NSVT. When we examined other 
burden measures, CKD severity was significantly associated with a higher percent of 
time in AF, higher frequency of long pause and VE episodes, and a lower frequency of 
AVB. When eGFR and albuminuria were examined separately, albuminuria was more 
strongly associated with arrhythmias.  
Conclusions: CKD is associated with the presence of AF and NSVT. Additionally, CKD 
is related to percent time of AF and higher frequency of long pause and VE. Using a 
novel 2-week monitoring approach, this study found a broader range of arrhythmias 
associated with CKD than previously reported. 
Introduction 
Chronic kidney disease (CKD) is associated with an increased risk of sudden 
cardiac death (SCD),9 implying a high burden of cardiac arrhythmias in CKD. Previous 
studies, however, have focused mainly on atrial fibrillation (AF) or studied patients on 
dialysis,59,65,79,95,98,99,104,133 which mainly reflects the difficulty in detecting arrhythmias 
that can often be asymptomatic and transient. Recent findings demonstrating that 
bradyarrhythmia can lead to SCD13,134 and that the vast majority of persons with CKD are 
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not on dialysis135 highlight our incomplete understanding of the range of tachy- and 
bradyarrhythmias that are associated with CKD.  
  Recent advancements in wearable continuous electrocardiogram (ECG) devices 
that can monitor for a longer time allow us to investigate other arrhythmias that are 
asymptomatic and transient in populations other than dialysis patient samples. In 
addition, they can provide information on different measures of arrhythmic burden, such 
as the frequency of episodes and percent time in arrhythmias. We therefore used data 
from a two-week continuous ECG monitoring device in the Atherosclerosis Risk in 
Communities (ARIC) study to comprehensively examine various arrhythmias (e.g., AF, 
ventricular tachycardia, long pause, atrioventricular block) and different burden measures 
(i.e., prevalence, frequency, and percent time) across CKD severity. We hypothesized 
that more severe CKD is associated with a broader range of arrhythmias, especially when 
burden measures beyond mere presence or absence of arrhythmias are investigated. 
Methods 
Study design 
This study is a cross-sectional analysis using data from visit 6 (2016-2017) of the 
ARIC study, which was originally designed to investigate the natural history of 
atherosclerotic disease from mid- to late-life.47 The ARIC study design has been 
published previously.47 Briefly, 15,792 participants were recruited during 1987-1989 
from four communities in the U.S. (Forsyth County, NC, Jackson, MS, Minneapolis, MN, 
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and Washington County, MD) and completed the first study visit (visit 1). The 
participants subsequently completed six study visits (visit 2 in 1990-1992; visit 3 in 
1993-1995; visit 4 in 1996-1998; visit 5 in 2011-2013; visit 6 in 2016-2017; and visit 7 in 
2018-19). Additionally, they were contacted annually (semi-annually beginning in 2012) 
to obtain updated information on medical history and lifestyle. In visit 6, 4,003 
participants attended the study examination which included assessment for cardiovascular 
disease, cognitive function, and their risk factors, biospecimen collection, medication 
assessment, and a two-week continuous ECG monitoring. The ARIC study was approved 
by the institutional review board of each participating center, and written informed 
consent was obtained from participants at each study visit. 
Study population 
Of 4,003 visit 6 participants, those who did not have a pacemaker or an 
implantable cardioverter defibrillator were asked to undergo a two-week ECG 
monitoring, as detailed below. We excluded participants who did not undergo the 
continuous ECG monitoring (n=1,387), were missing CKD measures (n=194), and were 
non-white and non-black (n=6). We also excluded those who were missing any covariate 
of interest (n=147) (Figure B-1). The final analytical sample of this study was 2,257.  
Kidney disease measures 
The primary exposure of interest was CKD status, which was defined according 
to the Kidney Disease: Improving Global Outcomes (KDIGO) staging criteria for CKD 
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based on the comprehensive risk of adverse clinical outcomes: no CKD (low risk group), 
CKD with moderate risk, CKD with high risk, and CKD with very high risk.136 The 
groups were categorized based on a combination of values of estimated glomerular 
filtration rate (eGFR), which indicates kidney function, and albuminuria, which reflects 
kidney damage (Figure B-2). We also secondarily examined eGFR and albuminuria 
separately. eGFR was calculated based on the CKD-EPI equation using cystatin C,137 
which was measured in serum using Gentian Cystatin C reagent on the Roche Modular P 
Chemistry analyzer (Roche Diagnostics, Indianapolis, IN) with a laboratory inter-assay 
CV of 6.1% at a mean concentration of 0.94 mg/L. We used cystatin C rather than serum 
creatinine, as there is concern that age-related reduced muscle mass can overestimate 
eGFR in older individuals when using a creatinine-based equation.138 Albuminuria was 
measured using albumin-to-creatinine ratio (ACR), which was calculated by dividing 
urine albumin by urine creatinine as recommended by the KDIGO clinical practice 
guideline for CKD.139 Urine albumin was measured in urine on the ProSpec 
nephelometric analyzer using an immunoturbidometric method (Dade Behring GMBH. 
Marburg, Germany) with a laboratory inter-assay CV of 4.0% at a mean concentration of 
19.7 mg/L. Urine creatinine was measured on a Roche Modular P Chemistry Analyzer 
(Roche Diagnostics Corporation) using a creatinase enzymatic method (Roche 




The Zio XT Patch (iRhythm Technologies Inc., San Francisco, CA) is a Food and 
Drug Administration (FDA)-approved ECG skin patch that is single-lead, non-invasive, 
lightweight, and water-resistant monitor that allows ECG recording for up to 14 days.16 
Compared to the standard 24-hour Holter monitor, the Zio Patch is demonstrated to detect 
more arrhythmic events and shown to be more comfortable to wear.16 ARIC study 
participants were asked to wear the Zio Patch for up to 14 days and mail the device back 
to the manufacturer, where the ECG data were analyzed using a FDA-approved 
proprietary algorithm and underwent technical review. The following arrhythmias were 
detected by the Zio Patch and were included in this study: major types including AF, non-
sustained ventricular tachycardia, long pause lasting >3 seconds, and Mobitz type II or 
third-degree atrioventricular block; and minor types including ventricular ectopy, 
supraventricular tachycardia (not including AF), and supraventricular ectopy.  
 As a result of continuous monitoring, we were able to examine different measures 
of arrhythmic burden. We first assessed the presence of arrhythmias, dichotomous 
information of the occurrence of any arrhythmic episode during the monitoring period, 
and this was measured for all types of arrhythmias. We also assessed the frequency of 
arrhythmia during the monitoring period, which was defined as the number of episodes 
per day, and this was measured for all types of arrhythmias except for AF. For AF, 
instead, we examined the percent time in arrhythmia because the frequency of episodes 
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will not appropriately reflect the burden of longer lasting AF (e.g., the frequency equals 
one in the case of continuous AF). 
Covariate measurements 
All variables were assessed at ARIC study visit 6, except for education, which 
was measured at visit 1. Educational background was categorized as less than high 
school, graduated from high school or vocational school, or obtained college or 
graduate/professional degrees. Body mass index was calculated by dividing body mass 
(kg) by height squared (m2). Cigarette smoking and alcohol drinking was self-reported 
and categorized as current or noncurrent. Diabetes was defined as fasting plasma glucose 
≥126 mg/dL, non-fasting glucose ≥200 mg/dL, using medication for diabetes, or self-
reported physician diagnosis of diabetes. Total cholesterol and high-density lipoprotein 
(HDL) cholesterol were measured using an enzymatic method and the Olympus HDL-
Cholesterol test, respectively.140 Prevalent cardiovascular disease included coronary heart 
disease, heart failure, and stroke, which included self-reported prevalence and visit 1 and 
relevant events between visit 1 and visit 6 adjudicated by physician reviewers based on 
medical records from hospitalization data. Systolic and diastolic blood pressure were 
measured in a sitting position after five minutes of rest using a validated automatic 
sphygmomanometer (OMRON HEM-907 XL). The average of the last two of three 
measures was used. Use of antihypertensive medication in the past 4 weeks was assessed 
by self-report and confirmed with drug containers if available. Similarly, the use of 
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antiarrhythmic medications was recorded by inspecting the participants’ drug containers 
for all classes of antiarrhythmic medications. For certain types of antiarrhythmic 
medications that may have overlapping indications (i.e., beta-blockers may be used for 
some arrhythmias or hypertension), we used self-reported data to confirm if individuals 
have hypertension and classified the medications as antihypertensive drugs accordingly. 
We also identified medications that are commonly reported to be QT-prolonging (Table 
B-1),141 as QT prolongation can affect the risk of arrhythmias.142 
Statistical analysis 
We examined the distributions of all variables and summarized them using mean 
and standard deviation (SD) for normally distributed continuous variables; median and 
interquartile interval (IQI) for non-normally distributed variables; and frequency and 
percentage for categorical variables.  
The associations between CKD status and the presence of each arrhythmia were 
estimated using Poisson regression with robust variance to accommodate the high 
prevalence of some arrhythmias.143 The group with no CKD served as the reference 
group. The same method was used to examine eGFR and ACR separately.  
 The relationships between CKD measures and the frequency of arrhythmia 
episodes were estimated using a zero-inflated Poisson regression with robust variance to 
account for an excess of zero counts, taking into consideration the total analyzable wear 
time of the device as the offset variable to explore frequency as the rate of arrhythmias 
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across CKD status. The zero-inflation portion of the model included the same set of 
covariates as the Poisson model. The associations between CKD measures and percent 
time in AF were examined using linear regression.  
For all associations, we adjusted for potential confounders in a series of models: 
model 1 was unadjusted; model 2 adjusted for age, sex, race, study center, and education; 
model 3 additionally included body mass index, current smoking, alcohol use, systolic 
blood pressure, antihypertensive medication, diabetes, prevalent cardiovascular disease, 
total cholesterol, HDL cholesterol, antiarrhythmic and QT-prolonging medications. In 
analyses that examined eGFR or ACR as the main exposure, we additionally adjusted for 
ACR or eGFR, respectively, in model 3. When examining minor arrhythmias originating 
from the supraventricular region (i.e., supraventricular tachycardia and supraventricular 
ectopy), we excluded participants who had continuous AF since continuous AF would 
likely preclude participants from experiencing these supraventricular arrhythmias. 
 To test the robustness of our findings, we performed the following sensitivity 
analyses. We ascertained additional prevalent cases of the major types of arrhythmias 
(AF, non-sustained ventricular tachycardia, long pause, and atrioventricular block) using 
hospitalization records collected within 1 year of visit 6. We chose a time frame of 1 year 
to capture current cases and avoid additionally including older events that may have been 
treated and no longer relevant. Using the additional prevalent events of arrhythmias, we 
re-examined the associations between CKD status and the presence of arrhythmias. As 
antiarrhythmic medications can potentially affect the risk of various arrhythmias, we also 
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performed the main set of analyses after excluding participants using antiarrhythmic 
medications.  
 All analyses were performed in R 3.5.1 and Stata/SE 15.1 (StataCorp, College 
Station, TX). A two-tailed P <0.05 was considered statistically significant.  
Results 
Baseline characteristics 
Of 2,257 participants, 58% had CKD (30% with moderate risk, 17% with high 
risk, and 11% with very high risk). Compared to participants without CKD, individuals 
with CKD were older, less educated, and less likely to drink alcohol; had higher body 
mass index and systolic blood pressure; were more likely to take antihypertensive 
medication and have diabetes and prevalent cardiovascular disease; and had slightly 
lower total cholesterol and HDL cholesterol (Table 1). The majority of participants wore 
the Zio Patch for the full two weeks. The device wear-time was comparable across CKD 
status, with a median wear-time of 13.7 days (IQI 12.7, 13.9) in the total study 
population. 
Descriptive statistics of arrhythmias across CKD  
Those who had CKD with moderate to very high risk had a higher two-week 
prevalence of major arrhythmias (i.e., AF, ventricular tachycardia, long pause, and 
atrioventricular block) compared to participants without CKD (39.1% in CKD vs. 28.5% 
in no CKD). In particular, CKD with very high risk showed the highest prevalence of AF 
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(12.8% vs. 5.0% in no CKD), non-sustained ventricular tachycardia (37.4% vs. 25.8%), 
and long pause (5.8% vs. 1.7%) (Table 2). The two-week prevalence of supraventricular 
tachycardia was slightly lower among those with CKD compared to those without. 
In addition to the presence of arrhythmias, those with CKD also had a higher 
percent time in AF and had more frequent episodes of ventricular ectopy and 
supraventricular ectopy (Table 2).  
Prevalence ratio for major arrhythmias across CKD 
In unadjusted models, CKD with moderate to very high risk demonstrated 
significant prevalence ratios for AF, non-sustained ventricular tachycardia, and long 
pause compared to no CKD (Model 1 in Figure 1 and Table B-2). In this model, a dose-
response relationship was generally observed for AF, ventricular tachycardia, and long 
pause. The adjustment for demographic factors only slightly attenuated these associations 
(Model 2 in Figure 1 and Table B-2). Additionally adjusting for clinical risk factors, 
cardiovascular disease, and medications (Model 3 in Figure 1 and Table B-2), the 
prevalence ratios remained statistically significant for AF in CKD with very high risk 
(prevalence ratio [PR] 1.91 [95% CI: 1.21, 3.01]) and for non-sustained ventricular 
tachycardia in CKD with high risk (PR 1.20 [95% CI: 1.01, 1.44]). In contrast, the results 
for atrioventricular block were quite different, with either similar or lower prevalence 
ratios in those with CKD compared to no CKD (bottom of Figure 1). 
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  When eGFR and ACR were examined separately, lower eGFR was associated 
with a higher prevalence of AF, non-sustained ventricular tachycardia, and long pause in 
crude (Model 1) and demographically-adjusted (Model 2) models (Figure B-3, Table B-
3); however, after adjusting for other potential confounders and ACR (Model 3), these 
associations were no longer significant. On the other hand, the associations of ACR with 
AF and non-sustained ventricular tachycardia were robust across all models (PR 1.27 
[1.13, 1.44] for AF and 1.07 [1.01, 1.13] for ventricular tachycardia in Model 3). Its 
association with long pause was statistically significant only in Model 1. Neither eGFR 
nor ACR was significantly associated with atrioventricular block, although both lower 
eGFR and higher ACR demonstrated inverse associations in Models 3. 
Percent time in atrial fibrillation and frequency of other major arrhythmias  
Compared to no CKD, CKD with moderate to very high risk had an increasingly 
higher percent time in AF, and the associations involving CKD with high and very high 
risk remained statistically significant throughout all models (Figure 2A, Table B-4).  
When examining the frequency of arrhythmia episodes, we found that CKD with 
moderate to very high risk had a higher frequency of long pause even after adjusting for 
potential confounders (Rate ratio [RR] 17.73 [95% CI: 3.91, 80.37]) compared to the no 
CKD group (Figure 2B, Table B-4). Conversely, CKD status was consistently associated 
with a lower frequency of atrioventricular block in all models. There were no significant 
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associations between CKD status and the frequency of non-sustained ventricular 
tachycardia.144 
 Both eGFR and ACR were generally associated with percent time in AF but only 
the association for ACR remained statistically significant in all four models (Figure B-
4A, Table B-5). Lower eGFR and higher ACR demonstrated similar associations with a 
higher frequency of long pause (Figure B-4B, Table B-5). Neither of eGFR or ACR 
showed significant associations with frequency of ventricular tachycardia. As for the 
frequency of atrioventricular block, both lower eGFR and higher ACR demonstrated 
inverse relationships in Model 1, but the relationship was robust only for eGFR across the 
three models. 
Prevalence and frequency of minor arrhythmias across CKD 
CKD with high risk and very high risk were associated a higher prevalence of 
ventricular ectopy in crude (Model 1) and demographically-adjusted (Model 2) models 
but not in Model 3 (Figure B-5, Table B-6). When we examined the frequency of 
ventricular ectopy, however, CKD with very high risk consistently demonstrated a 
significantly higher rate ratio in all models (Figure B-6, Table B-7). There were no clear 
robust patterns with respect to the prevalence or frequency of supraventricular 
tachycardia and supraventricular ectopy. 
 Lower eGFR and higher ACR were similarly associated with the prevalence of 
ventricular ectopy (Figure B-7, Table B-8) while only ACR was significantly associated 
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with a higher frequency of ventricular ectopy in all models (Figure B-8, Table B-9). 
Neither eGFR nor ACR was significantly associated with the prevalence or frequency of 
supraventricular tachycardia. For supraventricular ectopy, eGFR and ACR similarly 
demonstrated significant associations with its prevalence in Models 1 or 2 but not with its 
frequency. 
Sensitivity analysis 
Using hospitalization records, we ascertained 26 additional prevalent cases of AF, 
1 additional ventricular tachycardia, 3 additional long pause, and 3 additional 
atrioventricular block events. When we used the additional events to re-examine the 
relationship between CKD status and the prevalence of the major arrhythmias, the 
findings remained similar: CKD with higher risk groups were associated with a higher 
prevalence of AF and ventricular tachycardia (Table B-10). When we excluded 
participants taking antiarrhythmic medications, the results were also similar but the 
association between CKD status and ventricular tachycardia was attenuated (Table B-
11).  
Discussion 
In this community-based study with excellent adherence to a two-week 
continuous ECG monitor, we found a higher prevalence of clinically significant 
arrhythmias such as AF and non-sustained ventricular tachycardia among those with 
more severe CKD, indicating a dose-response relationship across the spectrum of CKD 
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severity. Of the major types of arrhythmias, AF demonstrated the most consistent 
association with CKD severity, regardless of the type of burden examined (i.e., the 
prevalence and percent time in arrhythmia). While the presence of other major 
arrhythmias such as long pause and atrioventricular block were not associated with CKD, 
when we further examined other types of arrhythmic burden, we found that CKD with 
higher risk was associated with higher frequency of long pause and with lower frequency 
of atrioventricular block. Similarly, we observed a robust association between CKD with 
very high risk and higher frequency of ventricular ectopy. When we examined eGFR and 
ACR separately, we found that ACR was associated with more arrhythmias overall. 
Despite several published studies suggesting that CKD is associated with a higher 
burden of AF,20,21,48,59 there still remains an important knowledge gap on the prevalence 
and burden of AF across the severity of CKD.41 In past studies, the prevalence of AF 
ranged from <1% to >49% in CKD,20,21,49,59,61,67,110 which is a fairly large range that can 
be attributed to different study populations (e.g., inpatients, population-based cohorts, 
patients receiving dialysis, etc.), different definitions of CKD (e.g., eGFR calculated 
using various formulae and filtration markers, proteinuria, dialysis status, etc.), and 
different methods used to record arrhythmias (e.g., Holter monitors, clinic or study visit 
ECGs, self-report, etc.). In our study of community-dwelling older adults using 
continuous ECG monitoring and a definition of CKD that includes both eGFR and ACR, 
we report a two-week prevalence of AF ranging from 5% to 13% depending on CKD 
severity, which remained similar even after using hospitalization records to ascertain 
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additional prevalent cases. The independent association between CKD and the prevalence 
of AF in the present study was consistent with previous studies.20,48,59 Moreover, we 
uniquely observed that CKD severity was also strongly associated with higher percent 
time of AF, further supporting the close link between CKD and AF. 
We also found that CKD status was associated with a higher prevalence of non-
sustained ventricular tachycardia, which corroborates past studies reporting that 
individuals with CKD have a higher risk of incident life-threatening ventricular 
arrhythmias as captured by implantable cardioverter defibrillators (ICDs).9,120 We also 
found that the frequency of ventricular ectopy (though not the binary presence of 
ventricular ectopy) was higher among those with more severe CKD, which has not been 
widely reported in the past. Taken together, our findings suggest that CKD is associated 
with a higher risk of ventricular arrhythmias of varying severity (ectopic beats to non-
sustained tachycardia), which can explain high burden of SCD among CKD;8,9 however, 
further studies are needed to more clearly examine the relationship between various 
ventricular arrhythmias and SCD.  
In addition to AF and ventricular arrhythmias, quantifying the burden of other 
arrhythmias is especially important as more recent studies have implicated the role of 
bradyarrhythmia in SCD among CKD.13,134 In this context, we observed the higher 
frequency of long pause in CKD vs. no CKD. To our knowledge, this is the first report of 
this relationship in a community-based cohort, although it is in line with recent small 
studies (n < 70) reporting bradycardia as an important terminal arrhythmia leading to 
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SCD in patients on dialysis.13,134 While further research is warranted to better understand 
the relationship between long pause and SCD in CKD, our results further support the 
need to pay attention to bradycardia in clinical practice and research in CKD patients.  
We unexpectedly observed that those with more severe CKD had a lower 
frequency of atrioventricular block. The pathophysiology underlying this association is 
unclear, and we are not aware of any previous reports showing this association. It is 
possible that less frequent episodes of heart block among those with more severe CKD 
might indicate longer durations of block; however, we cannot test this theory since the 
Zio Patch did not report durations of AV block. Thus, this observation needs to be 
confirmed in other studies, and if so, the clinical impact of AV block as detected by the 
Zio Patch should be also evaluated. 
When we compared eGFR and ACR separately, ACR was more strongly 
associated with the presence of major arrhythmias. While only a few studies have 
examined both eGFR and albuminuria with prevalent AF,48,61,63 one study similarly 
demonstrated that urinary ACR was more strongly associated with the presence of AF 
compared to eGFR.48 The present study extended our knowledge to ventricular 
tachycardia and other arrhythmias. The precise mechanism underlying the associations of 
ACR with arrhythmias is unknown; however, ACR is also considered a marker of 
microvascular damage, a pathophysiological condition known to play an important role in 
cardiac dysfunction. Indeed, ACR has been shown to strongly predict incident heart 
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failure.3 Thus, it is possible that ACR could broadly reflect subclinical cardiac 
abnormalities that increase vulnerability to major arrhythmias.  
In light of our findings, our study overall demonstrates the importance of 
examining different types of arrhythmia burden, as this provided additional insights into 
the relationships between CKD and various arrhythmias that would have been missed by 
relying only on the presence vs. absence of arrhythmias. Further, it highlights the value of 
continuous monitoring devices and supports recent statements from the American Heart 
Association emphasizing the importance of moving beyond examining arrhythmias only 
as a binary entity.145 Although the prognostic value of our findings cannot be investigated 
at this moment, the ARIC Study is an ongoing prospective study and thus will be able to 
eventually address this important question.  
There are several limitations of our study to be discussed. Although better 
detection than 24 hour Holter,16 2-week monitoring with the Zio Patch may still have 
missed some prevalent cases. Indeed, additional yield of detecting AF by repeating two 
sequences of Zio Patch has been reported.144 Also, it is possible that the study participants 
who attended visit 6 and underwent continuous monitoring may be healthier than those 
who did not. When we compared the two groups, those who underwent continuous 
monitoring were slightly younger, more likely to be white, and have less heart failure and 
better kidney function and albuminuria; however, were very similar otherwise (Table B-
12). The cross-sectional design of this study is certainly not a limitation for examining 
the two-week prevalent burden of arrhythmias; nonetheless, due to the study design, we 
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cannot establish any temporality in the associations between CKD and arrhythmias. We 
also could not examine the duration of episodes for most arrhythmias as we did not have 
access to this information; however, future studies consider examining this in addition to 
the frequency of episodes to better understand the relationships. Despite the limitations, 
the strength of our study is that we were able to address important gaps and limitations in 
the literature by examining various arrhythmias and the different types of arrhythmic 
burden in association with CKD severity using both eGFR and albuminuria.  
In conclusion, the presence of major arrhythmias, specifically, AF and non-
sustained ventricular tachycardia, are higher among individuals with more severe CKD. 
Those with worse CKD also had a higher frequency of long pause and ventricular ectopy. 
Using a novel 2-week monitoring approach, our study found a broader range of 
arrhythmias associated with CKD than previously reported.  
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CKD with  
moderate risk 
CKD with  
high risk 
CKD with  
very high risk 
n=2257 n=945 n=678 n=391 n=243 
Age, years (SD) 79.1 (4.6) 77.8 (3.8) 79.4 (4.6) 80.5 (5.0) 81.2 (4.9) 
Female, % 56.7 57.6 57.4 56.8 51 
Black, % 23.5 22.2 24.0 23.5 27.2 
Study center, %        
      Forsyth County, NC 22.8 22.1 23.9 23.3 21.8 
      Jackson, MS 21.9 20.6 22.4 22 25.1 
      Minneapolis, MN 29 34.1 28.2 22.3 22.6 
      Washington County, MD 26.3 23.2 25.5 32.5 30.5 
Education, %        
      < High school 12 8.4 11.9 16.9 18.5 
      High school graduate 41.5 40.1 42.3 44.2 40.3 
      College or graduate school 46.5 51.5 45.7 38.9 41.2 
Body mass index, kg/m2 (SD) 28.3 (5.3) 27.3 (4.6) 28.8 (5.3) 29.4 (5.9) 29.5 (5.8) 
Current cigarette smoker, % 7.0 6.8 7.5 5.9 8.6 
Current drinker, % 51.6 60.1 48.4 43 41.2 
Systolic blood pressure, mmHg (SD) 134.9 (18.8) 133.3 (18.2) 135.2 (18.2) 135.8 (18.8) 138.8 (21.9) 
Antihypertensive medication, % 76.3 66.2 78.2 87 93.4 
Diabetes, % 33.4 25.1 35.8 37.9 51.4 
Prevalent cardiovascular disease, % 23.8 17.2 22.4 32.5 39.5 
      Heart failure, % 12.5 8.3 10.5 18.2 25.4 
      Coronary heart disease, % 14.0 10.2 12.7 19.5 23.8 
      Stroke, % 4.4 3.1 3.4 7.2 7.9 
Medication for arrhythmia, % 8.9 7.2 9.7 11.5 9.5 
QT-prolonging medication, % 10.4 9.4 9.3 12.5 14.0 
Total cholesterol, SI Units (SD) 4.5 (1.0) 4.6 (1.0) 4.5 (1.0) 4.4 (1.0) 4.4 (1.1) 
High-density lipoprotein, SI Units 
(SD) 1.3 (0.4) 1.4 (0.4) 1.3 (0.3) 1.3 (0.3) 1.2 (0.3) 
eGFR, ml/min/1.73m2 (SD) 58.4 (18.3) 74.2 (11.4) 55.7 (9.8) 42.1 (7.5) 31.1 (9.7) 
Albumin-to-creatinine ratio, mg/g 















CKD with high risk 
CKD with very high 
risk 
n=2257 n=945 n=678 n=391 n=243 
Major arrhythmias 
Atrial fibrillation      
       Presence, % 7.4 5.0 7.7 9.7 12.8 
       Percent of time in arrhythmia (IQI)*, % 100 (5, 100) 11 (2, 100) 100 (4, 100) 100 (100, 100) 100 (100, 100) 
Non-sustained ventricular tachycardia      
       Presence, % 30.2 25.8 30.2 36.3 37.4 
       Frequency (number of episodes per day [IQI])* 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.3) 
Long pause      
       Presence, % 2.7 1.7 3.2 2.6 5.8 
       Frequency (number of episodes per day [IQI])* 0.2 (0.1, 1.4) 0.2 (0.1, 0.7) 0.2 (0.1, 1.3) 0.1 (0.1, 1.5) 0.5 (0.1, 5.4) 
Atrioventricular block      
       Presence, % 1.8 2.0 1.9 1.0 2.1 
       Frequency (number of episodes per day [IQI])* 0.2 (0.1, 0.7) 0.1 (0.1, 0.5) 0.4 (0.1, 0.7) 0.7 (0.4, 0.9) 0.2 (0.1, 0.3) 
Minor arrhythmias 
Ventricular ectopy      
       Presence, % 98.8 98.6 99.0 99.0 99.2 
       Frequency (number of episodes per day [IQI])* 68.8 (11.4, 421.7) 53.5 (7.9, 340.9) 70.4 (12.6, 429.9) 80.3 (15.7, 470.2) 122.3 (21.0, 642.3) 
Supraventricular tachycardia§      
       Presence, % 89.8 91.3 89.3 90.0 83.9 
       Frequency (number of episodes per day [IQI])* 0.9 (0.4, 2.3) 0.9 (0.4, 2.2) 0.8 (0.3, 2.1) 0.9 (0.3, 2.1) 0.9 (0.4, 2.3) 
Supraventricular ectopy§      
       Presence, % 99.9 99.8 100 99.7 100 
       Frequency (number of episodes per day [IQI])* 202.0 (62.9, 804.6) 170.8 (58.5, 727.0) 206.1 (63.5, 765.4) 230.6 (67.5, 831.4) 291.7 (87.8, 1368.3) 
*Characteristics are summarized only among participants with presence of the corresponding arrhythmia 




Figure 1. Associations of chronic kidney disease (CKD) status with prevalence of major arrhythmias  
 
 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
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Figure 2. Associations of chronic kidney disease (CKD) status with (A) percent time in atrial fibrillation and (B) 



























(A) Association of CKD status with percent time in atrial fibrillation; (B) Association of CKD status with frequency of 
non-sustained ventricular tachycardia, long pause, and atrioventricular block 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug
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Chapter 3. Cardiac biomarkers, electrolytes, and 
burden of arrhythmias by chronic kidney disease 
status: the Atherosclerosis Risk in Communities (ARIC) 
Study 
Co-authors: Ron C. Hoogeveen, Elizabeth Selvin, Christie M. Ballantyne, Elsayed Z. 
Soliman, Josef Coresh, Kunihiro Matsushita, Lin Y. Chen 
Abstract 
Background: Chronic kidney disease (CKD) increases the risk of arrhythmias and sudden 
cardiac death; however, it is unclear whether this association is due to cardiac overload, 
cardiac injury, electrolyte abnormalities, and/or anemia. We therefore investigated the 
relationships between several biomarkers representing these conditions with various 
arrhythmias in individuals with CKD.  
Methods: In 2016-17, 2233 ARIC participants (71-94 years) underwent 2-week 
continuous heart rhythm monitoring (Zio XT Patch). We used modified Poisson 
regression to examine the associations of natriuretic peptide (NT-proBNP) (representing 
cardiac overload), high-sensitivity cardiac troponin-T (hs-cTnT) (cardiac injury), 
potassium and magnesium (electrolyte abnormalities), and hemoglobin (anemia) with the 
burden of arrhythmias captured over a 2-week period: atrial fibrillation (AF), non-
sustained ventricular tachycardia (NSVT), long pause (>3 sec), Mobitz II or complete 
atrioventricular block (AVB), ventricular ectopy (VE), and supraventricular tachycardia 
(SVT) and ectopy (SVE). We analyzed CKD (n=1300) and no-CKD separately. 
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Results: There were 9% with AF, 33% with NSVT, 3% with long pause, 2% with AVB, 
and >90% with VE, SVT, and SVE in CKD. NT-proBNP was associated with all major 
arrhythmias except for AVB in CKD (prevalence ratio [95%CI] per 2-fold increment 
1.82 [1.66, 1.99] for AF; 1.15 [1.10, 1.20] for NSVT). hs-cTnT was also associated with 
AF and NSVT but the relationships were weaker. In general, the associations were 
similar in non-CKD. Electrolytes were associated with some arrhythmias, but not 
consistently between CKD and no-CKD (AF associated with lower potassium in CKD 
and with lower magnesium in non-CKD). Hemoglobin was not robustly associated with 
any arrhythmias.  
Conclusions: Of the biomarkers tested, cardiac biomarkers showed most robust 
associations with arrhythmias, followed by potassium and magnesium. Our results 
suggest cardiac overload and injury as key contributors or markers of high arrhythmia 
burden in older adults.  
Introduction 
Chronic kidney disease (CKD) is known as a risk factor of sudden cardiac death 
and atrial fibrillation.9,59 In addition, a few studies have reported that CKD may also be 
associated with other arrhythmias such as bradycardia.13,134 Given the limited treatment 
options to improve kidney function and the progressive nature of CKD, the identification 
of risk factors or markers of arrhythmias in persons with CKD is important. Specifically, 
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those factors can guide risk-centered prevention and management of arrhythmias (e.g., 
pacemaker), or shed light on potential preventive and therapeutic targets of arrhythmias 
in this high-risk population.  
There are several potential mechanisms linking CKD to elevated risk of 
arrhythmias such as cardiac overload and injury, electrolyte disturbance, and anemia. Of 
these, electrolyte abnormality has been most widely investigated. Indeed, several studies 
have reported that abnormal levels of potassium or magnesium predict sudden cardiac 
death or arrhythmias such as ventricular tachycardia or atrial fibrillation.27,146-152 
However, to our knowledge, bradycardia has not been studied in this regard. Also, data 
regarding the contribution of cardiac overload or injury and anemia to various types of 
arrhythmias are lacking.  
We therefore examined the associations of cardiac biomarkers (natriuretic 
peptide, a marker of cardiac stress, and cardiac troponin T [cTnT], a marker of cardiac 
damage), electrolytes (potassium and magnesium), and hemoglobin with the burden of 
various arrhythmias based on two-week monitoring in individuals with CKD from a large 
cohort of community-dwelling older individuals. To evaluate whether the associations of 
these biomarkers are unique to individuals with CKD, we also analyzed participants 




The Atherosclerosis Risk in Communities (ARIC) study47 recruited 15,792 
participants in visit 1 (1987-89) from four U.S communities (Forsyth County, NC, 
Jackson, MS, Minneapolis, MN, and Washington County, MD) and followed them up for 
6 subsequent visits (visit 2 in 1990-92, visit 3 in 1993-95, visit 4 in 1996-98, visit 5 in 
2011-13, visit 6 in 2016-17, and visit 7 2018-19). In addition, participants were contacted 
annually (semi-annually beginning in 2012) to provide updated information on medical 
history. In visit 6, 4,003 participants attended the study examination including assessment 
of cardiovascular disease, cognitive function, and their risk factors, biospecimen 
collection, medication review, and a two-week electrocardiogram (ECG) monitoring. Of 
the 4,003 participants, we excluded participants without the wearable ECG patch data 
(i.e., those who were ineligible due to pacemakers, implantable cardioverter 
defibrillators, or skin allergy to adhesive tape [n=323], those who did not agree to wear 
the device [n=1,030], and those whose devices were lost or returned without data 
[n=34]); participants who were missing CKD measures (n=194) and missing biomarker 
values (n=33); those who were not white or black (n=6); and those were missing 
covariates of interest (n=150). The final analytical sample therefore included 2,233 
participants (Figure C-1). The ARIC Study was approved by the institutional review 
board of each participating institution, and written informed consent was obtained from 
participants at each visit. 
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Measurement of cardiac biomarkers, electrolytes, and hemoglobin 
Cardiac biomarkers were measured using blood samples collected at visit 6. N-
terminal pro-B-type natriuretic peptide (NT-proBNP), a marker of cardiac stress or 
overload,153 was measured in EDTA plasma using an electrochemiluminescent 
immunoassay on a Roche Cobas e411 analyzer (Roche Diagnostics, Indianapolis, IN). 
The laboratory inter-assay coefficients of variation (CVs) for NT-proBNP were 9.9% at a 
mean concentration of 41.8 pg/mL, 4.8% at a mean concentration of 151.9 pg/mL and 
4.3% at a mean concentration of 4824.1 pg/mL. High sensitivity cTnT (hs-cTnT), a 
marker of cardiac damage,154 was measured using the same method with CVs of 9.6% at 
a mean concentration of 9 ng/L, 5.7% at a mean concentration of 27.1 ng/L and 4.8% at a 
mean concentration of 2230 ng/L. 
Potassium was measured in serum by an indirect ion-selective electrode (ISE) 
method on Roche C501 Chemistry analyzer (Roche Diagnostics, Indianapolis, IN). The 
inter-assay CVs were 2.0% and 1.3% at mean concentrations of 3.24 mmol/L and 4.55 
mmol/L, respectively. Magnesium was measured in serum, lithium heparin plasma, or 
urine using a colorimetric method on the Roche Cobas 6000 analyzer (Roche 
Diagnostics) with CVs of 3.5% and 1.9% at mean concentrations of 1.82 mg/dL and 3.44 
mg/dL, respectively. Hemoglobin was measured in EDTA whole blood that has been 
previously frozen for up to 9 weeks using a Sysmex XS-1000i (Sysmex America, Inc., 
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Lincolnshire, IL) with CVs of 0.6-0.8% at mean concentrations ranging from 5.73-16.95 
g/dL. 
Arrhythmia assessment 
The arrhythmias were detected using the Zio XT Patch (iRhythm Technologies 
Inc., San Francisco, CA), which is a Food and Drug Administration (FDA)-approved 
ECG skin patch that allows continuous monitoring of arrhythmias for up to 14 days.16 
The Zio Patch has been shown to detect more arrhythmic episodes than the standard 
Holter monitor and is more comfortable to wear long-term.16 The ECG data were 
processed and analyzed using a FDA-approved algorithm, and validated by technicians. 
The following arrhythmias were detected and included in this study: major types 
including atrial fibrillation, non-sustained ventricular tachycardia, long pause lasting >3 
seconds, and Mobitz type II or third-degree atrioventricular block; and minor types 
including ventricular ectopy (premature ventricular contraction), supraventricular 
tachycardia (not including atrial fibrillation), and supraventricular ectopy. 
The primary arrhythmia burden of interest was the presence of each arrhythmia 
during the two-week monitoring period. The continuous monitoring allowed us to 
additionally examine the frequency of episodes, which was defined as the number of 
episodes recorded per day. For atrial fibrillation, however, we examined the percent time 
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in arrhythmia instead of frequency, as the burden of chronic atrial fibrillation would not 
be appropriately reflected by frequency of episodes. 
We used only the Zio Patch data to ascertain arrhythmia cases in this study 
because when we used hospitalization records to capture a few additional arrhythmia 
events in this study, the associations of our interest remained very similar (data not 
shown).  
Covariate measurement 
All covariates of interest were measured at visit 6 with the exception of 
educational background, which was measured at visit 1 and categorized as basic (i.e., less 
than high school), intermediate (i.e., graduated from high school), or advanced (i.e., 
college or professional degrees). Age, sex, and race were self-reported. Body mass index 
was calculated by dividing measured weight by height squared (kg/m2). Current cigarette 
smoking and alcohol drinking were self-reported (yes vs. no). Systolic blood pressure 
was measured in a sitting position after 5-minutes of rest using a validated automatic 
sphygmomanometer (OMRON HEM-907 XL), and the averaged value of the second and 
third reading was used. Diabetes mellitus was defined as fasting plasma glucose ≥126 
mg/dL, non-fasting glucose ≥200 mg/dL, use of medication for diabetes, or self-reported 
physician diagnosis of diabetes. Prevalent cardiovascular disease included adjudicated 
cases of coronary heart disease, heart failure, and stroke prior to visit 6. Total and high-
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density lipoprotein (HDL) cholesterol concentrations were measured using an enzymatic 
method and the Olympus HDL-Cholesterol test.140 Use of antihypertensive medication in 
the past 4 weeks was recorded using self-reported data and review of medication 
containers when possible. Antiarrhythmic medication was also recorded by inspecting 
drug containers, and for some antiarrhythmic medications that have overlapping 
indications (e.g., beta-blockers that may also be used for hypertension or heart failure), 
we used self-report data to classify the medication accordingly. Using a similar method, 
commonly-used QT-prolonging medications were also identified (Table C-1), as these 
medications can also affect the risk of arrhythmias.  
CKD was defined as estimated glomerular filtration rate (eGFR) <60 
ml/min/1.73m2 or urinary albumin-creatinine ratio (ACR) ≥30 mg/g.136 eGFR was 
calculated using the CKD-EPI equation based on cystatin C,137 which was measured in 
serum using Gentian Cystatin C reagent on the Roche Modular P Chemistry analyzer 
(Roche Diagnostics). We used cystatin C rather than serum creatinine, as there is concern 
that age-related reduced muscle mass can overestimate eGFR in older individuals when 
using creatinine.138 ACR was calculated by dividing urine albumin by urine creatinine. 
Urine albumin was measured in urine on the ProSpec nephelometric analyzer using an 
immunoturbidometric method (Dade Behring GMBH. Marburg, Germany), and urine 
creatinine was measured by a creatinase enzymatic method on a Roche Modular P 
Chemistry Analyzer (Roche Diagnostics). 
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Statistical analysis 
The distributions of all variables were examined and summarized using mean 
with standard deviation for normally distributed variables; median with interquartile 
interval for non-normally distributed variables; and frequency with percentage for 
categorical variables.  
The associations of cardiac biomarkers, electrolytes, and hemoglobin with the 
presence of arrhythmias were assessed using Poisson regression with robust variance, 
taking into account the device wear-time as the offset variable. The associations of 
cardiac biomarkers, electrolytes, and hemoglobin with the number of episodes were 
modeled using a zero-inflated Poisson regression to accommodate a large proportion of 
zeroes in the data. To avoid unreliable estimates due to too few episodes, we restricted 
our analysis of the number of episodes to arrhythmias with average frequency of >0.14 
episodes/day (at least 2 episodes over 14 days) in the entire study population. With this 
criterion, atrioventricular block was excluded from this analysis examining the number of 
episodes. The associations of all biomarkers with percent time in atrial fibrillation were 
examined using linear regression. For all associations, we accounted for the following 
potential confounders: age, sex, race, study center, education, body mass index, current 
smoking, alcohol use, systolic blood pressure, antihypertensive medication, diabetes, 
prevalent cardiovascular disease, total cholesterol, HDL, and antiarrhythmic medications, 
and QT-prolonging medications, and CKD.  
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To examine whether the associations in our primary analysis are unique to CKD, 
we repeated the analysis in non-CKD. We also checked for statistical interactions 
between CKD status and all biomarkers using a likelihood ratio test.  
All analyses were performed in R 3.5.1 and Stata/SE 15.1 (StataCorp, College 
Station, TX). A two-tailed P <0.05 was considered statistically significant. 
Results 
Baseline characteristics 
Among the 2,233 participants, the mean age was 79 (SD 5) years, and the 
majority were female (56%) and white (76%); taking antihypertensive medication (76%); 
and had CKD (58%) (Table 1). Individuals with CKD were older and less educated, had 
higher body mass index and systolic blood pressure, were more likely to have diabetes 
and cardiovascular disease (i.e., heart failure, coronary heart disease, and stroke), and 
more likely to take antihypertensive, antiarrhythmic, and QT prolonging medications. In 
terms of biomarkers, those with CKD had significantly higher levels of NT-proBNP and 
hs-cTnT, similar levels of potassium and magnesium, and lower hemoglobin levels 
(Table 1). 
The presence of major types of arrhythmias including atrial fibrillation, 
ventricular tachycardia, and long pause was higher among CKD compared to no CKD, 
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whereas the presence of minor arrhythmias was similar (Table C-2). Similarly, when we 
compared other measures of arrhythmia burden, we found that the percent time in atrial 
fibrillation was higher in CKD, as well as the frequency (i.e., number of episodes per 
day) of ventricular and supraventricular ectopy (Table C-2). 
Major arrhythmias  
NT-proBNP was associated with the presence of most major arrhythmias in CKD, 
and the associations were similar in non-CKD (Table 2). Among CKD, higher levels of 
NT-proBNP was significantly associated with higher prevalence of atrial fibrillation, 
ventricular tachycardia, and long pause (prevalence ratio [PR] for atrial fibrillation 1.82 
[95% CI: 1.66, 1.99], PR for ventricular tachycardia 1.15 [1.10, 1.20], PR for long pause 
1.30 [1.10, 1.53] per 2-fold higher NT-proBNP in CKD). Atrioventricular block was not 
strongly associated with NT-proBNP. When we examined other types of arrhythmia 
burden, the relationships remained similar (Table 3).  
Similar to NT-proBNP, hs-cTnT was associated with the presence of atrial 
fibrillation and ventricular tachycardia, but it was not associated with long pause (Table 
2).  When other types of arrhythmia burden were examined in CKD, hs-cTnT remained 
associated with percent time in atrial fibrillation. In comparison, among no-CKD, higher 
levels of hs-cTnT were associated with lower frequency of ventricular tachycardia (P for 
interaction between CKD and hs-cTnT <0.001) and higher frequency of long pause 
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(Table 3). When we looked at the inverse association between hs-cTnT and ventricular 
tachycardia carefully in no-CKD, actually, there was a reverse J-shaped association, with 
the highest frequency in the lowest quartile of hs-cTnT and a slight increase in frequency 
along with hs-cTnT levels in the remaining quartiles (Table C-3).  
When we estimated prevalence ratio of major arrhythmias between CKD and no 
CKD across the entire range of NT-proBNP, CKD had higher prevalence ratio of atrial 
fibrillation, non-sustained ventricular tachycardia, and long pause than non-CKD unless 
NT-proBNP was around 300 pg/ml (Figure 1A-C). Above this range, non-CKD had 
similar or even higher prevalence ratio than CKD. There was no evident difference 
between CKD and non-CKD in AV block (Figure 1D). Generally, similar patterns were 
seen for hs-cTnT although the gradient of prevalence ratio appeared shallower than NT-
proBNP except AV block (Figure 1E-H). 
Potassium levels (their decrement below 4.1 mmol/l) were only associated with 
the presence of atrial fibrillation and no other major arrhythmias in CKD (PR 2.76 [1.38, 
5.55] per -1 mmol/l) (Table 2). There were no significant associations in non-CKD. In 
higher levels above 4.1 mmol/l, we observed a lower frequency of ventricular tachycardia 
in CKD (Table 3). 
Magnesium was also associated with a limited number of arrhythmias. Among 
CKD, higher magnesium levels above 2 mg/dl was associated with a higher prevalence of 
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long pause (Table 2). Among non-CKD, lower magnesium levels below 2 mg/dl was 
associated with a higher prevalence of and percent time in atrial fibrillation (Tables 2 
and 3). Higher magnesium levels were associated with higher frequency of ventricular 
tachycardia among non-CKD (Table 3). 
Hemoglobin demonstrated no statistically significant relationships with the 
presence, percent time, or frequency of major arrhythmias (Tables 2 and 3). 
Minor arrhythmias 
The presence of minor arrhythmias was not associated with any biomarkers 
except for ventricular ectopy, which was associated with NT-proBNP only in CKD 
(Table 4). The frequencies of minor arrhythmias, however, were associated with a few 
biomarkers. In both CKD and no-CKD, there was a higher frequency of ventricular and 
supraventricular ectopy with higher NT-proBNP levels; and there was a lower frequency 
of supraventricular ectopy with higher magnesium levels (Table 5). Other associations 
involving the frequency of minor arrhythmias were more inconsistent across CKD status: 
in CKD, supraventricular tachycardia was less frequent with higher magnesium level, and 
in no-CKD, supraventricular tachycardia was less frequent with lower hemoglobin while 
supraventricular ectopy was more frequent with higher hs-cTnT and lower potassium 
levels, respectively.  
Discussion 
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In community-dwelling older adults, among the biomarkers tested, we found that 
cardiac biomarkers were most strongly associated with the burden of various major 
arrhythmias (such as atrial fibrillation) in CKD and no CKD (Table C-4). Of the two 
cardiac biomarkers examined, NT-proBNP demonstrated stronger relationships than hs-
cTnT in general. Electrolytes were associated with a limited number of major 
arrhythmias, with inconsistent results between CKD and no CKD. For example, atrial 
fibrillation was associated with lower potassium in CKD but with higher magnesium 
levels in no-CKD. Hemoglobin did not demonstrate strong associations with major 
arrhythmias. There were less evident associations of the minor arrhythmias with 
biomarkers than the major arrhythmias. The positive associations of NT-proBNP with 
ventricular and supraventricular ectopy and the inverse associations of higher levels of 
magnesium with supraventricular ectopy were present in both CKD and no CKD.  
Similar to past studies,28-31 we found that NT-proBNP and hs-cTnT were strongly 
associated with the prevalence of atrial fibrillation in CKD and no-CKD. Additionally, 
we were able to corroborate past findings that the cardiac biomarkers were also 
associated with higher percent time in atrial fibrillation. Although the directionality of the 
relationships could not be established in our study, the robust link between these cardiac 
markers and atrial fibrillation is not surprising since the release of NT-proBNP and hs-
cTnT can increase as a result of cardiac stress and damage due to atrial fibrillation. The 
higher levels of these cardiac markers can reflect cardiac abnormality preceding the 
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development of atrial fibrillation.28,33,38 Our results indicate NT-proBNP and hs-cTnT as 
robust blood markers reflecting high risk status for atrial fibrillation. 
The associations of NT-proBNP and hs-cTnT with ventricular tachycardia in the 
general population are novel. Previous studies were restricted to select patient 
populations (i.e., those with preexisting ventricular premature complex, implantable 
cardioverter defibrillator, left ventricular assist device, or systemic sclerosis).32-37 Like 
atrial fibrillation, elevated levels of NT-proBNP and hs-cTnT may reflect either or both 
of cardiac abnormality predating non-sustained ventricular tachycardia or cardiac 
overload/damage due to this arrhythmia. 
We found a consistent association between NT-proBNP and the burden of long 
pause, which has never been reported to our knowledge. Overall, epidemiologic studies 
investigating bradycardia are scarce although a case report showed elevated NT-proBNP 
levels in a patient with junctional escape rhythm due to sinus arrest.155   
We found that lower levels of potassium were associated with a higher presence 
(but not necessarily percent time) of atrial fibrillation in CKD. This relationship has been 
previously observed in population-based cohorts and among those receiving dialysis 
treatments.41,151 In addition, we found that higher levels of potassium above 4.1 mmol/l 
associated with lower rate ratio of non-sustained ventricular tachycardia and its lower 
levels below this range with a higher frequency of ventricular ectopy in CKD. However, 
these associations were not consistent when we studied the presence of these arrhythmias 
and were not seen in non-CKD. These results should be interpreted cautiously.  
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Magnesium exhibited associations with some arrhythmias. Of those, there were 
two relationships that were consistent across different arrhythmias or CKD status. 
Specifically, lower magnesium levels were associated with higher prevalence and percent 
time of atrial fibrillation in non-CKD and higher levels of magnesium were associated 
with lower rate ratio of supraventricular ectopy in both CKD and no-CKD. Although we 
are unsure of the exact underlying mechanisms behind these observations, the importance 
of magnesium in cardiac arrhythmias has been recognized (e.g., magnesium deficiency 
prolonging QT duration).156,157 Nonetheless, epidemiological data regarding magnesium 
and arrhythmias are limited, and thus future studies are needed.  
Contrary to our hypothesis, lower hemoglobin was not associated almost all 
arrhythmias tested, except for lower frequency of supraventricular tachycardia in no-
CKD. This lack of associations of hemoglobin with arrhythmias in our study is in line 
with a previous study showing no association between chronic anemia and new-onset 
atrial fibrillation in community-dwelling older adults.158  
Our findings overall have a few clinical and research implications. Our findings 
suggest cardiac remodeling and myocardial injury as critical factors for increased risk of 
arrhythmias in CKD and emphasize the importance of cardiac biomarkers as a potential 
method of monitoring and managing risks of severe arrhythmias. For example, natriuretic 
peptide levels may guide clinical decision making of arrhythmia prevention and 
management (e.g., ICD implantation) in CKD, although this theory should be tested in 
future studies. In addition, clinical trials could be designed to enroll individuals with high 
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levels of NT-proBNP or hs-TnT to test if therapies which could modify cardiac overload 
such as more aggressive lowering of blood pressure as shown in the SPRINT trial would 
reduce arrhythmias.159 Our findings also highlight the importance of elucidating the 
temporality of associations between cardiac overload or injury and the risk of arrhythmias 
for better understanding the etiology of high-risk arrhythmias in CKD population. 
  In addition to the cross-sectional design, there are other limitations in our study. 
Some misclassification of arrhythmias by the continuous ECG monitoring device is 
possible; however, as the Zio Patch and its arrhythmia-detecting algorithm are FDA-
approved for clinical use, this concern remains minimal. Our study population consisted 
of older, relatively healthy individuals who attended the study visit and underwent two-
week ECG monitoring. Consequently, our findings may not be generalizable to younger 
or sicker individuals. It is also possible that some inconsistent or weak associations that 
we observed by CKD status were due to small sample sizes of subgroups, limited number 
of episodes of some arrhythmias, or the result of multiple testing.  
In conclusion, our study demonstrates that cardiac biomarkers, especially NT-
proBNP, were more consistently associated with the burden of many arrhythmias 
including atrial fibrillation, non-sustained ventricular tachycardia, and long pause 
compared to electrolytes and hemoglobin. Our findings suggest that cardiac overload and 
injury are likely the key contributors or markers associated with the high burden of major 
arrhythmias in CKD among older adults. Future studies are warranted to further quantify 
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Table 1. Baseline characteristics by chronic kidney disease (CKD) status 
Characteristics 
Total No CKD CKD 
n=2233 n=933 n=1300 
Age, years (SD) 79.2 (4.6) 77.8 (3.8) 80.1 (4.8) 
Female, % 56.7 57.7 56.1 
White, % 76.5 77.9 75.5 
Study center, %      
      Forsyth County, NC 22.8 22.2 23.2 
      Jackson, MS 21.9 20.5 22.8 
      Minneapolis, MN 29 34.1 25.3 
      Washington County, MD 26.4 23.3 28.6 
Education, %      
      < High school 12.1 8.4 14.8 
      High school graduate 41.6 40.2 42.5 
      College or graduate school 46.4 51.4 42.7 
Body mass index, kg/m2 (SD) 28.3 (5.3) 27.3 (4.6) 29.1 (5.6) 
Current cigarette smoker, % 7.1 6.9 7.2 
Current drinker, % 51.5 60.3 45.2 
Systolic blood pressure, mmHg (SD) 134.9 (18.7) 133.3 (18.1) 136.0 (19.1) 
Antihypertensive medication, % 76.4 66.5 83.5 
Diabetes, % 33.2 24.9 39.2 
Prevalent cardiovascular disease, % 23.8 17.3 28.5 
      Heart failure, % 12.5 8.3 15.5 
      Coronary heart disease, % 14 10.2 16.7 
      Stroke, % 4.4 3.1 5.3 
Medication for arrhythmia, % 9 7.3 10.2 
QT-prolonging medication, % 10.4 9.4 11.2 
Total cholesterol, SI Units (SD) 4.5 (1.0) 4.6 (1.0) 4.4 (1.0) 
High-density lipoprotein, SI Units (SD) 1.3 (0.4) 1.4 (0.4) 1.3 (0.3) 
eGFR, ml/min/1.73m2 (SD) 58.3 (18.3) 74.1 (11.4) 47.0 (13.3) 
Albumin-to-creatinine ratio, mg/g (IQI) 7.1 (3.5, 18.3) 5.0 (3.0, 9.4) 10.5 (4.2, 37.6) 
N-terminal pro-B-type natriuretic peptide, pg/ml (IQI) 143.0 (72.9, 300.9) 107.0 (57.5, 189.6) 192.7 (90.0, 415.0) 
High sensitivity cardiac troponin T, ng/l (IQI) 12.0 (9.0, 18.0) 10.0 (7.0, 13.0) 14.0 (10.0, 21.0) 
Serum potassium, mmol/l (IQI) 4.1 (3.9, 4.3) 4.1 (3.9, 4.3) 4.1 (3.9, 4.4) 
Serum magnesium, mg/dl (IQI) 2.0 (1.9, 2.1) 2.0 (1.9, 2.1) 2.0 (1.9, 2.1) 
 91 













Prevalence Ratio (95% CI) 
Chronic kidney disease 
NT-proBNP, per 2-fold 1.82 (1.66, 1.99) 1.15 (1.10, 1.20) 1.30 (1.10, 1.53) 1.10 (0.87, 1.39) 
hs-cTnT, per 2-fold 1.24 (1.01, 1.52) 1.14 (1.04, 1.25) 1.10 (0.76, 1.60) 1.53 (0.99, 2.33) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 2.76 (1.38, 5.55) 1.30 (0.87, 1.93) 2.61 (0.76, 8.93) 1.98 (0.49, 8.06) 
>4.1 mmol/l, per 1 mmol/l 0.83 (0.36, 1.95) 0.92 (0.65, 1.30) 0.34 (0.08, 1.46) 0.43 (0.07, 2.61) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 1.04 (0.58, 1.85) 0.95 (0.73, 1.25) 1.25 (0.52, 3.02) 1.08 (0.28, 4.15) 
>2 mg/dl, per 0.5 mg/dl 0.52 (0.21, 1.30) 0.73 (0.48, 1.11) 3.88 (1.04, 14.49) 0.71 (0.04, 14.21) 
Hemoglobin, per -1 g/dl 0.97 (0.89, 1.05) 0.97 (0.93, 1.01) 0.97 (0.84, 1.11) 1.02 (0.83, 1.25) 
No chronic kidney disease 
NT-proBNP, per 2-fold 2.49 (2.06, 3.01) 1.21 (1.13, 1.30) 1.77 (1.20, 2.62) 0.90 (0.66, 1.24) 
hs-cTnT, per 2-fold 2.03 (1.42, 2.90) 1.19 (1.02, 1.39) 1.17 (0.57, 2.40) 0.81 (0.40, 1.63) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 1.87 (0.38, 9.12) 1.30 (0.73, 2.30) 3.09 (0.31, 30.30) 1.11 (0.07, 17.03) 
>4.1 mmol/l, per 1 mmol/l 2.19 (0.33, 14.42) 1.20 (0.71, 2.02) 0.44 (0.02, 11.47) 0.04 (0.00, 6.01) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 3.08 (1.34, 7.08) 1.10 (0.68, 1.78) 2.51 (0.73, 8.58) 1.28 (0.27, 5.97) 
>2 mg/dl, per 0.5 mg/dl 2.79 (0.71, 10.94) 1.14 (0.63, 2.08) 0.76 (0.03, 19.65) 0.89 (0.11, 7.54) 
Hemoglobin, per -1 g/dl 0.94 (0.78, 1.14) 0.96 (0.90, 1.02) 1.20 (0.83, 1.75) 1.06 (0.81, 1.39) 
Models adjusted for age, sex, race, study center, education, body mass index, current smoking status, current drinking 
status, systolic blood pressure, antihypertensive medication, diabetes, prevalent cardiovascular disease, total and HDL 





Table 3. Association of all biomarkers with percent time and frequency of major arrhythmias by chronic kidney 







Difference in percent time 
(95% CI) 
Rate Ratio (95% CI) 
Chronic kidney disease 
NT-proBNP, per 2-fold 0.06 (0.05, 0.07) 1.29 (1.12, 1.50) 1.36 (1.02, 1.82) 
hs-cTnT, per 2-fold 0.01 (0.00, 0.03) 1.76 (0.97, 3.19) 0.95 (0.53, 1.71) 
Potassium 
<4.1 mmol/l, per -1 
mmol/l 0.05 (-0.01, 0.11) 0.02 (0.00, 1.00) 0.27 (0.01, 4.99) 
>4.1 mmol/l, per 1 mmol/l -0.01 (-0.06, 0.04) 0.02 (0.00, 0.79) 0.04 (0.00, 3.45) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 0.01 (-0.04, 0.05) 0.67 (0.09, 5.19) 3.35 (0.99, 11.35) 
>2 mg/dl, per 0.5 mg/dl -0.04 (-0.10, 0.02) 1.12 (0.42, 3.02) 3.03 (0.60, 15.24) 
Hemoglobin, per -1 g/dl -0.00 (-0.01, 0.00) 1.09 (0.94, 1.26) 0.79 (0.58, 1.09) 
No chronic kidney disease 
NT-proBNP, per 2-fold 0.04 (0.03, 0.05) 1.31 (1.09, 1.59) 2.79 (1.81, 4.28) 
hs-cTnT, per 2-fold 0.01 (-0.01, 0.03) 0.17 (0.03, 0.86) 2.05 (1.01, 4.14) 
Potassium 
<4.1 mmol/l, per -1 
mmol/l 0.03 (-0.04, 0.10) 0.52 (0.12, 2.31) 0.93 (0.12, 6.99) 
>4.1 mmol/l, per 1 mmol/l -0.01 (-0.08, 0.05) 0.04 (0.00, 7.28) 0.45 (0.00, 57.15) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 0.08 (0.02, 0.15) 0.25 (0.01, 5.33) 8.32 (0.82, 84.22) 
>2 mg/dl, per 0.5 mg/dl 0.05 (-0.02, 0.13) 17.86 (1.85, 172.74) 1.93 (0.03, 138.35) 
Hemoglobin, per -1 g/dl 0.00 (-0.01, 0.01) 0.85 (0.66, 1.10) 0.96 (0.56, 1.65) 
Models adjusted for age, sex, race, study center, education, body mass index, current smoking status, current drinking 
status, systolic blood pressure, antihypertensive medication, diabetes, prevalent cardiovascular disease, total and HDL 
cholesterol, antiarrhythmic medication, QT-prolonging medication 
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Figure 1. Associations of NT-proBNP and hs-cTnT with prevalence of major 
arrhythmias by chronic kidney disease status 
 
A), E) Prevalence ratio for atrial fibrillation; B), F) Prevalence ratio for non-sustained 
ventricular tachycardia; C), G) Prevalence ratio for long pause; D), H) Prevalence ratio 
for atrioventricular block; Blue lines and bins represent non-CKD; Pink lines and bins 
represent CKD; NT-proBNP and hs-cTnT are log-transformed to the base of 2; Reference 
for NT-proBNP set at 6.7 log-pg/ml in no CKD, and for hs-cTnT, at 3.3 log-ng/l in no 
CKD 
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Table 4. Association of all biomarkers with prevalence of minor arrhythmias by chronic kidney disease status  
Biomarkers 
Arrhythmias 
Ventricular ectopy  




(Isolated, couplet, or triplet) 
Prevalence Ratio (95% CI) 
Chronic kidney disease 
NT-proBNP, per 2-fold 1.01 (1.00, 1.02) 1.02 (0.99, 1.03) 1.01 (0.99, 1.02) 
hs-cTnT, per 2-fold 1.02 (0.99, 1.04) 0.99 (0.96, 1.02) 1.02 (0.99, 1.04) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 0.99 (0.90, 1.08) 1.00 (0.89, 1.13) 0.97 (0.89, 1.06) 
>4.1 mmol/l, per 1 mmol/l 0.99 (0.92, 1.07) 0.98 (0.89, 1.09) 0.95 (0.90, 1.01) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 1.11 (0.99, 1.23) 1.00 (0.85, 1.16) 1.09 (0.98, 1.21) 
>2 mg/dl, per 0.5 mg/dl 1.04 (0.96, 1.13) 1.00 (0.88, 1.13) 1.02 (0.94, 1.11) 
Hemoglobin, per -1 g/dl 1.00 (0.99, 1.02) 1.00 (0.99, 1.02) 1.00 (0.99, 1.01) 
No chronic kidney disease 
NT-proBNP, per 2-fold 1.00 (0.98, 1.01) 1.02 (0.99, 1.04) 1.00 (0.98, 1.01) 
hs-cTnT, per 2-fold 1.00 (0.98, 1.03) 1.02 (0.98, 1.05) 1.00 (0.97, 1.02) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 1.02 (0.94, 1.11) 1.01 (0.88, 1.15) 1.05 (0.96, 1.15) 
>4.1 mmol/l, per 1 mmol/l 0.99 (0.92, 1.07) 0.93 (0.82, 1.04) 1.00 (0.93, 1.08) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 1.00 (0.95, 1.06) 1.00 (0.92, 1.09) 1.00 (0.94, 1.05) 
>2 mg/dl, per 0.5 mg/dl 0.98 (0.91, 1.06) 1.00 (0.88, 1.12) 1.01 (0.93, 1.08) 
Hemoglobin, per -1 g/dl 1.00 (0.99, 1.01) 0.99 (0.98, 1.01) 1.00 (0.99, 1.01) 
Models adjusted for age, sex, race, study center, education, body mass index, current smoking status, current drinking 
status, systolic blood pressure, antihypertensive medication, diabetes, prevalent cardiovascular disease, total and HDL 




Table 5. Association of all biomarkers with frequency of minor arrhythmias by chronic kidney disease status  
Biomarkers 
Arrhythmias 
Ventricular ectopy  




(Isolated, couplet, or triplet) 
Rate Ratio (95% CI) 
Chronic kidney disease 
NT-proBNP, per 2-fold 1.36 (1.23, 1.51) 1.08 (0.87, 1.33) 1.17 (1.09, 1.26) 
hs-cTnT, per 2-fold 1.21 (0.99, 1.47) 1.02 (0.84, 1.25) 1.13 (0.93, 1.36) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 0.76 (0.35, 1.62) 0.30 (0.05, 1.62) 0.76 (0.40, 1.47) 
>4.1 mmol/l, per 1 mmol/l 1.19 (0.50, 2.82) 0.62 (0.13, 2.87) 0.99 (0.51, 1.92) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 1.42 (0.92, 2.19) 0.30 (0.08, 1.12) 0.84 (0.53, 1.33) 
>2 mg/dl, per 0.5 mg/dl 0.73 (0.29, 1.81) 0.11 (0.03, 0.38) 0.32 (0.16, 0.63)  
Hemoglobin, per -1 g/dl 1.07 (0.98, 1.16) 1.05 (0.86, 1.28) 0.96 (0.86, 1.07) 
No chronic kidney disease 
NT-proBNP, per 2-fold 1.32 (1.16, 1.50) 1.21 (0.84, 1.74) 1.15 (1.00, 1.31) 
hs-cTnT, per 2-fold 1.23 (0.93, 1.62) 0.92 (0.47, 1.79) 1.32 (1.04, 1.68) 
Potassium 
<4.1 mmol/l, per -1 mmol/l 3.56 (1.34, 9.45) 0.81 (0.40, 1.64) 0.73 (0.26, 2.11) 
>4.1 mmol/l, per 1 mmol/l 1.21 (0.19, 7.72) 0.96 (0.31, 2.92) 1.03 (0.47, 2.26) 
Magnesium 
<2 mg/dl, per -0.5 mg/dl 0.83 (0.31, 2.27) 0.28 (0.03, 3.02) 0.84 (0.24, 2.96) 
>2 mg/dl, per 0.5 mg/dl 0.95 (0.40, 2.24) 1.06 (0.10, 11.61) 0.28 (0.10, 0.77) 
Hemoglobin, per -1 g/dl 1.01 (0.89, 1.15) 0.79 (0.68, 0.91) 0.95 (0.84, 1.08) 
Models adjusted for age, sex, race, study center, education, body mass index, current smoking status, current drinking 
status, systolic blood pressure, antihypertensive medication, diabetes, prevalent cardiovascular disease, total and HDL 
cholesterol, antiarrhythmic medication, QT-prolonging medication   
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Chapter 4. Diurnal patterns of intermittent atrial 
fibrillation by chronic kidney disease status: The 
Atherosclerosis Risk in Communities (ARIC) Study 
Co-authors: Elsayed Z. Soliman, Josef Coresh, Lin Y. Chen, Kunihiro Matsushita, Vadim 
Zipunnikov  
Abstract 
Background: Atrial fibrillation (AF) represents an overwhelming economic burden; 
however, most studies examined the presence or incidence of atrial fibrillation as a 
dichotomous outcome, and the diurnal patterns of AF and how these may vary by major 
comorbid conditions like chronic kidney disease (CKD) status have not yet been 
characterized. 
Methods: We examined 67 participants from the ARIC Study who had intermittent AF in 
2-week non-invasive continuous heart rhythm monitoring using the Zio XT Patch. We 
characterized the probability of AF onset over the course of 24 hours using a generalized 
multilevel function-on-scalar regression model in CKD (reduced kidney function or 
elevated albuminuria) and no-CKD. 
Results: The median device wear-time was 13.7 (IQI 12.6-13.9) days, and 40 participants 
had CKD. There was a biphasic pattern of AF with a peak occurring around midnight and 
a nadir around noon. The highest and lowest probability of AF were 11.4% and 7.8%, 
respectively, in CKD, and 6.2% and 3.1%, respectively, in no-CKD. Those with CKD 
had a constantly higher presence of AF throughout day compared to no-CKD, and the 
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largest and smallest difference was observed around 9pm (odds ratio [OR] 3.28, 95% CI: 
1.69, 7.33) and 3am (OR 1.99, 95% CI: 1.18, 3.64). There was a similar level of 
fluctuation in the diurnal patterns by CKD status. 
Conclusions: In community-dwelling older adults, intermittent AF exhibits a biphasic 
diurnal pattern with a peak occurring around midnight and a nadir around noon regardless 
of CKD status. Compared to no-CKD, those with CKD have a constantly elevated 
probability of AF throughout the day, with the greatest difference occurring around 9pm. 
Further studies are needed to evaluate clinical implications of diurnal variation of 
intermittent AF. 
Introduction 
  Atrial fibrillation affects more than 5 million Americans annually, and this figure 
is projected to grow to 12 million by 2030.160 Atrial fibrillation represents an 
overwhelming economic burden with an annual medical cost ranging from US$6 to $26 
billion,160 and is strongly associated with cardiovascular disease (CVD) and 
mortality.161,162 Yet, despite the high burden, most studies on atrial fibrillation have 
mainly examined the binary presence or incidence of atrial fibrillation, and to date, only a 
handful number of studies have explored the diurnal patterns of intermittent atrial 
fibrillation, which is important to consider as this can have meaningful implications on 
detection and management of atrial fibrillation.  
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  Past studies that examined the diurnal patterns of atrial fibrillation reported some 
consistent and inconsistent results on the timing of peaks and nadirs, and had significant 
caveats in data collection (monitoring only for 24-hour or with a transtelephonic ECG 
relying on patient action triggered by symptoms), study population (patients with 
implantable devices), and methods (investigating only the first episodes and treating all 
episodes within the same individual as independent uncorrelated events).42-46  Moreover, 
data regarding whether diurnal patterns vary by the presence and absence of 
comorbidities like chronic kidney disease (CKD) are scarce.44  
  To overcome these caveats, using data from a two-week continuous ECG patch in 
a community-based cohort of older adults, we sought to characterize the diurnal patterns 
of intermittent atrial fibrillation and assess whether they vary by CKD status. We selected 
CKD as a comorbidity of interest in this study because atrial fibrillation is especially 
prevalent in individuals with CKD.9,41,163,164 As the importance of chronobiology in 
cardiovascular pathophysiology has been described previously (e.g., blood pressure),40 
findings from this study may provide unique insights on strategies to optimize the 
detection and management of atrial fibrillation. For example, high-risk time windows, if 
any, can potentially inform the optimal timing of ECG monitoring or treatment strategy 




This study used data from visit 6 (2016-2017) of the ARIC study, which was 
originally designed to investigate the natural history of atherosclerotic disease from mid- 
to late-life and has been described previously.47 Briefly, 15,792 participants were 
recruited from four communities in the U.S. (Forsyth County, NC, Jackson, MS, 
Minneapolis, MN, and Washington County, MD) and completed the first study visit (visit 
1) during 1987-1989. Since then, there have been six study visits (visit 2 in 1990-1992; 
visit 3 in 1993-1995; visit 4 in 1996-1998; visit 5 in 2011-2013; visit 6 in 2016-2017; 
visit 7 in 2018-2019). In addition to these visits, the participants were contacted annually 
(semi-annually beginning in 2012) for us to obtain updated information on their medical 
history and lifestyle. In visit 6, 4,003 participants attended the study examination which 
included a two-week continuous ECG monitoring, biospecimen collection, and 
assessment for cardiovascular disease, cognitive function, and medications. The ARIC 
study was approved by the institutional review board of each participating center, and 
written informed consent was obtained from participants at each study visit. 
Study population 
Of 4,003 participants who attended visit 6, there were 2,616 participants who 
underwent two-week ECG monitoring after excluding those who had pacemakers, 
implantable cardioverter defibrillators, or skin allergy to adhesive tape (n=323), those 
who did not agree to wear the device (n=1,030), and those whose devices were lost or 
returned without data (n=34) (Figure D-1). There were 67 participants who had 
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intermittent atrial fibrillation defined as the occurrence of atrial fibrillation over the 
monitoring period that did not persist for the entire duration of device wear time. For this 
analysis, we excluded participants who were missing CKD measures (n=194) and who 
were non-white and non-black (n=6). Our final analytical sample therefore included 67 
participants with intermittent atrial fibrillation.  
Atrial fibrillation measurement  
Atrial fibrillation was measured using the Zio XT Patch (iRhythm Technologies 
Inc., San Francisco, CA), which is a Food and Drug Administration (FDA)-approved 
ECG skin patch that is single-lead, non-invasive, lightweight, and water-resistant, and 
allows ECG recording for up to 14 days.16 The Zio Patch is demonstrated to detect more 
arrhythmic events and shown to be more comfortable to wear than the standard 24-hour 
Holter monitor.16 Study participants were asked to wear the Zio Patch for up to 14 days 
and mail the device back to the manufacturer who analyzed the ECG recordings using a 
FDA-approved proprietary algorithm. For this analysis, we used episodic data, which 
were comprised of every episode of atrial fibrillation per participant, including the date 
and time of onset and termination for each episode. 
Chronic kidney disease measurement 
CKD was defined as a combination of values of estimated glomerular filtration 
rate (eGFR) <60 ml/min/1.73m2 or urinary albumin-to-creatinine ratio (ACR) ≥30 mg/g 
according to the Kidney Disease: Improving Global Outcomes (KDIGO) CKD 
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Guideline.136 eGFR was calculated based on the CKD-EPI equation using cystatin C,137 
which was measured in serum using Gentian Cystatin C reagent on the Roche Modular P 
Chemistry analyzer (Roche Diagnostics, Indianapolis, IN) with a laboratory inter-assay 
CV of 6.1% at a mean concentration of 0.94 mg/L. We used a cystatin C based equation 
rather than one based on serum creatinine, as there is concern that age-related reduced 
muscle mass can overestimate eGFR in older individuals when using a creatinine-based 
equation.138 ACR was calculated by dividing urine albumin by urine creatinine.139 Urine 
albumin was measured in urine on the ProSpec nephelometric analyzer using an 
immunoturbidometric method (Dade Behring GMBH. Marburg, Germany) with a 
laboratory inter-assay CV of 4.0% at a mean concentration of 19.7 mg/L. Urine creatinine 
was measured on a Roche Modular P Chemistry Analyzer (Roche Diagnostics 
Corporation) using a creatinase enzymatic method (Roche Diagnostics, Indianapolis, IN) 
that yielded a CV of 4.5% at a mean concentration of 17 mg/dL. 
Covariate measurement 
All variables except education were measured at ARIC study visit 6. Educational 
attainment was measured at visit 1 and categorized as less than high school, graduated 
from high school or vocational school, or obtained college or graduate/professional 
degrees. Body mass index was calculated by body weight (kg) divided by the square of 
height (m) and dichotomized to ≥25 kg/m2 (overweight/obese) and <25 kg/m2. Current 
cigarette smoking and alcohol drinking were self-reported. Diabetes was defined as 
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fasting plasma glucose ≥126 mg/dL, non-fasting glucose ≥200 mg/dL, using medication 
for diabetes, or self-reported physician diagnosis of diabetes. Prevalent cardiovascular 
disease included coronary heart disease, heart failure, and stroke, and these were assessed 
based on prior events adjudicated by physician reviewers using medical records and/or 
hospitalization data. Systolic and diastolic blood pressure measures were the average of 
the last two of three recordings in a sitting position after five minutes of rest using a 
validated automatic sphygmomanometer (OMRON HEM-907 XL). Antihypertensive 
medication use in the past 4 weeks was assessed by self-report and confirmed with drug 
containers. We assessed the use of antiarrhythmic medication in a similar manner and 
additionally assessed QT-prolonging medications as these are also associated with the 
risk of arrhythmias. 142 The list of QT-prolonging medications can be found in Table D-
1).141 
Statistical analysis 
  We checked the distributions of all variables and summarized them by CKD 
status. Continuous variables were described with mean and standard deviation [SD] if 
normally distributed or with median and interquartile interval [IQI] if non-normally 
distributed. Categorical variables were summarized using frequency and percentages.  
  For all analyses, we formatted the data so that the presence of atrial fibrillation 
was summarized in moving time-windows for each day of the monitoring period with the 
intention of smoothing over time. After some exploratory analysis, we decided to use a 
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10-minute time window with 5 minutes of overlap between the windows, hence, we 
created 288 time windows for each day.  
  We first performed a series of visual exploratory data analysis to check for crude 
patterns of atrial fibrillation presence by CKD status. First, for every participant, we 
visualized the occurrence of atrial fibrillation episodes over all the days of the monitoring 
period by plotting the time and duration of each episode over 24 hours and by day to 
roughly inspect any patterns or potential outliers. Second, to visualize a crude 
(unadjusted) diurnal pattern, we created a probability plot of atrial fibrillation over the 
course of the day. For this visualization, we first summarized the presence or absence of 
atrial fibrillation that accumulated over the entire monitoring period of 2 weeks. We then 
plotted the binary presence of atrial fibrillation over 24 hours, and fit binomial smoothing 
curves to estimate the probability of being on intermittent atrial fibrillation.   
  To appropriately characterize the diurnal pattern of atrial fibrillation and how this 
may differ by CKD status, we analyzed the effect of CKD on the presence of atrial 
fibrillation over time adjusting for covariates by fitting a generalized multilevel function-
on-scalar regression,165 which involved the following two steps. First, at every time 
window, we used a generalized estimating equation (GEE) with a logit link function to 
estimate the marginal effect of CKD as well as other covariates on the binary presence of 
atrial fibrillation accounting for multiple days per subject and using an exchangeable 
correlation structure. We generated bootstrapped 95% confidence intervals (CIs) using 
1000 resamples at each time window. Then, we smoothed the coefficients and the 95% 
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CIs from the models as a function of time and plotted the smoothed lines to visualize the 
patterns over time. We additionally generated and visualized the predicted probabilities 
of atrial fibrillation to compare those with and without CKD. Due to a small sample size, 
we only adjusted for age (centered at mean age of 80 years) and sex.  
Results 
Baseline characteristics 
Of 67 participants with intermittent atrial fibrillation, 40 (60%) had CKD. 
Compared to those without CKD, those with CKD were slightly older, less likely to be 
black, had higher body mass index and burden of cardiovascular diseases and its risk 
factors (Table 1).  
Exploratory data analysis of atrial fibrillation episodes by chronic kidney disease status 
Figure 1 illustrates the timing of onset and duration of atrial fibrillation episodes 
over the course of ECG monitoring by CKD status. In general, we observed that those 
with CKD had a higher frequency of episodes and longer duration of atrial fibrillation 
compared to those without CKD.  
 Figure 2 depicts the crude unadjusted probabilities of atrial fibrillation 
summarized over all days of the monitoring period. Roughly, in the overall group of 
participants, atrial fibrillation exhibited a biphasic pattern with higher presence around 
midnight and had a lower probability of occurring around noon. When examined by CKD 
status, we found that the general pattern remained similar in the subgroups; however, the 
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presence of atrial fibrillation was consistently higher among those with CKD than those 
without CKD. 
Diurnal patterns of intermittent atrial fibrillation by CKD status  
Based on the generalized estimating equation, we observed similar diurnal 
variation of the probabilities of atrial fibrillation in both those with and without CKD 
(Figure 3), with a peak at midnight and a nadir around noon. At a given day, the peak 
probability of atrial fibrillation around midnight was 11.4% in CKD and 6.2% in no-
CKD, and the lowest probability around noon was 7.8% in CKD and 3.1% in no-CKD. In 
this approach, we also observed a few other peaks smaller than the peak at midnight in 
both CKD and no-CKD (e.g., around 9 am). Also, no-CKD demonstrated a dip around 9 
pm. Nonetheless, when comparing the absolute change in the probability of atrial 
fibrillation over 24 hours, the mean slopes were similar by CKD status (0.0004 [SD 
0.0002] per 10 min in CKD vs. 0.0004 [SD 0.0003] per 10 min in no-CKD) (Figure D-
2), indicating a similar level of fluctuation in the diurnal patterns by CKD status. 
 Overall, CKD was associated with a significantly higher odds of having an 
episode of atrial fibrillation throughout the entire day than no-CKD (Figure 4). The 
highest difference in the probability of atrial fibrillation in CKD vs. no-CKD was seen 
around 9pm (Odds ratio [OR] 3.29, 95% CI: 1.69, 7.33), when no-CKD had a dip of the 
probability of atrial fibrillation. The smallest difference between CKD status in the 
presence of atrial fibrillation was observed around 3am (OR 1.99, 95% CI: 1.18, 3.64).  
 107 
Discussion 
Among community-dwelling older adults, we found that intermittent atrial 
fibrillation exhibited an overall biphasic diurnal pattern with a peak around midnight, and 
a nadir around noon. The patterns were largely similar regardless of CKD status. 
Although no-CKD demonstrated a dip of the probability of atrial fibrillation around 9 pm, 
the overall fluctuation, expressed as the 24-h average of the absolute change in the 
probability of atrial fibrillation, was not different between CKD and no-CKD. The 
probability of atrial fibrillation was consistently higher in CKD than in no-CKD 
throughout the day, but their difference was the largest around 9pm with an OR of 3.29 
(95% CI: 1.69, 7.33).  
 Only a handful number of studies have previously described the diurnal patterns 
of intermittent atrial fibrillation. All studies42,44-46,166,167 except one with a transtelephonic 
ECG43  reported a peak occurring at night. Of these six studies, five reported a peak 
around midnight,42,44-46,167 as in our study. Some of these studies reported additional 
peaks occurring in the morning or in the afternoon,42,46,166 and we observed some peaks 
smaller than the midnight peak in our study as well. Some differences across past studies 
and our study may reflect differences in study participant characteristics (e.g., age, 
cardiovascular disease profile, and various indications for undergoing heart rhythm 
monitoring) and methods of atrial fibrillation ascertainment (e.g., Holter monitor or 
implantable device). Regarding a nadir, most previous studies reported around noon,42,44-
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46,166 similarly as our study. Of interest, a few studies also reported a peak termination 
time of intermittent atrial fibrillation around noon.42,45,46  
There are a few plausible mechanisms behind diurnal pattern of intermittent atrial 
fibrillation. Sleep disturbances (including sleep apnea) are known to increase the risk of 
atrial fibrillation and thus may contribute to the peak around midnight.168 However, this 
may be unlikely as the average bedtime in older adults is around this time,169 although we 
do not have data on bedtime in our study population. More likely mechanism is a vagal 
arrhythmogenic activity. Indeed, atrial fibrillation is induced by vagal stimulation,45 and 
past studies have characterized the biphasic circadian rhythm of the cardiac autonomic 
activity, with a peak around midnight and a nadir around noon,170 which is identical to 
the overall diurnal pattern of intermittent atrial fibrillation in our study (Figure 2). 
Nonetheless, future studies are needed to better understand biological or 
pathophysiological mechanisms of the diurnal pattern of atrial fibrillation.  
  To our knowledge, very few studies have described the diurnal patterns of atrial 
fibrillation by major comorbid conditions. One study compared the patterns by body 
mass index (<25, 25-30, and >30 kg/m2) and found no significant differences.44 In this 
study, we found that overall, the shape of the pattern including the level of fluctuation 
was similar by CKD status. The lack of differences in diurnal pattern of intermittent atrial 
fibrillation by BMI and CKD may indicate that the diurnal pattern of atrial fibrillation 
may reflect biological circadian rhythm like autonomic nervous system.  
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This study has a few clinical and research implications. Based on our finding that 
atrial fibrillation exhibits a peak around midnight, screening or monitoring for atrial 
fibrillation should cover nighttime. In this context, at a given duration of monitoring, 
Holter and Zio XT Patch seem to have advantage over a transtelephonic ECG relying on 
patient symptom (patient would not be able to recognize palpitation while sleeping) or a 
watch-type device as some people may not prefer to wear it while sleeping. However, a 
watch-type device may be able to overcome this caveat by longer wearing time. Our 
findings may also potentially guide strategies for managing intermittent atrial fibrillation. 
For example, antiarrhythmic medications are still often used to manage atrial fibrillation, 
and thus strategies to maintain therapeutic concentration at midnight may be effective. 
Nonetheless, further studies are first needed to confirm our findings and to better 
understand the mechanisms and extrinsic factors underlying the diurnal patterns of atrial 
fibrillation. Furthermore, in light of all of our findings, future studies are needed to 
understand the prognostic impact of the diurnal patterns of atrial fibrillation. For 
example, it is unknown whether deviating from known diurnal patterns of atrial 
fibrillation during specific time windows could translate to a higher or lower risk of 
adverse outcomes such as stroke (like dipper vs. non-dipper for blood pressure).171 
A limitation worth noting in our study includes a small sample size that may have 
limited our statistical power in detecting true differences in diurnal patterns by CKD 
status. Nonetheless, we were able to detect consistently significant differences in the odds 
of atrial fibrillation across CKD throughout the day and found consistent diurnal patterns 
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after accounting for age and sex. Another limitation includes the fact that our analytical 
sample consisted of mostly white older individuals, which may affect the generalizability 
of our findings. As diurnal patterns could be influenced by extrinsic lifestyle factors, such 
as eating schedule, physical activity, and sleep, it is important to consider the 
characteristics of our population when extending or validating our results to other 
populations. There is also potential for some misclassification of arrhythmias by the ECG 
monitoring device; however, as the Zio Patch and its arrhythmia-detecting algorithm are 
FDA-approved for clinical use, this concern remains minimal. Despite the limitations, 
using a wearable ECG patch still allowed us to continuously capture atrial fibrillation 
events over 14 days, which we used to characterize more robust diurnal patterns of atrial 
fibrillation. Our modeling approach also allowed us to also adjust for important 
covariates of age and sex, which has not been commonly done in the past.  
 In conclusion, our findings suggest that intermittent atrial fibrillation exhibits an 
overall biphasic diurnal pattern with a peak occurring around midnight and a nadir 
around noon in both CKD and no-CKD. Compared to no-CKD, those with CKD have a 
constantly elevated probability of atrial fibrillation throughout the day, with the greatest 
difference around 9pm. Future studies are needed to evaluate clinical implications of 
diurnal variation of intermittent atrial fibrillation. 
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Table 1. Baseline characteristics of 67 study participants by chronic kidney disease 
status (CKD) 
 CKD No CKD 
 N=40 N=27 
Mean age (SD), years 80.8 (4.9) 78.9 (3.5) 
Female (%) 52.5 51.9 
Black (%) 10 11.1 
Study center (%)   
      Forsyth County, NC 27.5 14.8 
      Jackson, MS 7.5 7.4 
      Minneapolis, MN 30 55.6 
      Washington County, MD 35 22.2 
College or equivalent (%) 40 48.1 
Mean BMI (SD), kg/m2 29.6 (5.8) 26.7 (4.3) 
Current smokers (%) 15.4 7.4 
Current drinker (%) 48.7 66.7 
Mean systolic BP (SD), mmHg 134.4 (22.7) 134.7 (17.9) 
Antihypertensive medication (%) 87.2 69.2 
Diabetes (%) 32.5 14.8 
Prevalent cardiovascular disease 
(%) 29.7 11.1 
      Heart failure (%) 8.1 3.7 
      Coronary heart disease (%) 25.7 7.4 
      Stroke (%) 5.4 3.7 
Antiarrhythmic medication (%) 25 22.2 
QT prolonging medication* (%) 20.5 23.1 
Median analysis time (SD), days 
13.8 [12.6, 
13.9] 13.6 [12.4, 13.8] 
*List of QT prolonging medication listed in Table D-1 
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Figure 1. Plot of atrial fibrillation episode onset (represented by circles) and duration (represented by horizontal 
bars in red or green) in a random sample of 10 participants with chronic kidney disease (top row displayed in 
red) and no-CKD (bottom row displayed in green) 
 
Random subjects 1-5 depicted in red have chronic kidney disease; random subjects 6-10 depicted in green do not have 
chronic kidney disease 
 113 
Figure 2. Crude (unadjusted) 24-hour probability plots of atrial fibrillation presence summarized over 14 days 
  
Jittered dots in black represent presence (y=1) or absence (y=0) of atrial fibrillation episodes at a given time  
 114 
Figure 3. Predicted probability of atrial fibrillation in a given day from GEE models by chronic kidney disease 
status among males with a mean age of 80 years 
 
A) Chronic kidney disease; B) no chronic kidney disease 
Blue shaded area represents bootstrapped 95% confidence interval.  
Green dashed line represents the time of minimum predicted probability; red dashed line represents the time of 
maximum predicted probability.  
This model included CKD, age, and sex. 
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Figure 4. Association of chronic kidney disease with presence of atrial fibrillation over 24 hours 
 
Shaded area in dark grey represents bootstrapped 95% confidence interval.  





This dissertation investigated critical topics related to the burden of arrhythmias 
in CKD by leveraging a new wearable ECG patch in a large community-based cohort 
study. Quantification of disease burden is a vital initial step for acknowledging disease 
importance and strategizing public health and clinical practice. We thus identified large 
gaps in knowledge through a systematic review of the literature and addressed the gaps 
by establishing a crucial knowledge basis of clinically significant arrhythmias in CKD 
patients. Since there are no established treatments for recovering kidney function, we also 
identified modifiable risk factors or markers of clinically significant arrhythmias in CKD 
that would have clinical implications for preventing arrhythmias and identifying 
individuals at a high risk of arrhythmias with CKD. We lastly characterized the diurnal 
patterns of AF that may help identify windows of time with high arrhythmic risk which 
may guide timing of ECG assessment and antiarrhythmic medication administration.  
Summary of findings and implications 
In Chapter 1, we screened 16,245 articles and reviewed and analyzed 58 articles 
that reported relationships between CKD measures and arrhythmias in diverse study 
populations. Most studies were prospective and cross-sectional in design, and of high 
quality. These studies mainly examined AF in relationship with eGFR and demonstrated 
that lower kidney function was independently associated with a higher risk of AF. Some 
studies also demonstrated a significant burden of incident life-threatening ventricular 
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arrhythmias among CKD. Fewer studies examined albuminuria and these mainly focused 
on the relationship between albuminuria and AF, which was consistent and similar as 
with eGFR. There were, however, no studies that examined albuminuria with other 
arrhythmias, and there were only a few studies that examined other types of arrhythmia in 
the context of CKD. 
The robust relationship between CKD and AF is important given the high risk of 
stroke in CKD.132 This finding suggests that clinicians should better monitor or manage 
AF in patients with CKD, and consider optimal methods for screening (e.g., 24-holter or 
longer monitoring using wearable devices16). Moreover, the excess risk of severe 
ventricular arrhythmias in CKD highlights the need to study arrhythmias beyond AF in 
CKD. This study also highlights critical gaps in knowledge that future studies should 
tackle. Specifically, we found that there were limited data on arrhythmias other than AF 
and ventricular arrhythmia and few studies explored one of the two key kidney measures, 
albuminuria, in this regard.  
Chapter 2 addressed the key knowledge gaps found in Chapter 1 by analyzing the 
burden of various arrhythmias as well as the two major kidney measures, eGFR and 
albuminuria, in a community-based cohort of older individuals. We found a higher 
prevalence of clinically significant arrhythmias such as AF and non-sustained ventricular 
tachycardia among those with more severe CKD. AF showed the most consistent 
association with CKD severity, regardless of the type of burden examined (i.e., the 
prevalence and percent time in arrhythmia). This study also found that CKD with higher 
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risk was associated with higher frequency of long pause, which has not been widely 
reported in past literature. There was also a robust association between CKD and higher 
frequency of ventricular ectopy. When we examined the two CKD measures, eGFR and 
ACR, separately, ACR was associated with more arrhythmias overall. 
In support of the research conducted in Chapter 1, this study also found a robust 
CKD-AF relationship and corroborated past studies by demonstrating consistent 
relationships regardless of the arrhythmia burden and CKD measures that were examined, 
which further highlights the importance of AF management among CKD. This study also 
adds to the small but growing knowledge base on the relationship between CKD and 
bradycardia13,134 and supports the need to pay attention to bradycardia in clinical practice 
and research in CKD patients. Furthermore, this research strengthens recent statements 
from the American Heart Association emphasizing the importance of moving beyond 
examining arrhythmias only as a binary entity.145 We found that by examining different 
types of arrhythmia burden, we gained additional insights into the relationships between 
CKD and various arrhythmias that would have been missed by relying only on the 
presence vs. absence of arrhythmias.  
Chapter 3 tested various cardiac biomarkers (i.e., NT-proBNP and hs-cTnT), 
electrolytes (i.e., potassium and magnesium), and hemoglobin with the burden of 
arrhythmias. This study found that the cardiac biomarkers, especially NT-proBNP, were 
strongly associated with the burden of various arrhythmias in CKD and no-CKD. 
Compared to cardiac biomarkers, electrolytes were only associated with very few 
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arrhythmias in CKD. For example, atrial fibrillation was associated with lower potassium 
in CKD but with higher magnesium levels in no-CKD. Hemoglobin did not demonstrate 
strong associations with arrhythmias.  
This research provides a few implications for future research and clinical practice. 
This research supports the need for future studies to elucidate the temporality of 
associations and to better understand the extent to which cardiac overload or injury 
contribute or mediate the risk of arrhythmias among the high-risk CKD population. The 
findings also suggest that cardiac overload and injury are key markers of high arrhythmic 
burden in CKD, which highlights the potential value of cardiac biomarkers guiding 
targeted monitoring or management of severe arrhythmias in individuals with CKD.  
In Chapter 4, we identified a biphasic diurnal pattern of intermittent AF. 
Regardless of CKD status, there was a peak occurring around midnight and a nadir 
around noon. Compared to no-CKD, those with CKD had a constantly elevated 
probability of AF throughout the day, with the greatest difference occurring around 9pm.  
This research overall suggests that there seems to be a biphasic diurnal pattern of 
intermittent AF among a small group of community-dwelling older individuals. The peak 
observed around midnight suggests that monitoring for AF should cover nighttime, in 
which case, the use of Holter monitors or the Zio XT Patch may be advantageous, as 
individuals could more easily wear these while sleeping in contrast to perhaps a wearable 
watch, which some individuals may be not prefer to wear during bedtime. Our findings 
also have implications for treatment of AF. As AF is often treated using antiarrhythmic 
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medications, keeping a therapeutic concentration around midnight would be helpful for 
managing AF. However, further studies are needed to confirm our findings and to better 
understand the mechanisms and extrinsic factors underlying the diurnal patterns of atrial 
fibrillation. 
Future directions 
Prognostic value of ECG patch-detected arrhythmias  
 First, this dissertation demonstrated that by leveraging a new continuous 
monitoring ECG patch, we can study various types of arrhythmia that would be difficult 
to capture using conventional devices due to the transient and asymptomatic nature of 
arrhythmias. Some examples are long pause and atrioventricular block which are not as 
commonly occurring as atrial fibrillation or ventricular tachycardia. This dissertation 
therefore established crucial knowledge base on the burden of different arrhythmia types; 
however, it will be crucial for future studies to discern the prognostic value of the 
relationships observed in this research. For example, the association between atrial 
fibrillation and stroke has been relatively well-studied,41 but whether lesser-studied 
arrhythmias also confer higher risk of adverse outcomes such as cardiovascular disease or 
mortality remains unknown. Furthermore, the wearable ECG patch was able to capture 
both diagnosed and undiagnosed arrhythmias, thus, future studies will also need to 
elucidate the prognostic value of undiagnosed or asymptomatic arrhythmias. In this 
dissertation, we did not distinguish between diagnosed and undiagnosed arrhythmias but 
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past studies have shown that undiagnosed atrial fibrillation detected through more 
invasive forms of long-term monitoring is also associated with a higher risk of stroke.12,14 
Therefore, future research are needed to address the prognostic values of ECG patch-
detected arrhythmias to better understand the value of continuous monitoring and 
strategies for prevention and management of arrhythmias in CKD.  
Second, this dissertation demonstrated that it is important to consider various 
aspects of arrhythmia burden and not only examine the binary presence of arrhythmias. 
With newer continuous monitoring devices that can help measure different measures of 
arrhythmia burden such as frequency and duration more easily, it will be crucial for 
future studies to evaluate their prognostic impact to understand the values of these 
comprehensive measures. For example, in the case of atrial fibrillation, we demonstrated 
in this research that CKD severity is associated with both the presence of atrial 
fibrillation and percent time spent in atrial fibrillation. However, the relationships 
between different measures of atrial fibrillation burden and the risk of an adverse 
outcome such as stroke are not well-characterized. This will be important to investigate in 
the future, as current guidelines for stroke prevention in atrial fibrillation do not consider 
the percent time of atrial fibrillation as a clinical parameter for guiding treatment.145 
Similarly, the prognostic impact of the burden of other types of arrhythmia should be 
further examined in the future. 
Prognostic value of diurnal patterns of arrhythmias  
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 Our research explored the diurnal patterns of intermittent AF and found a biphasic 
pattern throughout the day. This is an important step in better understanding the burden 
of atrial fibrillation, as diurnal patterns can highlight the underlying biological 
mechanisms, such as the role of the autonomic nervous system. Although the circadian 
rhythm of the cardiac autonomic activity may contribute to the observed diurnal pattern 
of AF, our study did not examine the potential role of extrinsic factors (e.g., sleep, diet, 
physical activity); therefore, future studies should also consider the role of various 
extrinsic factors on the occurrence of AF. In our study, we also could not characterize the 
diurnal patterns of other arrhythmias due to data availability; however, future studies 
should build on our work and investigate the diurnal patterns of other clinically 
significant arrhythmias, as past studies have suggested that ventricular 
tachycardia/fibrillation and SCD are more likely to occur in the morning and could be 
sympathetically-driven.172,173 
Summary 
 This dissertation established a crucial knowledge basis of clinically significant 
arrhythmias in CKD, identified key markers of clinically significant arrhythmias in CKD, 
and characterized the diurnal patterns of atrial fibrillation. Our research further highlights 
the relevance of arrhythmias in CKD, sheds light on the importance of cardiac overload 
and injury in the pathophysiology of arrhythmias, and demonstrates a diurnal pattern of 
AF as an entity with potential clinical implications. This dissertation will guide future 
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studies in a few aspects: the need to focus on several arrhythmias including 
bradyarrhytmias in CKD, the importance of further investigating cardiac overload and 
injury for preventing and managing arrhythmias, and the potential value of diurnal 








Appendix A: Supplementary materials for Chapter 1 
 
Table A-1. Literature search strategy  
 
Chronic kidney disease Arrhythmia Study filter 
PubMed 
"Kidney Diseases"[Mesh] OR kidney 
disease*[tw] OR renal disease*[tw] 
OR "Renal Insufficiency"[Mesh] OR 
renal insufficienc*[tw] OR kidney 
insufficienc*[tw] OR “kidney 
dysfunction”[tw] OR “renal 
dysfunction”[tw] OR  
"Dialysis"[Mesh] OR “dialysis”[tw] 
OR “hemodialysis”[tw] OR 
“haemodialysis”[tw] OR kidney 
failure*[tw] OR renal failure*[tw] 
OR "Uremia"[Mesh] OR 
“uremia”[tw] OR “ESRF”[tw] OR 
“ESKF”[tw]  OR “ESRD”[tw] OR 
“ESKD”[tw] OR “CKF”[tw] OR 
“CKD”[tw] OR “CRF”[tw] OR 
“CRD”[tw] OR "Creatinine"[Mesh] 
OR “serum creatinine”[tw] OR 
“creatinine clearance”[tw] OR 
"Glomerular Filtration Rate"[Mesh] 
OR “glomerular filtration rate”[tw] 
OR “GFR”[tw] OR “eGFR”[tw] OR 
"Albuminuria"[Mesh] OR 
“albuminuria”[tw] OR “albumin 
creatinine ratio”[tw] OR “albumin-
to-creatinine ratio”[tw] OR “albumin 
to creatinine ratio”[tw] OR 
“albumin/creatinine ratio”[tw] OR 
“ACR”[tw] OR "Proteinuria"[Mesh] 
OR “proteinuria”[tw] OR “protein 
creatinine ratio”[tw] OR “protein-to-
creatinine ratio”[tw] OR “protein to 
creatinine ratio”[tw] OR 
“protein/creatinine ratio”[tw] OR 
"beta 2-Microglobulin"[Mesh] OR 
"Arrhythmias, 
Cardiac"[Mesh] OR 
Arrhythmia*[tw] OR "Atrial 
Fibrillation"[Mesh] OR 




OR Long pause*[tw] OR 





ventricular ectop*[tw] OR 
supraventricular ectop*[tw] 




Pointes"[Mesh] OR “torsade 









flutter*[tw] OR premature 
atrial contraction* [tw] OR 
premature ventricular 
contraction* [tw] OR “heart 





Type]  OR 
"Observational Studies 





















“beta 2-Microglobulin”[tw] OR 
“beta-2-microglobulin”[tw] OR 
“B2M”[tw] OR beta-trace 
protein*[tw] OR beta trace 
protein*[tw] OR "Cystatin C"[Mesh] 
OR “cystatin C”[tw] OR “urine 
albumin excretion”[tw] OR “urinary 
albumin excretion”[tw] OR “urine 





Syndrome"[Mesh] OR “sick 
sinus syndrome” [tw] OR 
heart rhythm disorder*[tw] 




'renal replacement therapy'/exp OR 
'kidney disease'/exp OR 'uremia'/exp 
OR 'creatinine'/exp OR 'estimated 
glomerular filtration rate'/exp OR 
'glomerulus filtration rate'/exp OR 
'albuminuria'/exp OR 
'proteinuria'/exp OR 'beta 2 
microglobulin'/exp OR 'urine 
albumin to creatinine ratio'/exp OR 
'urine protein to creatinine ratio'/exp 
OR 'urine protein creatinine ratio'/exp 
OR 'urine albumin creatinine 
ratio'/exp OR 'cystatin C'/exp OR 
'protein urine level'/exp OR (‘kidney 
disease*’ OR ‘renal disease*’ OR 
‘renal insufficienc*’ OR ‘kidney 
insufficienc*’ OR 'dialysis' OR 
'hemodialysis' OR 'haemodialysis' 
OR ‘kidney failure*’ OR ‘renal 
failure*’ OR 'uremia' OR 'esrf' OR 
'eskf' OR 'esrd' OR 'eskd' OR 'ckf' 
OR 'ckd' OR 'crf' OR 'crd' OR 'serum 
creatinine' OR ‘creatinine clearance’ 
OR ‘glomerular filtration rate’ OR 
‘eGFR’ OR ‘GFR’ OR ‘albuminuria’ 
OR ‘albumin to creatinine ratio’ OR 
‘albumin-to-creatinine ratio’ OR 
‘albumin creatinine ratio’ OR 
‘albumin/creatinine ratio’ OR ‘ACR’ 
OR ‘proteinuria’ OR ‘protein 
creatinine ratio’ OR protein-to-
'heart arrhythmia'/exp OR 
'sick sinus syndrome'/exp 
OR (arrhythmia* OR 'atrial 
fibrillation' OR 
‘atrioventricular block*’ OR 
‘long pause*’ OR ‘long 
pausing*’ OR ‘ventricular 
ectop*’ OR ‘ventricular 
premature complex*’ OR 
‘supraventricular ectop*’ 










contraction*’ OR ‘heart 
block’ OR ‘sick sinus 
syndrome’ OR ‘heart 











study'/exp OR 'clinical 
study'/de OR 'case 
control study'/exp OR 
'cross-sectional 
study'/exp) OR ('case 
control'):ti,ab OR 
(cohort NEXT/1 (study 




NEXT/1 (study OR 
studies)):ab,ti OR 
((retrospective or 
"cross sectional") AND 





creatinine ratio’ OR ‘protein to 
creatinine ratio’ OR 
‘protein/creatinine ratio’ OR ‘beta-2 
microglobulin’ OR ‘beta 2-
microglobulin’ OR ‘B2M’ OR ‘beta 
trace protein*’ OR ‘beta-trace 
protein’ OR ‘urine albumin 
excretion’ OR ‘ urinary albumin 
excretion’ OR ‘urine protein 
excretion’ OR ‘urinary protein 











Table A-2. Data extraction elements 
 
Heading Elements 
Study details Author, year, journal, country of origin 
Study 
population 
Number of participants, setting, population characteristics, enrollment 
period, follow-up years 
Eligibility 
criteria 




CKD measure, CKD measure categorization 
Arrhythmia 
measurement 
Arrhythmia, atrial fibrillation measurement/definition, ventricular 
tachycardia measurement/definition, ventricular fibrillation 
measurement/definition, prolonged pause measurement/definition, 
atrioventricular block measurement/definition, premature atrial 
contraction measurement/definition, premature ventricular contraction 
measurement/definition, other arrhythmia measurement/definition, 






Age, male, race, body mass index, obesity, coronary heart disease, 
heart failure, stroke, other cardiovascular disease, hypertension, 
current smoking, systolic blood pressure, diastolic blood pressure, 
dyslipidemia, total cholesterol, low-density lipoprotein, diabetes, left 
ventricular ejection fraction, other echocardiographic parameters, 
eGFR, albuminuria/proteinuria, cystatin C, other CKD measure, atrial 
fibrillation, atrial flutter, ventricular tachycardia, ventricular 
fibrillation, prolonged pause, atrioventricular block, premature atrial 
contraction, premature ventricular contraction, other arrhythmia, 
antihypertensive medication, angiotensin-converting-enzyme inhibitor 
or angiotensin II receptor blocker, beta-blocker, calcium channel 
blocker, antiplatelet, diuretic, antidiabetic medication, statin, 
antiarrhythmic medication, implantable cardioverter defibrillator, 
pacemaker, other arrhythmia therapy 
Results Arrhythmia type, effect estimate without adjustment, effect estimate 





Table A-3. Newcastle Ottawa Scales for cohort studies 
 
Newcastle Ottawa Scales for Cohort Studies 
Note: A study can be awarded a maximum of one star for each numbered item within 
the Selection and Outcome categories. A maximum of two stars can be given for 
Comparability. 
Selection 1) Representativeness of the exposed cohort 
a) truly representative of the average _______________ (describe) 
in the community * 
b) somewhat representative of the average ______________ in the 
community * 
c) selected group of users (e.g. nurses, volunteers) 
d) no description of the derivation of the cohort 
2) Selection of the non-exposed cohort 
a) drawn from the same community as the exposed cohort * 
b) drawn from a different source 
c) no description of the derivation of the non-exposed cohort  
3) Ascertainment of exposure 
a) secure record (e.g. surgical records) * 
b) structured interview * 
c) written self report 
d) no description 
4) Demonstration that outcome of interest was not present at start of 
study 
a) yes * 
b) no 
Comparability 1) Comparability of cohorts on the basis of the design or analysis 
a) study controls for _____________ (select the most important 
factor) * 
b) study controls for any additional factor * (This criterion could 
be modified to indicate specific control for a second important 
factor.)  
Outcome 1) Assessment of outcome  
a) independent blind assessment * 
b) record linkage * 
c) self report  
d) no description 
2) Was follow-up long enough for outcomes to occur 




3) Adequacy of follow up of cohorts 
a) complete follow up - all subjects accounted for * 
b) subjects lost to follow up unlikely to introduce bias - small 
number lost - > ____ % (select an adequate %) follow up, or 
description provided of those lost) * 
c) follow up rate < ____% (select an adequate %) and no 
description of those lost 




Table A-4. Newcastle Ottawa Scales adapted for cross-sectional studies 
 
Selection 1) Representativeness of the sample: 
a) Truly representative of the average in the target population. * 
(all subjects or random sampling) 
b) Somewhat representative of the average in the target 
population. * (non-random sampling) 
c) Selected group of users. 
d) No description of the sampling strategy. 
2) Sample size: 
     a) Justified and satisfactory. * 
     b) Not justified. 
3) Non-respondents: 
     a) Comparability between respondents and non-respondents 
characteristics is established, and the response rate is satisfactory. 
* 
     b) The response rate is unsatisfactory, or the comparability 
between respondents and non-respondents is unsatisfactory. 
     c) No description of the response rate or the characteristics of the 
responders and the non-responders. 
4) Ascertainment of the exposure (risk factor): 
     a) Validated measurement tool. ** 
     b) Non-validated measurement tool, but the tool is available or 
described*  
c) No description of the measurement tool.  
Comparability 1) The subjects in different outcome groups are comparable, based 
on the study design or analysis. Confounding factors are controlled. 
     a) The study controls for the most important factor (select one). * 
b) The study control for any additional factor. * 
Outcome 1) Assessment of the outcome: 
     a) Independent blind assessment. ** 
     b) Record linkage. ** 
     c) Self report.  * 
     d) No description. 
2) Statistical test: 
     a) The statistical test used to analyze the data is clearly described 
and appropriate, and the measurement of the association is 
presented, including confidence intervals and the probability level 
(p value). * 
     b) The statistical test is not appropriate, not described or 
incomplete. 
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Table A-5. Newcastle Ottawa Scales for case-control studies 
 
Selection 1) Is the case definition adequate? 
a) yes, with independent validation* 
b) yes, eg record linkage or based on self reports  
c) no description 
2) Representativeness of the cases 
a) consecutive or obviously representative series of cases*  
b) potential for selection biases or not stated 
3) Selection of Controls 
a) community controls*  
b) hospital controls 
c) no description 
4) Definition of Controls 
a) no history of disease (endpoint)*  
b) no description of source 
Comparability 1) Comparability of cases and controls on the basis of the design or 
analysis 
a) study controls for _______________ (Select the most important 
factor.)* 
b) study controls for any additional factor* (This criteria could be 
modified to indicate specific control for a second important 
factor.) 
Exposure 1) Ascertainment of exposure 
a) secure record (eg surgical records)* 
b) structured interview where blind to case/control status*  
c) interview not blinded to case/control status 
d) written self report or medical record only 
e) no description 
2) Same method of ascertainment for cases and controls  
a) yes* 
b) no 
3) Non-Response rate 
a) same rate for both groups* 
b) non respondents described 
c) rate different and no designation 
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 Table A-6. Quality assessment of the 58 studies included in the systematic review 
using the Newcastle Ottawa Scales 
 
Prospective study 
Reference Year Selection/4 Comparability/2 Outcome/3 Total score/9 
Alonso  2011 4 2 3 9 
Babu 2016 4 2 3 9 
Bansal 2017 4 2 3 9 
Deo§ 2010 4 2 3 9 
Eisen 2017 4 2 3 9 
Elahi 2003 4 2 3 9 
Hage  2011 4 2 2 8 
Hai 2017 4 2 3 9 
Horio 2010 4 2 3 9 
Hreybe 2006 3 2 3 8 
Hsu 2013 4 2 3 9 
Iguchi 2010 4 2 2 8 
Jensen 2013 4 2 3 9 
Jensen 2014 4 2 3 9 
Khurshid  2018 4 2 3 9 
Kreuz 2010 4 2 3 9 
Kreuz 2011 4 2 3 9 
Laukkanen 2016 3 2 3 8 
Lee 2016 4 2 3 9 
Liao 2017 4 2 3 9 
Liao 2015 4 2 3 9 
Lim 2017 4 2 3 9 
Marcos 2017 4 2 2 8 
Molnar 2017 4 2 3 9 
Naruse 2011 4 2 2 8 
Nelson 2012 3 2 3 8 
Robin 2006 4 2 3 9 
Sciacqua 2014 4 2 3 9 
Shen 2016 3 2 3 8 
Takahashi 2009 4 2 3 9 
Tokuda 2011 4 2 2 8 
Watanabe 2009 4 2 3 9 
Xu 2015 4 2 3 9 
Cross-sectional studies 
Reference Year Selection/5 Comparability/2 Outcome/3 Total score/10 
Ananthapanyasut 2010 3 2 3 8 
Auer 2007 4 2 3 9 
Baber 2011 4 2 3 9 
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Chua 2013 4 2 3 9 
Deo§ 2010 3 2 3 8 
Deshmukh 2017 4 2 3 9 
Gorczyca-Michta 2013 4 2 1 7 
Hashemzadeh 2013 1 2 3 6 
Iguchi 2008 4 2 3 9 
Karatas 2015 1 2 3 6 
Limite 2016 4 2 3 9 
Liu  2011 3 2 3 8 
McManus 2009 4 2 3 9 
Nisanoglu 2007 2 2 3 7 
Ohsawa 2016 4 2 3 9 
Ohyama 2013 3 2 3 8 
Soliman 2010 4 2 3 9 
Soman 2002 5 2 3 10 
Suzuki 2012 4 2 3 9 
Todorov 2017 2 2 3 7 
Yonezawa 2018 4 2 3 9 
Case-control studies 
Reference Year Selection/4 Comparability/2 Outcome/3 Total score/9 
Dalal 2012 4 2 2 8 
Liu  2015 3 2 1 6 
Lu 2016 3 2 2 7 
Mene-Afejuku 2017 3 2 1 6 
 
§ This study is listed as both prospective and cross-sectional because it includes 
examinations of incident and prevalent atrial fibrillation 
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Table A-7. Summary of 21 cross-sectional studies included in the systematic review  
 


































(15.0)  51.5 91.1 32.2 
136.0 
(19.0) 34.1 30 11.6 59.3 NA 








(11.0) 60.1 62.8 - - - - - 24.9 NA 




(9.2) 45.1 58.7 14.5 - 13.2 4.8 - 20.6 NA 








) 77 77 43.4 - - 34 - 54 NA 





(5.3) 41.7 41.6 9.7 - 21.6 6 - 15.5 NA 
Deshmuk








(12.8) 77.3 75.5 - - - - - 49.2 NA 
Gorczyca








89)† 54.6 100 - - 30.4 37.7 5 25.3 NA 
Hashemz-








(15.7) 68.9 8 40.2 - - - 3 20.5 NA 




78)* 33.7 35.4 26.5 
125.7 
(16.2) - - - 12.2 NA 
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(11.9) 74.7 41.7 65.9 
120.0 
(20.0)† 44.4 - - 19.3 NA 








(11.5) 73.6 49.1 11 - 38.6 - 1.6 16.5 NA 







(12.0) 49.4 100 25.1 
149.7 
(27.5) - - - - NA 







(10.1) 81.5 70.3 - 
132.8 
(21.0) - 17 - 26.8 NA 
Nisanogl








(4.4) 69.5 41.8 49.5 - -  1.9 18.5 NA 











131.4)‡ - - - 7.9 NA 




(9.2)  62 30.8 26.5 
125.7 
(16.2) - - - 8 NA 








(10.8) 54 86 14 - - 10 - 45 NA 






(13.8) 57.8 62.9 - - - - - 28.9 NA 




















75)† 72.1 - - - - - - - NA 
Yonezaw






(13.3) 48.2 23.2 37.7 
125.8 
(17.1) - - - 6.9 NA 
 
* Median with interquartile interval 
† Median with interquartile interval or interquartile range among those without atrial fibrillation 
‡ Median with interquartile interval among community-dwelling males 
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Table A-8. Summary of 4 case-control studies included in the systematic review  
 

































80.0 28.3 64.9 - 57.4 - - 76.9 NA 






49.5 - - 141.3 (15.7) 
- - - - NA 
























Table A-9. List of covariates adjusted for in prospective studies examining the association between eGFR groups 
and atrial fibrillation  
 
Study Year Adjusted variables 
Watanabe 2010 Age, sex, body mass index, systolic blood pressure, 
diastolic blood pressure, treated hypertension, diabetes 
Deo 2010 Age, sex, race, diabetes, C-reactive protein, low-density 
lipoprotein, high-density lipoprotein, prevalent 
coronary heart disease, prevalent heart failure, left 
ventricular hypertrophy, systolic blood pressure, 
diastolic blood pressure, angiotensin-converting-
enzyme inhibitor, beta blocker, calcium channel 
blocker, diuretic 
Horio 2010 Age, smoking, diuretic, left atrial diameter, left 
ventricular mass index 
Alonso 2011 Age, sex, race, study site, education, income, height, 
smoking, drinking, diabetes, systolic blood pressure, 
antihypertensive medication, body mass index, high 
sensitivity C-reactive protein, prevalent coronary heart 
disease, prevalent heart failure, incident heart failure or 
myocardial infarction during follow-up, any 
hospitalization before end of follow-up 
Naruse 2011 Age, sex, persistent atrial fibrillation, left atrial volume, 
left ventricular ejection fraction, left ventricular mass 
index 
Hsu 2013 Age, sex, race, CD4 cell count, HIV RNA viral load, 
hypertension, diabetes, coronary artery disease, 
congestive heart failure, chronic lung disease, smoking, 
alcoholism, hyperthyroidism, hypothyroidism, body 
mass index, proteinuria 
Sciacqua 2014 Smoking, age, hypercholesterolemia, sex, hypertension, 
diabetes, obesity, metabolic syndrome, left ventricular 
hypertrophy, left atrial volume index 
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Xu 2015 Age, sex, systolic blood pressure, diastolic blood 
pressure, body mass index, total cholesterol, 




2016 Age, sex, examination year, systolic blood pressure, 
smoking, body mass index, alcohol, diabetes, 
antihypertensive medication, myocardial infarction, 
coronary heart disease, heart failure 
Molnar 2017 Age, sex, income, index year, diabetes, hypertension, 
chronic obstructive pulmonary disease, coronary artery 
disease, myocardial infarction, stroke/ transient 
ischemic attack, hemorrhage, heart failure, peripheral 
vascular disease, coronary artery bypass graft 
Bansal: 
JHS 
2017 Age, age squared, sex, education, height, weight, 
smoking, diabetes, heart failure, myocardial fraction, 
stroke, systolic blood pressure, diastolic blood pressure, 
antihypertension medication, left ventricular mass, left 
ventricular ejection fraction, PR duration 
Bansal: 
MESA 
2017 Age, age squared, sex, education, height, weight, 
smoking, diabetes, heart failure, myocardial fraction, 
stroke, systolic blood pressure, diastolic blood pressure, 
antihypertension medication, left ventricular mass, left 
ventricular ejection fraction, PR duration 
Bansal: 
CHS 
2017 Age, age squared, sex, education, height, weight, 
smoking, diabetes, heart failure, myocardial infarction, 
stroke, systolic blood pressure, diastolic blood pressure, 
antihypertension medication, left ventricular mass, left 





Table A-10. List of covariates adjusted for in prospective studies examining the association between continuous 
eGFR and atrial fibrillation  
 
Study Year Adjusted variables 
Watanabe 2009 Age, sex, body mass index, systolic and diastolic blood pressure, 
hypertension, diabetes 
Iguchi 2010 Age, sex, cardiac disease, diabetes, hypertension, 
hypercholesterolemia 
Tokuda 2011 Hypertension, left atrial diameter 
Sciacqua 2014 Smoking, fasting glucose, low-density lipoprotein, age, gender, 
systolic blood pressure, body mass index, left ventricular mass 
index, E/A ratio, left atrial volume index 
Eisen: No 
CVD 
2017 Age, gender, hypertension, diabetes, chronic obstructive pulmonary 




2017 Age, gender, hypertension, diabetes, chronic obstructive pulmonary 
disease, beta blockers, angiotensin-converting-enzyme inhibitor, 
statin, prior cardiovascular disease 
Bansal: JHS 2017 Age, age squared, sex, education, height, weight, smoking, diabetes, 
heart failure, myocardial infarction, stroke, systolic and diastolic 
blood pressure, antihypertension medication, left ventricular mass, 
left ventricular ejection fraction, PR duration 
Bansal: MESA 2017 Age, age squared, sex, education, height, weight, smoking, diabetes, 
heart failure, myocardial infarction, stroke, systolic and diastolic 
blood pressure, antihypertension medication, left ventricular mass, 
left ventricular ejection fraction, PR duration 
Bansal: CHS 2017 Age, age squared, sex, education, height, weight, smoking, diabetes, 
heart failure, myocardial infarction, stroke, systolic and diastolic 
blood pressure, antihypertension medication, left ventricular mass, 
left ventricular ejection fraction, PR duration 
Macros 2017 Age, sex, body mass index, antihypertensive, heart failure, previous 
myocardial infarction, diabetes, peripheral artery disease, smoking, 
PR interval duration, N-terminal pro b-type natriuretic peptide, 
interim myocardial infarction, interim heart failure 
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Table A-11. Summary of cross-sectional study results on the association between eGFR groups and atrial 
fibrillation 
 





Unadjusted OR (95% CI)  Adjusted OR (95% CI) Adjusted variables 
Baber 2011 ≥60 & ACR <30,  
≥60 & ACR ≥30,  
30-59,  
<30 
≥60 & ACR <30 Not reported ≥60 & ACR ≥30: 2.20 (1.64-2.94),  
30-59: 1.51 (1.21-2.05),  
<30: 2.86 (1.38-5.92) 
Age, race, sex, geographic 
region, current smoking, 
body mass index, 
hypertension, diabetes, 
coronary artery disease, 
symptoms of heart failure, 
ECG-detected left 
ventricular hypertrophy, 
elevated cholesterol, statin, 
renin-angiotensin-system 
inhibitor, CRP ≥3 mg/L 
Deo 2010 ≥60,  
<60 
≥60 1.92 (1.45-2.56) 1.22 (0.89-1.66) Age, gender, race, diabetes, 
C-reactive protein, low and 
high-density lipoprotein, 
coronary heart disease, 
heart failure, left ventricular 
hypertrophy, systolic and 
diastolic blood pressure, 
angiotensin-converting-
enzyme inhibitor, beta-
blocker, calcium channel 
blocker, diuretic 
Iguchi 2008 >75.5,  
62.6-75.5,  
<62.6 
<62.6 Not reported 62.6-75.5: 1.12 (0.88-1.42),  
<62.6: 1.91 (1.54-2.38) 
Age, gender, vascular risk 
factors, cardiac disease 
Limite 2016 ≥90,  
60-89,  
<60 
≥90 60-89: 1.83 (1.20-2.79),  
<60: 3.0 (1.67-5.39) 
60-89: 1.59 (1.01-2.5),  
<60: 2.35 (1.25-4.48) 




McManus 2009 >85,  
66-85,  
<66 
>85 66-85:  1.26 (0.49-3.23),  
<66:  2.89 (1.27-6.59) 
66-85: 1.00 (0.33-3.01),  
<66: 1.59 (0.57-4.40) 
Age, Age2, gender, race, 
body mass index, systolic 
and diastolic blood 





Ohyama 2013 ≥90,  
60-89,  
<60 
≥90 Not reported 60-89: 1.55 (0.66-3.65),  
<60: 2.66 (1.07-6.60) 
Age, gender, hypertension, 
diabetes, smoking, cardiac 
disease, proteinuria 
Suzuki 2012 >73.7,  
60.1-73.7,  
<60.1 
>73.7 60.1-73.7: 1.49 (1.16-1.91),  
<60.1: 2.23 (1.74-2.85) 
60.1-73.7: 1.71 (1.22-2.41),  
<60.1: 2.15 (0.79-1.94) 
Age, heart failure, organic 




infarction or transient 
ischemic attack, 
antiarrhythmic drug class 1 
and 4, digitalis, proteinuria 
Yonezawa 2018 ≥90,  
60-89,  
<60 
≥90 Not reported 60-89: 1.48 (0.86-2.77),  
<60: 1.58 (0.86-3.09) 






 Figure A-1. Odds ratios (ORs) of atrial fibrillation comparing reduced to referent eGFR groups from cross-
sectional studies  
  
The diamonds and their widths represent ORs and 95% confidence intervals, respectively. The cutoffs (in 
ml/min/1.73m2) for reduced and referent eGFR groups are: Iguchi (2008) <62.6 vs. >75.5, McManus (2009) <66 vs. 
>85, Deo (2010) <60 vs. ≥60, Baber (2011) <30 vs. ≥60 & ACR <30, Suzuki (2012) <60.07 vs. >73.67, Ohyama 
(2013) <60 vs. ≥90, Limite (2016) <60 vs. ≥90, Yonezawa (2018) <60 vs. ≥90. 
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Table A-12. Summary of cross-sectional study results on the association between continuous eGFR and atrial 
fibrillation 
 
Study Year eGFR scale  
(ml/min/1.73m2) 
Unadjusted OR (95% CI)  Adjusted OR (95% CI)  Adjusted variables 
Auer 2007 Per -10  Not reported 1.21 (1.02-1.39) Age, weight, sex, surgery for 
valvular heart disease, number of 
bypass grafts, use of arterial 
conduit, beta-blocker, 
preoperative heart rate, smoking, 
serum potassium 
Ananthapanyasut 2010 Per 1 1.01 (1.00-1.02) 1.01 (0.99-1.02) Age, age ≥65 years, race, systolic 
blood pressure, heart failure, left 
atrial diameter 
Liu 2011 Per 1 Not reported 0.978 (0.954-1.002) Age, hypertension duration, 
creatinine, interventricular 
septum thickness, left ventricular 
posterior wall thickness 
Suzuki 2012 Per 1 0.98 (0.97-0.99) 0.98 (0.97-0.99) Age, heart failure, organic 
cardiac disease, valvular heart 
disease, cardiomyopathy, 
diabetes, dyslipidemia, cerebral 
infarction or transient ischemic 
attack, antiarrhythmic drug class 
1 and 4, digitalis, proteinuria 
Gorczyca-Michta 2013 Per 1 Not reported 0.9275 (0.7073-1.2163) Hypothyroidism, ischemic heart 
disease, hyperthyroidism, 
euthyroid goiter, myocardial 
infarction, heart failure, 
hyperlipidemia, age, left 
ventricular ejection fraction, 
hemoglobin, triglycerides, low-





Figure A-2. Odds ratios (ORs) of atrial fibrillation per -15 ml/min/1.73m2 of eGFR from cross-sectional studies  
 
 




Table A-13. List of covariates adjusted for in prospective studies examining the 
association between albuminuria groups and atrial fibrillation 
 
Study Year Adjusted variables 
Alonso 2011 Age, sex, race, study site, education, income, height, 
smoking, drinking, diabetes, systolic blood pressure, 
antihypertensive medication, body mass index, high 
sensitivity C-reactive protein, prevalent coronary 
heart disease, prevalent heart failure, incident heart 
failure or myocardial infarction during follow-up, any 
hospitalization before end of follow-up 
Hsu 2013 Age, sex, race, CD4 cell count, HIV RNA viral load, 
hypertension, diabetes, coronary artery disease, 
congestive heart failure, chronic lung disease, 
smoking, alcoholism, hyperthyroidism, 
hypothyroidism, body mass index, proteinuria 
Lim 2017 Age, sex, body mass index, smoking, alcohol 
consumption, exercise frequency, diabetes, 
hypertension, dyslipidemia, ischemic heart disease, 




2017 Age, age squared, sex, education, height, weight, 
smoking, diabetes, heart failure, myocardial 
infarction, stroke, systolic and diastolic blood 
pressure, antihypertension medication, left 




2017 Age, age squared, sex, education, height, weight, 
smoking, diabetes, heart failure, myocardial 
infarction, stroke, systolic and diastolic blood 
pressure, antihypertension medication, left 
ventricular mass, left ventricular ejection fraction, PR 
duration 
Molnar 2017 Age, sex, income, index year, diabetes, hypertension, 
chronic obstructive pulmonary disease, coronary 
artery disease, myocardial infarction, stroke/ transient 
ischemic attack, hemorrhage, heart failure, peripheral 
vascular disease, coronary artery bypass graft 
 
 147 
Table A-14. Summary of cross-sectional study results on the association between albuminuria groups and atrial 
fibrillation 
 




Unadjusted OR (95% 
CI)  
Adjusted OR (95% 
CI)  
Adjusted variables 






7-15: 2.27 (0.78-6.63),  
>15: 3.88 (1.42-10.61) 
7-15: 2.55 (0.83-7.83),  
>15: 4.61 (1.56-13.66) 
Age, Age2, gender, race, 
body mass index, 





Suzuki 2012 Urine protein: 





1.73 (1.17-2.56) 1.23 (0.78-1.95) Age, heart failure, 
organic cardiac disease, 
valvular heart disease, 
cardiomyopathy, 
diabetes, dyslipidemia, 
cerebral infarction or 
TIA, antiarrhythmic 
drug class 1 and 4, 
digitalis, eGFR  














Figure A-3. Odds ratios (ORs) of atrial fibrillation comparing high to low albuminuria groups from cross-
sectional studies  
 
 
The diamonds and their widths represent ORs and 95% confidence intervals, respectively. The cutoff values for high 
and low albuminuria groups are: McManus (2009): ACR >15 vs. <7 mg/g; Suzuki (2012): Proteinuria positive vs. 








(A) Includes prospective studies examining the association of reduced vs. referent eGFR groups with atrial fibrillation; 
(B) Includes prospective studies examining the association of continuous eGFR (per -15 ml/min/1.73m2) with atrial 




Table A-15. List of covariates adjusted for in prospective studies examining the association between eGFR 
groups and ICD shock 
 
Study Year Adjusted variables 
Takahashi 2009 ICD for secondary prevention, beta-blocker, QTs interval 
>120ms, left ventricular ejection fraction <35%, >10 VPBs/h 
Hage 2011 Age, gender, hypertension, atrial fibrillation, myocardial 
infarction, left ventricular ejection fraction, left bundle branch 
block, biventricular pacing, antiarrhythmic medications 
Babu 2016 Age, gender, left ventricular ejection fraction, heart failure 
etiology (ischemic vs. non-ischemic), angiotensin-converting-
enzyme inhibitors, beta blockers, amiodarone 
Hai 2017 Age, hypertension, coronary artery disease, early ventricular 
tachycardia, left ventricular ejection fraction ≤35%, triple-
vessel disease, successful revascularization 
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 Table A-16. Summary of results on the associations of chronic kidney disease measures with various 
arrhythmias from prospective, cross-sectional, and case-control studies 
 
Study design Study Year Arrhythmia CKD measure Referent 
group  
Unadjusted estimate (HR 
or OR) 












<1 Not reported HR (no 95% CI):  
1-1.4: Not reported 
>1.4: 6.00 
Age, sex, left ventricular 
ejection fraction, 
indication for ICD, beta-
blockers 
Khurshid  2018 Supraventricular 
arrhythmias 
CKD based on 
diagnosis codes 
No CKD Not reported HR (95% CI): 
2.43 (1.56-3.79) 
Age, sex, body mass 
index, tobacco use, 








peripheral artery disease, 
stroke, coronary artery 
disease, heart failure 
Khurshid  2018 Ventricular 
arrhythmias 
CKD based on 
diagnosis codes 
No CKD Not reported HR (95% CI): 
2.46 (1.80-3.37) 
Age, sex, body mass 
index, tobacco use, 








peripheral artery disease, 
stroke, coronary artery 
disease, heart failure 








1 Not reported OR (95% CI): 
2: 3.96 (1.2-13.04) 
Baseline NYHA class 





1 Not reported OR (95% CI): 






Robin 2006 ICD shock for VF ESRD No ESRD HR (95% CI): 
2.3 (1.17-4.54) 
HR (95% CI): 
2.67 (1.38-5.17) 
Ejection fraction, ICD 
implant indication 
Bradycardia 
Khurshid  2018 Bradyarrhythmias CKD based on 
diagnosis codes 
No CKD Not reported HR (95% CI): 
1.37 (0.98-1.91) 
Age, sex, body mass 
index, tobacco use, 








peripheral artery disease, 
stroke, coronary artery 
disease, heart failure 
Khurshid  2018 Conduction system 
diseases 
CKD based on 
diagnosis codes 
No CKD Not reported HR (95% CI): 
1.87 (1.44-2.42) 
Age, sex, body mass 
index, tobacco use, 








peripheral artery disease, 
stroke, coronary artery 
disease, heart failure 




≥60 Not reported HR (95% CI): 
1.14 (0.63-2.17) 
Age, sex, race, study 
clinic, hypertension, 
diabetes, body mass 
index, current smoking, 
low-density lipoprotein, 













>81.5 OR (95% CI): 
63.1-81.5: 1.28 (0.97-1.70), 
46.2-≤63.1: 1.53 (1.17-2),  
≤46.2: 1.39 (1.06-1.83), 
Dialysis: 1.91 (1.3-2.8) 
OR (95% CI): 
63.1-81.5: 1.31 (0.96-1.8),  
46.2-≤63.1: 1.55 (1.10-
2.17),  
≤46.2: 1.56 (1.07-2.28),  
Age, gender, race, 
admission diagnosis, 






Dialysis: 2.43 (1.40-4.20) inhibitor, diabetes, 
hemoglobin 










>81.5 OR (95% CI): 
63.1-81.5: 1.30 (0.93-1.82), 
46.2-≤63.1: 1.75 (1.27-2.40), 
≤46.2: 1.45 (1.05-2.02),  
Dialysis: 1.04 (0.59-1.84) 
OR (95% CI): 
63.1-81.5: 1.41 (1-1.2),  
46.2-≤63.1: 1.7 (1.14-2.53),  
≤46.2: 1.39 (0.89-2.18),  
Dialysis: 1.24 (0.6-2.6) 
Age, gender, race, 
admission diagnosis, 














>81.5 OR (95% CI): 
63.1-81.5: 1.43 (0.99-2.05), 
46.2-≤63.1: 1.69 (1.19-2.41), 
≤46.2: 1.82 (1.28-2.57),  
Dialysis: 1.7 (1.01-2.88) 
OR (95% CI): 
63.1-81.5: 1.66 (1.10-2.5),  
46.2-≤63.1: 2 (1.29-3.13),  
≤46.2: 2.19 (1.36-3.5),  
Dialysis: 2.07 (1.02-4.22) 
Age, gender, race, 
admission diagnosis, 














>81.5 OR (95% CI): 
63.1-81.5: 1.55 (1.09-2.20), 
46.2-≤63.1: 1.59 (1.12-2.25), 
≤46.2: 1.99 (1.42-2.78),  
Dialysis: 1.47 (0.85-2.52) 
OR (95% CI): 
63.1-81.5: 1.63 (1.08-2.47),  
46.2-≤63.1: 1.91 (1.22-
2.98),  
≤46.2: 2.05 (1.29-3.26),  
Dialysis: 2.42 (1.13-5.15) 
Age, gender, race, 
admission diagnosis, 















>81.5 OR (95% CI): 
63.1-81.5: 1.79 (1.18-2.72), 
46.2-≤63.1: 2.27 (1.52-3.4),  
≤46.2: 2.94 (1.99-4.35),  
Dialysis: 3.56 (2.14-5.9) 
OR (95% CI): 
63.1-81.5: 1.73 (1.08-2.77),  
46.2-≤63.1: 2.73 (1.68-
4.43),  
≤46.2: 2.82 (1.71-4.65),  
Dialysis: 3.64 (1.77-7.48) 
Age, gender, race, 
admission diagnosis, 












>81.5 OR (95% CI): 
63.1-81.5: 1.65 (1.07-2.56), 
46.2-≤63.1: 1.65 (1.07-2.56), 
≤46.2: 3.13 (2.10-4.65),  
Dialysis: 1.84 (0.98-3.46) 
OR (95% CI): 
63.1-81.5: 1.75 (1.08-2.83),  
46.2-≤63.1: 1.57 (0.92-
2.66),  
≤46.2: 2.8 (1.69-4.63),  
Dialysis: 2.3 (1.00-5.57) 
Age, gender, race, 
admission diagnosis, 

















101-115 OR (95% CI): 
115-190: 0.9 (0.5-1.6),  
90-101: 1.2 (0.7-2),  
79-90: 1.9 (1.1-3.1),  
29-79: 4.3 (2.7-7.1) 
OR (95% CI): 
115-190: 1 (0.5-1.9),  
90-101: 1.5 (0.8-2.9),  
79-90: 2.8 (1.5-5.3),  
29-79: 6.7 (3.6-12.4) 
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Per 1 unit 
(ml/min/1.73m2) 
eGFR:  
Per 1 unit  
OR (95% CI): 
0.97 (0.96-0.98) 
OR (95% CI): 
0.98 (0.96-1.00) 
Age, sex, hypertension, 
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index, Malay vs non-
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OR (95% CI): 
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0.99 (0.97-1.01) 
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Appendix B: Supplementary materials for Chapter 2 




Figure B-2. Categorization of glomerular filtration rate (GFR) and albuminuria 




*The figure is from the 2017 KDIGO Clinical Practice Guideline: 
 
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work 
Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, 
Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder 
(CKD-MBD). Kidney Int Suppl. 2017;7:1–59.  
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Table B-1. List of drugs commonly associated with QT-prolongation and torsades 
de pointes  
 
Antiarrhythmic Antimicrobial Antidepressant Antipsychotic Others 
Amiodarone Levofloxacin Amitriptyline Haloperidol Cisapride 
Sotalol Ciprofloxacin Desipramine Droperidol Sumatriptan 
Quinidine Gatifloxacin Imipramine Quetiapine Zolmitriptan 
Procainamide Moxifloxacin Doxepin Thioridazine Arsenic 
Dofetilide Clarithromycin Fluoxetine Ziprasidone Dolasetron 
Ibutilide Erythromycin Setraline  Methadone 
 Ketoconazole Venlafaxine   
 Itraconazole    
 




Table B-2. Associations of chronic kidney disease (CKD) status with prevalence of major arrhythmias 
    
No CKD 
CKD with moderate risk CKD with high risk CKD with very high risk 
PR (95% CI) P  PR (95% CI) P  PR (95% CI) P  
Atrial fibrillation 
Model 1 ref 1.54 (1.05, 2.26) 0.03 2.02 (1.34, 3.06) 0.001 2.65 (1.72, 4.09) <0.001 
Model 2 ref 1.45 (0.98, 2.14) 0.07 1.78 (1.15, 2.73) 0.01 2.22 (1.42, 3.49) 0.001 




Model 1 ref 1.17 (1.00, 1.37) 0.05 1.46 (1.23, 1.73) <0.001 1.50 (1.24, 1.82) <0.001 
Model 2 ref 1.13 (0.97, 1.32) 0.12 1.35 (1.14, 1.60) 0.001 1.34 (1.09, 1.63) 0.004 
Model 3 ref 1.07 (0.91, 1.25) 0.43 1.20 (1.01, 1.44) 0.04 1.14 (0.93, 1.41) 0.21 
Long pause 
Model 1 ref 1.91 (1.01, 3.62) 0.05 1.56 (0.72, 3.41) 0.26 3.52 (1.74, 7.12) <0.001 
Model 2 ref 1.65 (0.88, 3.13) 0.12 1.17 (0.51, 2.69) 0.71 2.39 (1.10, 5.20) 0.03 
Model 3 ref 1.49 (0.77, 2.87) 0.23 0.92 (0.39, 2.17) 0.85 1.91 (0.82, 4.49) 0.14 
Atrioventricular 
block 
Model 1 ref 0.95 (0.47, 1.92) 0.89 0.53 (0.18, 1.54) 0.24 1.06 (0.40, 2.81) 0.91 
Model 2 ref 0.92 (0.47, 1.83) 0.82 0.49 (0.17, 1.46) 0.20 0.95 (0.34, 2.65) 0.92 
Model 3 ref 0.72 (0.36, 1.46) 0.36 0.36 (0.12, 1.07) 0.07 0.60 (0.22, 1.66) 0.33 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, medication, QT-prolonging drug 
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Figure B-2. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) 




Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
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Table B-3. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) with 
prevalence of major arrhythmias 
    
eGFR, per -15 ml/min/1.73m2 ACR, per 4-fold increase 
PR (95% CI) P  PR (95% CI) P  
Atrial fibrillation 
Model 1 1.32 (1.18, 1.47) <0.001 1.32 (1.19, 1.47) <0.001 
Model 2 1.26 (1.12, 1.42) <0.001 1.27 (1.13, 1.41) <0.001 




Model 1 1.14 (1.08, 1.20) <0.001 1.15 (1.09, 1.21) <0.001 
Model 2 1.11 (1.05, 1.17) <0.001 1.11 (1.05, 1.17) <0.001 
Model 3 1.04 (0.98, 1.10) 0.19 1.07 (1.01, 1.13) 0.03 
Long pause 
Model 1 1.38 (1.13, 1.68) 0.001 1.35 (1.12, 1.64) 0.002 
Model 2 1.27 (1.01, 1.60) 0.05 1.21 (0.99, 1.48) 0.07 
Model 3 1.11 (0.85, 1.45) 0.45 1.13 (0.90, 1.42) 0.30 
Atrioventricular 
block 
Model 1 1.01 (0.79, 1.29) 0.94 1.03 (0.79, 1.35) 0.80 
Model 2 1.01 (0.78, 1.30) 0.96 1.01 (0.78, 1.31) 0.92 
Model 3 0.88 (0.68, 1.15) 0.36 0.96 (0.74, 1.25) 0.78 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, medication, QT-prolonging drug, eGFR or ACR 
  
 161 
Table B-4. Associations of chronic kidney disease (CKD) status with percent time in atrial fibrillation and 
frequency of non-sustained ventricular tachycardia, long pause, and atrioventricular block 
    
No CKD CKD with moderate risk CKD with high risk CKD with very high risk 
Percent time   
Difference in 
percent time  
(95% CI), % P 
Difference in  
percent time  
(95% CI), % P 
Difference in 
percent time  
(95% CI), % P 
Atrial fibrillation 
Model 1 ref 0.03 (0.01, 0.05) 0.01 0.05 (0.03, 0.08) <0.001 0.08 (0.05, 0.11) <0.001 
Model 2 ref 0.02 (0.00, 0.04) 0.05 0.05 (0.02, 0.07) 0.001 0.07 (0.04, 0.10) <0.001 
Model 3 ref 0.02 (-0.01, 0.04) 0.14 0.03 (0.01, 0.06) 0.01 0.06 (0.03, 0.09) <0.001 




Model 1 ref 0.37 (0.11, 1.22) 0.10 1.82 (0.37, 8.96) 0.46 0.67 (0.20, 2.23) 0.52 
Model 2 ref 0.39 (0.13, 1.16) 0.09 1.87 (0.48, 7.37) 0.37 0.69 (0.22, 2.17) 0.53 
Model 3 ref 0.36 (0.10, 1.30) 0.12 1.73 (0.43, 7.02) 0.44 0.52 (0.12, 2.21) 0.37 
Long pause 
Model 1 ref 9.86 (2.92, 33.34) <0.001 4.06 (1.01, 16.31) 0.05 
27.81 (5.89, 
131.24) <0.001 
Model 2 ref 
12.12 (3.50, 
41.95) <0.001 6.22 (1.29, 29.97) 0.02 
34.09 (4.89, 
237.60) <0.001 





Model 1 ref 0.15 (0.02, 1.12) 0.07 0.07 (0.01, 0.43) 0.004 0.02 (0.00, 0.10) <0.001 
Model 2 ref 
57.50 (3.74, 
884.55) 0.004 0.03 (0.01, 0.05) <0.001 0.01 (0.00, 0.11) <0.001 
Model 3 ref 0.08 (0.01, 0.65) 0.02 0.00 (0.00, 0.04) <0.001 0.01 (0.00, 0.14) <0.001 
RR=rate ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
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Figure B-3. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) 
with (A) percent time in atrial fibrillation and (B) frequency of non-sustained ventricular tachycardia, long 

























(A) Association of eGFR or ACR with percent time in atrial fibrillation; (B) Association of eGFR or ACR with 
frequency of non-sustained ventricular tachycardia, long pause, and atrioventricular block 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
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Table B-5. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) with 
percent time in atrial fibrillation and frequency of non-sustained ventricular tachycardia, long pause, and 
atrioventricular block 
    eGFR, per -15 ml/min/1.73m2 ACR, per 4-fold increase 
Percent time 
Difference in percent 
time (95% CI), % P 
Difference in percent 
time (95% CI), % P 
Atrial fibrillation 
Model 1 0.02 (0.01, 0.03) <0.001 0.02 (0.02, 0.03) <0.001 
Model 2 0.02 (0.01, 0.02) <0.001 0.02 (0.01, 0.03) <0.001 
Model 3 0.01 (-0.00, 0.02) 0.08 0.02 (0.01, 0.03) <0.001 




Model 1 1.08 (0.89, 1.31) 0.44 1.22 (0.63, 2.36) 0.55 
Model 2 1.08 (0.93, 1.26) 0.31 1.23 (0.62, 2.41) 0.56 
Model 3 1.02 (0.71, 1.48) 0.90 1.11 (0.48, 2.58) 0.80 
Long pause 
Model 1 1.82 (1.38, 2.39) <0.001 2.07 (1.05, 4.06) 0.04 
Model 2 2.05 (1.34, 3.13) 0.001 1.98 (1.06, 3.72) 0.03 
Model 3 1.22 (0.74, 2.00) 0.43 1.51 (0.85, 2.69) 0.16 
Atrioventricular 
block 
Model 1 0.22 (0.10, 0.52) <0.001 0.42 (0.19, 0.91) 0.03 
Model 2 0.30 (0.20, 0.46) <0.001 0.50 (0.21, 1.18) 0.11 
Model 3 0.26 (0.19, 0.35) <0.001 1.81 (0.72, 4.55) 0.21 
RR=rate ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
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Figure B-4. Associations of chronic kidney disease (CKD) status with prevalence of minor arrhythmias  
 
  
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
*Supraventricular tachycardia and ectopy were examined among participants who do not have chronic atrial fibrillation   
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Table B-6. Associations of chronic kidney disease (CKD) status with prevalence of minor arrhythmias 
    
No CKD 
CKD with moderate risk CKD with high risk CKD with very high risk 
PR (95% CI) P  PR (95% CI) P  PR (95% CI) P  
Ventricular ectopy 
Model 1 ref 1.00 (0.98, 1.03) 0.86 1.04 (1.01, 1.07) 0.02 1.04 (1.00, 1.08) 0.05 
Model 2 ref 1.00 (0.98, 1.03) 0.81 1.04 (1.00, 1.07) 0.03 1.04 (1.00, 1.09) 0.05 
Model 3 ref 1.00 (0.97, 1.02) 0.82 1.03 (1.00, 1.06) 0.09 1.03 (0.99, 1.08) 0.12 
Supraventricular 
tachycardia§ 
Model 1 ref 0.98 (0.95, 1.02) 0.28 1.02 (0.97, 1.06) 0.50 0.95 (0.89, 1.01) 0.10 
Model 2 ref 0.98 (0.95, 1.02) 0.41 1.02 (0.97, 1.07) 0.42 0.96 (0.90, 1.02) 0.22 
Model 3 ref 0.99 (0.95, 1.03) 0.53 1.03 (0.98, 1.08) 0.30 0.97 (0.91, 1.04) 0.37 
Supraventricular 
ectopy§ 
Model 1 ref 1.00 (0.98, 1.03) 0.73 1.03 (1.00, 1.06) 0.07 1.03 (0.99, 1.07) 0.11 
Model 2 ref 1.01 (0.98, 1.03) 0.64 1.03 (1.00, 1.07) 0.08 1.04 (0.99, 1.08) 0.09 
Model 3 ref 1.00 (0.97, 1.02) 0.88 1.02 (0.99, 1.05) 0.26 1.03 (0.98, 1.07) 0.23 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, medication, QT-prolonging drug 
§Among participants who do not have chronic atrial fibrillation   
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Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
* Supraventricular tachycardia and ectopy were examined among participants who do not have chronic atrial fibrillation   
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Table B-7. Associations of chronic kidney disease (CKD) status with frequency of minor arrhythmias 
    
No CKD CKD with moderate risk CKD with high risk CKD with very high risk 
Frequency of arrhythmia 
episodes  RR (95% CI) P RR (95% CI) P RR (95% CI) P 
Ventricular ectopy 
Model 1 ref 0.85 (0.63, 1.14) 0.28 1.39 (0.97, 2.00) 0.07 1.86 (1.23, 2.82) 0.003 
Model 2 ref 0.80 (0.60, 1.07) 0.13 1.23 (0.83, 1.82) 0.30 1.55 (1.04, 2.32) 0.03 
Model 3 ref 0.82 (0.62, 1.10) 0.20 1.23 (0.79, 1.92) 0.35 1.58 (1.01, 2.47) 0.04 
Supraventricular 
tachycardia§ 
Model 1 ref 0.86 (0.43, 1.70) 0.66 1.26 (0.68, 2.32) 0.46 1.20 (0.55, 2.61) 0.65 
Model 2 ref 0.82 (0.41, 1.62) 0.56 1.17 (0.64, 2.13) 0.61 1.10 (0.50, 2.43) 0.81 
Model 3 ref 0.84 (0.44, 1.61) 0.60 1.24 (0.66, 2.35) 0.50 1.20 (0.53, 2.73) 0.66 
Supraventricular 
ectopy§ 
Model 1 ref 1.05 (0.80, 1.39) 0.70 0.95 (0.70, 1.30) 0.76 1.43 (1.03, 2.00) 0.03 
Model 2 ref 0.96 (0.72, 1.28) 0.79 0.81 (0.59, 1.11) 0.20 1.17 (0.85, 1.63) 0.34 
Model 3 ref 0.96 (0.71, 1.29) 0.77 0.80 (0.57, 1.12) 0.19 1.16 (0.82, 1.63) 0.40 
RR=rate ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 




Figure B-6. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) 




Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
*Supraventricular tachycardia and ectopy were examined among participants who do not have chronic atrial fibrillation   
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Table B-8. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) with 
prevalence of minor arrhythmias 
    
eGFR, per -15 ml/min/1.73m2 ACR, per 4-fold increase 
PR (95% CI) P  PR (95% CI) P  
Ventricular ectopy 
Model 1 1.01 (1.00, 1.02) 0.004 1.01 (1.00, 1.02) 0.07 
Model 2 1.01 (1.00, 1.02) 0.01 1.01 (1.00, 1.02) 0.06 
Model 3 1.01 (1.00, 1.02) 0.21 1.01 (1.00, 1.02) 0.07 
Supraventricular 
tachycardia§ 
Model 1 1.00 (0.98, 1.01) 0.64 1.00 (0.98, 1.01) 0.81 
Model 2 1.00 (0.98, 1.01) 0.74 1.00 (0.99, 1.02) 0.63 
Model 3 1.00 (0.98, 1.01) 0.92 1.01 (0.99, 1.02) 0.49 
Supraventricular 
ectopy§ 
Model 1 1.01 (1.00, 1.02) 0.01 1.01 (1.00, 1.02) 0.07 
Model 2 1.01 (1.00, 1.02) 0.01 1.01 (1.00, 1.02) 0.04 
Model 3 1.00 (1.00, 1.01) 0.33 1.01 (1.00, 1.02) 0.05 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, medication, QT-prolonging drug, eGFR or ACR 
§Among participants who do not have chronic atrial fibrillation   
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Figure B-7. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) 




Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
*Supraventricular tachycardia and ectopy were examined among participants who do not have chronic atrial fibrillation  
 171 
Table B-9. Associations of estimated glomerular filtration rate (eGFR) and albumin-creatinine ratio (ACR) with 
frequency of minor arrhythmias 
    eGFR, per -15 ml/min/1.73m2 ACR, per 4-fold increase 
Frequency of arrhythmia 
episodes RR (95% CI) P RR (95% CI) P 
Ventricular ectopy 
Model 1 1.12 (1.00, 1.26) 0.05 1.26 (1.13, 1.40) <0.001 
Model 2 1.07 (0.95, 1.21) 0.25 1.20 (1.08, 1.32) 0.001 
Model 3 1.01 (0.89, 1.15) 0.89 1.22 (1.08, 1.38) 0.001 
Supraventricular 
tachycardia§ 
Model 1 1.07 (0.93, 1.23) 0.37 1.22 (0.94, 1.59) 0.14 
Model 2 1.04 (0.91, 1.19) 0.54 1.19 (0.92, 1.55) 0.19 
Model 3 1.03 (0.84, 1.25) 0.79 1.23 (0.86, 1.76) 0.26 
Supraventricular 
ectopy§ 
Model 1 1.08 (0.97, 1.20) 0.14 1.05 (0.96, 1.16) 0.30 
Model 2 1.03 (0.92, 1.15) 0.64 1.00 (0.91, 1.11) 0.94 
Model 3 1.02 (0.89, 1.16) 0.80 1.02 (0.91, 1.13) 0.76 
RR=rate ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug, 
eGFR or ACR 
§Among participants who do not have chronic atrial fibrillation 
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Table B-10. Associations of chronic kidney disease (CKD) status with prevalence of major arrhythmias using 
additional arrhythmia events captured from hospitalization records 
    
No CKD 
CKD with moderate risk CKD with high risk CKD with very high risk 
PR (95% CI) P  PR (95% CI) P  PR (95% CI) P  
Atrial fibrillation 
Model 1 ref 1.60 (1.12, 2.29) 0.01 2.12 (1.45, 3.11) <0.001 2.66 (1.77, 3.98) <0.001 
Model 2 ref 1.50 (1.05, 2.16) 0.03 1.87 (1.26, 2.78) 0.002 2.24 (1.47, 3.41) <0.001 




Model 1 ref 1.17 (1.00, 1.37) 0.05 1.47 (1.24, 1.74) <0.001 1.50 (1.24, 1.82) <0.001 
Model 2 ref 1.13 (0.97, 1.32) 0.11 1.36 (1.15, 1.61) <0.001 1.34 (1.10, 1.63) 0.004 
Model 3 ref 1.07 (0.91, 1.25) 0.43 1.21 (1.02, 1.45) 0.03 1.14 (0.93, 1.41) 0.20 
Long pause 
Model 1 ref 1.88 (1.01, 3.50) 0.05 1.62 (0.77, 3.42) 0.21 3.31 (1.65, 6.63) 0.001 
Model 2 ref 1.64 (0.88, 3.05) 0.12 1.23 (0.55, 2.73) 0.61 2.28 (1.06, 4.88) 0.03 
Model 3 ref 1.51 (0.80, 2.86) 0.21 0.99 (0.43, 2.30) 0.99 1.90 (0.82, 4.43) 0.14 
Atrioventricular 
block 
Model 1 ref 0.95 (0.47, 1.92) 0.89 0.92 (0.39, 2.18) 0.85 1.06 (0.40, 2.81) 0.91 
Model 2 ref 0.91 (0.46, 1.80) 0.78 0.84 (0.36, 1.95) 0.68 0.92 (0.33, 2.56) 0.87 
Model 3 ref 0.72 (0.36, 1.46) 0.37 0.62 (0.26, 1.46) 0.27 0.61 (0.22, 1.67) 0.33 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
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Table B-11. Associations of chronic kidney disease (CKD) status with prevalence of major arrhythmias after 
excluding participants taking antiarrhythmic medications 
    
No CKD 
CKD with moderate risk CKD with high risk CKD with very high risk 
PR (95% CI) P  PR (95% CI) P  PR (95% CI) P  
Atrial fibrillation 
Model 1 ref 1.27 (0.80, 2.03) 0.31 2.02 (1.25, 3.27) 0.00 2.75 (1.67, 4.53) <0.001 
Model 2 ref 1.19 (0.74, 1.92) 0.46 1.81 (1.09, 3.00) 0.02 2.25 (1.35, 3.75) 0.002 




Model 1 ref 1.19 (1.01, 1.40) 0.04 1.43 (1.20, 1.71) 0.00 1.49 (1.21, 1.82) <0.001 
Model 2 ref 1.14 (0.97, 1.34) 0.11 1.32 (1.11, 1.58) 0.00 1.30 (1.05, 1.61) 0.02 
Model 3 ref 1.07 (0.91, 1.26) 0.42 1.19 (0.98, 1.43) 0.07 1.10 (0.88, 1.37) 0.39 
Long pause 
Model 1 ref 1.87 (0.92, 3.83) 0.09 1.20 (0.46, 3.13) 0.71 3.81 (1.76, 8.25) 0.001 
Model 2 ref 1.53 (0.74, 3.16) 0.25 0.88 (0.31, 2.49) 0.81 2.38 (0.97, 5.80) 0.06 
Model 3 ref 1.37 (0.64, 2.95) 0.42 0.74 (0.26, 2.10) 0.58 1.74 (0.64, 4.69) 0.28 
Atrioventricular 
block 
Model 1 ref 1.03 (0.51, 2.10) 0.93 0.43 (0.13, 1.46) 0.18 1.15 (0.43, 3.06) 0.79 
Model 2 ref 0.98 (0.49, 1.96) 0.95 0.39 (0.12, 1.32) 0.13 0.99 (0.35, 2.80) 0.99 
Model 3 ref 0.74 (0.37, 1.51) 0.41 0.28 (0.08, 0.97) 0.04 0.60 (0.22, 1.69) 0.34 
PR=prevalence ratio; CI=confidence interval 
Model 1: Crude 
Model 2: Age, sex, race, study center, education 
Model 3: Model 2 + body mass index, current smoking and alcohol, systolic blood pressure, antihypertensive drugs, 
diabetes, prevalent cardiovascular disease, total and HDL cholesterol, antiarrhythmic medication, QT-prolonging drug 
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Table B-12. Baseline characteristics comparing participants who did and did not 








Age, years (SD) 79.1 (4.6) 80.2 (4.9) 
Male, % 56.7 60.1 
White, % 23.5 18.3 
Study center, %   
      Forsyth County, NC 22.8 23.1 
      Jackson, MS 21.9 16.5 
      Minneapolis, MN 29.0 35.0 
      Washington County, MD 26.3 25.4 
Education, %   
      < High school 12.0 11.4 
      High school graduate 41.5 40.0 
      College or graduate school 46.5 48.6 
Body mass index, kg/m2 (SD) 28.3 (5.3) 28.2 (5.6) 
Current cigarette smoker, % 7.0 6.7 
Current drinker, % 51.6 50.7 
Systolic blood pressure, mmHg (SD) 134.9 (18.8) 135.5 (19.1) 
Antihypertensive medication, % 76.3 77.6 
Diabetes, % 33.4 32.5 
Prevalent cardiovascular disease, % 23.8 27.8 
      Heart failure, % 12.5 16.7 
      Coronary heart disease, % 14.0 15.4 
      Stroke, % 4.4 5.2 
Medication for arrhythmia, % 8.9 10.4 
QT-prolonging medication, % 10.4 10.4 
Total cholesterol, SI Units (SD) 4.5 (1.0) 4.5 (1.0) 
High-density lipoprotein, SI Units 
(SD) 1.3 (0.4) 1.4 (0.4) 
eGFR, ml/min/1.73m2 (SD) 58.4 (18.3) 55.4 (18.6) 
Albumin-to-creatinine ratio, mg/g 
(IQI) 7.1 (3.5, 18.5) 8.2 (3.8, 23.7) 
*Number represents participants who did not undergo two-week continuous ECG 
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 Table C-1. List of drugs commonly associated with QT-prolongation and torsades 
de pointes  
 
Antiarrhythmic Antimicrobial Antidepressant Antipsychotic Others 
Amiodarone Levofloxacin Amitriptyline Haloperidol Cisapride 
Sotalol Ciprofloxacin Desipramine Droperidol Sumatriptan 
Quinidine Gatifloxacin Imipramine Quetiapine Zolmitriptan 
Procainamide Moxifloxacin Doxepin Thioridazine Arsenic 
Dofetilide Clarithromycin Fluoxetine Ziprasidone Dolasetron 
Ibutilide Erythromycin Setraline  Methadone 
 Ketoconazole Venlafaxine   
 Itraconazole    
 
*Accessed from https://www.uspharmacist.com/article/drug-induced-qt-prolongation 
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Table C-2. Burden of major and minor arrhythmias by chronic kidney disease (CKD) status 
Characteristics 
Total No CKD CKD 
n=2233 n=933 n=1300 
Major arrhythmias 
Atrial fibrillation    
       Presence, % 7.4 5.0 9.2 
       Percent of time in arrhythmia (IQI)*, % 100 (6, 100) 11 (2, 100) 100 (5, 100) 
Non-sustained ventricular tachycardia    
       Presence, % 30.2 25.8 33.4 
       Frequency (number of episodes per day [IQI])* 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 0.1 (0.1, 0.2) 
Long pause    
       Presence, % 2.7 1.7 3.4 
       Frequency (number of episodes per day [IQI])* 0.2 (0.1, 1.3) 0.2 (0.1, 0.7) 0.2 (0.1, 1.8) 
Atrioventricular block    
       Presence, % 1.7 1.9 1.6 
       Frequency (number of episodes per day [IQI])* 0.2 (0.1, 0.6) 0.1 (0.1, 0.6) 0.3 (0.1, 0.7) 
Minor arrhythmias 
Ventricular ectopy    
       Presence, % 98.8 98.6 99.0 
       Frequency (number of episodes per day [IQI])* 68.7 (11.6, 420.9) 54.3 (7.9, 339.4) 78.2 (14.8, 488.6) 
Supraventricular tachycardia§    
       Presence, % 89.7 91.2 88.6 
       Frequency (number of episodes per day [IQI])* 0.9 (0.4, 2.2) 0.9 (0.4, 2.2) 0.8 (0.3, 2.2) 
Supraventricular ectopy§    
       Presence, % 99.9 99.8 99.9 
       Frequency (number of episodes per day [IQI])* 202.3 (63.5, 803.7) 170.8 (58.5, 722.8) 227.8 (67.3, 846.5) 
*Characteristics are summarized only among participants with presence of the corresponding arrhythmia 




Table C-3. Number of non-sustained ventricular tachycardia episodes per day by quartiles of hs-cTnT in no-
CKD and in CKD 
 




































hs-cTnT=high-sensitivity cardiac troponin T; CKD=chronic kidney disease; Q1=quartile 1; Q2=quartile 2; Q3=quartile 
3; Q4=quartile 4; SD=standard deviation  
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Table C-4. Summary of associations of cardiac biomarkers, electrolytes, and hemoglobin with arrhythmias by 
chronic kidney disease status 
  
NTproBNP,  
per 2-fold higher 
hs-cTnT,  
per 2-fold higher 
Potassium <4.1 
mmol/l,  




per 1 mmol/l higher 
Magnesium <2 
mg/dl,  
per 0.5 mg/dl lower 
Magnesium >2 
mg/dl,  
per 0.5 mg/dl higher 
Hemoglobin, 
per 1 g/dl lower 
















fibrillation                             
Presence ↑ ↑ ↑ ↑ ↑      ↑      
% time ↑ ↑ ↑         ↑      
Ventricular 
tachycardia                             
Presence ↑ ↑ ↑ ↑              
Frequency ↑ ↑    ↓      ↓         ↑     
Long pause                             
Presence ↑ ↑           ↑     
Frequency ↑ ↑  ↑              
Atrioventricular 
block                             
Presence                   
Frequency   ↑  ↓         ↑    ↓    ↓     
Ventricular 
ectopy                             
Presence ↑                 
Frequency ↑ ↑       ↑                 
Supraventricula
r tachycardia                             
Presence                   
Frequency                      ↓      ↓ 
Supraventricula
r ectopy                             
Presence                   
Frequency ↑ ↑   ↑              ↓  ↓     
               
 ↑ Indicates positive association after adjusting for potential confounders 
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Figure D-1. Study flow diagram 
 
  
ARIC study participants from V6
N=4,003
V6 participants with complete CKD and 
Zio Patch data
N=2,422




Missing CKD measures (n=194):
- Missing eGFR (n=91)
- Missing albumin-to-creatinine ratio (n=103)
Race other than white and black (n=6)







Table D-1. List of drugs commonly associated with QT-prolongation and torsades 
de pointes  
Antiarrhythmic Antimicrobial Antidepressant Antipsychotic Others 
Amiodarone Levofloxacin Amitriptyline Haloperidol Cisapride 
Sotalol Ciprofloxacin Desipramine Droperidol Sumatriptan 
Quinidine Gatifloxacin Imipramine Quetiapine Zolmitriptan 
Procainamide Moxifloxacin Doxepin Thioridazine Arsenic 
Dofetilide Clarithromycin Fluoxetine Ziprasidone Dolasetron 
Ibutilide Erythromycin Setraline  Methadone 
 Ketoconazole Venlafaxine   
 Itraconazole    
 
*Accessed from https://www.uspharmacist.com/article/drug-induced-qt-prolongation 
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Figure D-2. Absolute change in probabilities of atrial fibrillation over time by 
chronic kidney disease status 
 
 
Blue line represents the mean absolute change in probability of atrial fibrillation per 10 
min over 24 hours.  
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